

# National Head and Neck Cancer Audit

## Key findings for England and Wales for the audit period October 2006 to November 2007

DAHNO third annual report

Prepared in partnership with:



British Association of Head and Neck Oncologists



# National Head and Neck Cancer Audit

## Key findings for England and Wales for the audit period November 2006 to October 2007

This third report for the National Head and Neck Cancer Audit presents data collected on new registrations from 1 November 2006 to 31 October 2007 and treatment data up to the 19 November 2007. The report reflects the analysis of that data, and provides recommendations for improving data quality and completeness. DAHNO, by means of a continuous electronic audit on the management of head and neck cancer in England and Wales, aims to provide comparative feedback to NHS Provider Trusts, with the ultimate aim of improving patient care.

A brief summary report will compliment this report following its publication.

Electronic copies of this report can be found at:  
[www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits)

<http://www.ic.nhs.uk/our-services/improving-patient-care/national-clinical-audit-support-programme-ncasp/audit-reports/head-and-neck-cancer>

Printed copies of this report can be ordered from The NHS IC for health and social care's (The IC) Contact Centre **0845 300 6016** or email: [enquiries@ic.nhs.uk](mailto:enquiries@ic.nhs.uk) quoting document reference 28010408.

For further information about this report, contact The NHS IC's Contact Centre **0845 300 6016** or email: [enquiries@ic.nhs.uk](mailto:enquiries@ic.nhs.uk)

# Contents

<b>i</b>	<b>Acknowledgements</b>	<b>i</b>	<b>2.2 Measuring clinical care</b>	<b>16</b>
<b>ii</b>	<b>Foreword</b>	<b>ii</b>	2.2.1 Sources of existing information and differences that the head and neck cancer audit provides	16
<b>1.0</b>	<b>Executive Summary</b>	<b>1</b>	<b>2.3 Key partners and drivers in developing clinical audit</b>	<b>17</b>
<b>1.1</b>	<b>What is DAHNO?</b>	<b>1</b>	2.3.1 The National Clinical Audit Support Programme (NCASP) and Patient's Outcomes Programme	17
<b>1.2</b>	<b>What DAHNO adds to existing information</b>	<b>1</b>	2.3.2 "NHS Plan" in England and "Designed to tackle cancer" in Wales, and cancer audit	17
<b>1.3</b>	<b>Where head and neck cancer care happens – submission rates</b>	<b>1</b>	2.3.3 National Institute for Clinical Excellence (NICE) Improving Outcomes Guidance (IOG) for head and neck cancer	17
1.3.1	Contributing Cancer Networks in England and Wales	1		
1.3.2	Overview of case ascertainment	2		
<b>1.4</b>	<b>Key overall findings</b>	<b>2</b>	<b>3.0 DAHNO application infrastructure</b>	<b>19</b>
1.4.1	The pivotal role of the MDT meeting	2	<b>3.1 The DAHNO System</b>	<b>19</b>
1.4.2	Speech and language and dietetic provision	2	3.1.1 DAHNO Application	19
<b>1.5</b>	<b>Who receives the care?</b>	<b>2</b>	3.1.2 Data submission from Wales	19
1.5.1	The patient journey	2	<b>3.2 DAHNO application security and patient confidentiality</b>	<b>19</b>
1.5.2	Care provided	3	3.2.1 DAHNO application security	19
<b>1.6</b>	<b>Recommendations</b>	<b>3</b>	3.2.2 Patient confidentiality	20
<b>1.7</b>	<b>Key aspects for the current collection year November 2007 – October 2008</b>	<b>4</b>		
<b>1.8</b>	<b>Good Practice</b>	<b>4</b>	<b>4.0 Methods and Approaches</b>	<b>21</b>
<b>1.9</b>	<b>Summary report</b>	<b>4</b>	<b>4.1 Methodology</b>	<b>21</b>
<b>1.10</b>	<b>Participating Trusts</b>	<b>5</b>	<b>4.2 Clinical aspects</b>	<b>21</b>
<b>1.11</b>	<b>Routes of Submission by Trust</b>	<b>10</b>	4.2.1 Inclusions and exclusions in the head and neck cancer audit Phase I	21
<b>2.0</b>	<b>Background to head and neck cancer and comparative audit</b>	<b>16</b>	<b>4.3 Determining cancer centres: Provider Trusts managing head and neck cancer</b>	<b>21</b>
<b>2.1</b>	<b>What is head and neck cancer?</b>	<b>16</b>	<b>4.4 DAHNO improvements rolled out in 2007</b>	<b>21</b>
2.1.1	Cancer sites	16	<b>4.5 Priority outputs and rationale</b>	<b>22</b>
2.1.2	Impact of head and neck cancer on patients	16	<b>4.6 Data standards</b>	<b>22</b>
2.1.3	Outcome in head and neck cancer	16		

<b>5.0 Benefits of participation in the audit</b>	<b>23</b>	6.2.7 Application issues-web DAHNO and Phase II	32
<b>5.1 The Healthcare Commission and Annual Health Check</b>	<b>23</b>	6.2.8 Audit data to support clinical process	32
<b>5.2 England</b>	<b>23</b>	<b>7.0 Statistical methods used for data analysis</b>	<b>33</b>
<b>5.3 Wales</b>	<b>24</b>	<b>8.0 Findings</b>	<b>34</b>
<b>5.4 Benefits of participation across the healthcare pathway</b>	<b>24</b>	<b>8.1 Introduction</b>	<b>34</b>
5.4.1 For Patients	24	<b>8.2 Analysed data</b>	<b>34</b>
5.4.2 For National Monitoring Bodies	24	<b>8.3 Where head and neck cancer care happens</b>	<b>35</b>
5.4.3 For Commissioners of Services	24	8.3.1 Number of patients registered with new head and neck primaries of the larynx and oral cavity	35
5.4.4 For Clinicians and Clinical Teams	24	8.3.2 Estimate of total number of patients with new head and neck primaries of the larynx and oral cavity in the index period	37
5.4.5 For Provider Organisations	25	8.3.3 Submission by Network and Provider Trust of patients with new head and neck primaries of the larynx and oral cavity in the index period	39
<b>5.5 Realising the benefits</b>	<b>25</b>	8.3.4 Submission by Network and Provider Trust of patients with new head and neck primaries of the larynx and oral cavity in the index period, where cases had pre treatment recorded T and N staging category	43
<b>6.0 Improvements and Recommendations</b>	<b>26</b>	<b>8.4 Who receives the care – demography, casemix and socio economic status</b>	<b>47</b>
<b>6.1 Improvements</b>	<b>26</b>	8.4.1 Age and sex distributions of registrations	47
6.1.1 Case ascertainment	26	8.4.2 Distribution of stage	53
6.1.2 Data quality	26	8.4.2.1 Larynx	53
6.1.2.1 Co-morbidity	27	8.4.2.1.1 Stage at diagnosis	53
6.1.3 Number of patients seen at MDT	27		
<b>6.2 Issues and recommendations</b>	<b>29</b>		
6.2.1 Developing a local response to the audit findings	29		
6.2.2 Developing a Network response to the audit findings	29		
6.2.3 Clinical issues for multi-disciplinary teams	30		
6.2.4 Standards in clinical care	30		
6.2.5 Data quality and completeness	31		
6.2.6 Data process issues	31		

8.4.2.1.2 Comparison of stage at diagnosis and post-surgery staging	54	8.4.5.2 Deprivation and stage in England	65
8.4.2.1.3 Summary of recorded stage certainty	54	8.4.5.3 Deprivation and interval from onset of first symptom to referral in England	66
8.4.2.2 Oral cavity	55	8.4.5.4 Deprivation and interval from referral to treatment in England	67
8.4.2.2.1 Stage at diagnosis	55	8.4.5.5 Proportion of registrations in each cancer network in England and Wales by quintile of deprivation January 2004 - October 2007	68
8.4.2.2.2 Comparison of stage at diagnosis and post-surgery staging	56	<b>8.5 The patient journey - diagnostic and staging process, waiting intervals</b>	<b>72</b>
8.4.2.2.3 Summary of recorded stage certainty	57	8.5.1 Source of referral to specialist team in England	72
8.4.2.3 Comparison of low to high stage disease by tumour site	58	8.5.1.1 Larynx	72
8.4.2.4 Submission by Network of patients with new head and neck primaries of the larynx and oral cavity by ratio of low to high stage disease January 2004-October 2007	59	8.5.1.2 Oral cavity	72
8.4.2.5 Submission by Network of patients who underwent surgery of the larynx and oral cavity where recording of pre-treatment and post resective pathological staging is identified in the index period	60	8.5.2 Summary as percentage of cases with both 'primary referral priority' and 'primary referral source' completed in England	73
8.4.3 Distribution of performance status at point of treatment decision	61	8.5.2.1 Larynx	73
8.4.4 Presence or absence of significant co-morbidity at index point of diagnosis (ACE-27)	62	8.5.2.2 Oral cavity	74
8.4.4.1 Summary of recorded co-morbidity	62	8.5.3 Interval from first symptom to referral to specialist team	75
8.4.5 Deprivation analysis: Distribution of diagnosis, treatment and outcome by socio-economic Lower Super Output Areas, derived from the postcode in England and Wales	63	8.5.4 Interval from referral to first appointment in England	77
8.4.5.1 Summary of registrations by deprivation in England	64	8.5.5 Interval from referral to diagnosis in England and Wales	78
		8.5.5.1 Time from biopsy to reporting	79
		8.5.6 The multi-disciplinary team (MDT) and its functions	82
		8.5.6.b Analysis of multi-disciplinary discussion for index year by provider trust	83
		8.5.7 Interval from diagnosis to decision to treat	85
		8.5.7.1 Interval from diagnosis to MDT ('triage' date)	85

8.5.7.2	Interval from diagnosis to date care plan agreed	87	8.6.3	Percentage having pre-treatment dental assessment	101
8.5.7.3	Interval from date care plan agreed to sending communication to primary care	88	8.6.4	Percentage having pre-operative / pre-treatment speech and swallowing assessment (includes for laser cordectomy) and percentage having pre-operative / pre-treatment (includes radio and chemotherapy) dietetic assessment	101
8.5.8	Number and percentage with histological confirmation prior to cancer care plan	88	8.6.5	Percentage receiving each category of surgical procedure (including surgery to neck, surgical voice restoration)	102
8.5.9	Number and percentage with staging information recorded at time of cancer care plan	89	8.6.6	Percentage having radical radiotherapy with curative intent	103
8.5.10	Percentage having chest imaging by chest x-ray (CXR) or chest computerised tomography (CT) prior to cancer care plan	90	8.6.7	Percentage having palliative treatment by type (ie radiotherapy, chemotherapy and surgery)	103
8.5.11	Interval from imaging request to date imaging performed (CT/MRI) contributory to pre-treatment staging complying with the Royal College of Radiologists' guidelines	90	8.6.8	Percentage having chemotherapy (including categories such as 'adjuvant' and 'neo-adjuvant')	104
8.5.11.1	Imaging types where interval from imaging requests from data imaging is performed is four weeks or more	91	8.6.9	Percentage referred to specialist palliative care team	104
8.5.12	Interval from diagnosis to first definitive treatment	91	8.6.10	Percentage receiving no specific treatment (including active monitoring category)	104
8.5.12.1	Interval from diagnosis to first definitive treatment by trust and by type of treatment	93	8.6.11	Percentage of patients where careplan agreed matches careplan delivered	104
8.5.13	Interval from referral to first definitive treatment in England	97	<b>8.7</b>	<b>Care provided - squamous cell carcinoma oral cavity</b>	<b>105</b>
8.5.14	Interval from surgical resection to reporting on resective specimen	98	8.7.1	Percentage having pre-treatment dental assessment	105
8.5.15	Interval from date of surgery to post-operative radiotherapy	99	8.7.2	Percentage having surgical resection with curative intent	105
<b>8.6</b>	<b>Care provided - squamous cell carcinoma larynx</b>	<b>100</b>	8.7.3	Percentage by category of clearance for surgical resection margins	106
8.6.1	Percentage having surgical resection with curative intent	100	8.7.4	Percentage having pre-operative speech and swallowing assessment and percentage having pre-operative / pre-treatment dietetic assessment	106
8.6.2	Percentage by category of clearance for surgical resection margins	100	8.7.5	Percentage receiving each category of surgical procedure (including surgery to neck, and flap repair)	107

8.7.6	Percentage having radical radiotherapy (including brachytherapy, post-operative planned and unplanned)	108	<b>6</b>	<b>UICC 6 TMN Classification of Malignant Tumours</b>	120
8.7.7	Percentage having palliative treatment by type (ie. radiotherapy, chemotherapy, surgery)	108	<b>7</b>	<b>Adult Co-morbidity Evaluation (ACE-27) UK Values</b>	123
8.7.8	Percentage having chemotherapy (including categories such as 'adjuvant' and 'neo adjuvant')	108	<b>8</b>	<b>Data Quality Trust Score Evaluation</b>	126
8.7.9	Percentage referred to specialist palliative care team	109		<b>Glossary</b>	127
8.7.10	Percentage receiving no specific treatment (including active monitoring category)	109		<b>References</b>	131
8.7.11	Percentage of patients where careplan agreed matches careplan delivered	109			
<b>8.8</b>	<b>Patient outcomes</b>	109			
8.8.1	One year, two year and three year survival	109			
8.8.2	Locoregional recurrence within one year and two years of diagnosis	110			
8.8.3	Number of treatment-related deaths (to include death within 30 days of surgery and / or within the same admission)	110			
<b>8.9</b>	<b>Clinical trials</b>	110			
<b>9.0</b>	<b>Future work</b>	111			
<b>9.1</b>	<b>Introduction</b>	111			
<b>9.2</b>	<b>Web DAHNO</b>	111			
<b>9.3</b>	<b>Casemix Adjustment</b>	111			
	<b>Appendices</b>	113			
<b>1</b>	<b>Project structure and membership</b>	113			
<b>2</b>	<b>Contributing professional organisations</b>	115			
<b>3</b>	<b>Technical Infrastructure</b>	115			
<b>4</b>	<b>Dataset and manual</b>	116			
<b>5</b>	<b>First priority outputs</b>	118			

# Acknowledgements

The National Head and Neck Cancer Audit was commissioned and sponsored by the Healthcare Commission and developed in partnership with the British Association of Head and Neck Oncologists (BAHNO).

The audit team wishes to acknowledge the following individuals and groups who have supported the audit and provided guidance during the data collection period, 1 November 2006 to 31 October 2007, and during the compilation of this report:

Dick Waite and Helen Laing of the Healthcare Commission, for their continued sponsorship and support for the audit.

The audit project team: Chair Richard Wight, Vice Chair, Graham Putnam, Project Manager Julie Michalowski, Former Project Manager Paul Theato, Senior Project Manager (Cancer Audits) Steve Dean, DAHNO Application Developer Ronnie Brar, Data Manager Nancy Horseman, Project Support Officer Clare Bailey and Former Project Support Officer Mary Boden.

Charlotte Tye, of the NHS IC Marketing and Communications Team, for her assistance throughout the year in publicising the audit and with the publication of this report. Isis Hreczuk-Hirst of the IC Datasets team for her support of data-related issues.

Jeff Stamatakis, Simon Hodder and Jackie Davies at Informing Healthcare for their contribution from Wales to the audit.

The following groups have supported the audit; the Data Management and Analysis Group, the User Group and the Head and Neck Clinical Reference Group.

We would like to acknowledge the Expert Panels (larynx and oral cavity) who contributed greatly to the annual report; Patrick Bradley, Martin Birchall, Mark Watson, David Howard, Jon Hayter, Cyrus Kerawala, Iain McVicar, Chris Nutting and Simon Hodder.

NHS Connecting for Health, and previously the NHS Information Authority, supported the technical infrastructure. We would particularly like to acknowledge Gary Sargent and Sandy Garrity who provided helpdesk support to users.

We would also like to acknowledge David Cunningham, for the initial development of the DAHNO application, and Ronnie Brar for continued development and system maintenance.

The analysis for this report was undertaken by the cancer registries and special thanks must be given to; Sandra Edwards from the Oxford Cancer Intelligence Unit, Ceri White from the Welsh Cancer Intelligence and Surveillance Unit, Sarah Cuthbertson and Jason Poole from Trent Cancer Registry, with the support of Ruth Jack and Henrik Møller at the Thames Cancer Registry.

Finally, thanks go to all those organisations that have participated in the audit so far, and for the individual contributions of clinicians, managers and administrative staff without whose efforts the audit would not be able to deliver. Thank you also to all those patients whose data is contributing towards bringing about improvements in the provision of care and outcomes for all those similarly afflicted by head and neck cancer.

## Foreword



I welcome this third annual report of the National Head and Neck Cancer Audit. I am delighted that case ascertainment across England and Wales has risen and that completeness of data on staging has improved. However, with only two thirds of incident cases being reported there is clearly a need for

further improvement. In particular, those organisations which have yet to contribute data should now make this a priority.

The Cancer Reform Strategy for England, published in December 2007, emphasises the importance of complete and accurate information as a driver for quality improvement. Comparative information can help clinical teams to identify areas where action needs to be taken to improve performance and outcomes. Information is also needed for strong commissioning and by patients who wish to make informed choices.

This audit provides useful information on the average intervals between diagnosis and treatment for patients with laryngeal and oral cancer. This should provide a useful baseline for Trusts in England as they prepare to achieve the waiting time targets set out in the Cancer Reform Strategy.

**Professor Mike Richards CBE**  
National Cancer Director



Considerable progress has been made in overall case ascertainment. The central role of the MDT meeting with multi professional discussion and agreement of a care plan for each newly diagnosed patient supported by collection of clinical data, as emphasised in this report, must remain priorities.

Whilst case ascertainment has dropped a little this year, case ascertainment for the Welsh Cancer Networks remains very good and may be due to the fact that our national cancer information system, CANISC, is also used to collect and report on the 31/62 day waiting times targets. Our next priority is to improve on recording the stage of disease. During 2008 roll out will commence of on-screen histopathology reporting that will feed directly into CANISC. We expect this will make a significant improvement that will be reflected in future National Head and Neck Cancer Annual Reports.

**Dr Jane Hanson**  
Advisor for Cancer Services to the Wales Assembly  
Government and Director of the Cancer Services  
Co-ordinating Group

The third annual report, examines data submitted from November 2006 until October 2007. Milestones have been achieved with over 2,000 cases of larynx and oral cavity cancer submitted this year and over 4,500 since the inception of the audit in 2004. 34 out of 36 networks are now actively submitting data across England and Wales.

The aim of the audit remains to achieve comprehensive and consistent data collection producing meaningful results, that provide a vehicle to improve delivery of care to patients with head and neck cancer. The benefits section sets out some of the achievements so far and will expand as the audit progresses.

The success of the audit is dependent on contributions made by individual clinicians and their support staff across the country. This annual report represents their continuing labours, facilitated and supported by NHS Provider Trusts and Cancer Networks.

This audit benefits from the knowledge and commitment of the National Clinical Audit Support Programme (NCASP) team, and the continued support of the Healthcare Commission.

For patients, the third report has extensive sections showing, for the first time, trust identifiable information and this will be expanded in future years.

Further pieces of the complex puzzle of head and neck cancer care have been revealed, and as comprehensive submissions continue to rise, a more complete picture of head and neck cancer will emerge. This report is another stride along this road.



*Richard Wight*

**Richard Wight FRCS**

Consultant Head and Neck Surgeon  
National Head and Neck Cancer Audit Project Chair



*Graham Putnam*

**Graham Putnam FRCS**

Consultant Head and Neck Surgeon  
National Head and Neck Cancer Audit Project  
Vice Chair

# 1 Executive Summary

The National Head and Neck Cancer Audit third annual report on the management of head and neck cancer in England and Wales includes a brief background to head and neck cancer (Section 2) and a description of the infrastructure, methods and analysis used within the audit (Section 3, 4 and 7).

Benefits and improvements and benefits from the audit and detailed recommendations are in sections 5 and 6.

Detailed findings in section 8 cover outcomes in both carcinoma of the larynx and oral cavity.

**The third annual report includes a wide variety of outcomes provided in a trust identifiable format for the first time.**

Throughout the document significant points for consideration are shown in shaded green boxes, whilst practical examples of methods that improve data collection and collation can be found in the Good Practice Example boxes and at: [www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits).

Submission by Provider Trust/Cancer Network is found in section 1, as well as listing those organisations who submit on behalf of other trusts.

## 1.1 What is DAHNO?

**DAHNO** (Data for Head and Neck Oncology), provides a continuous electronic comparative audit on management of head and neck cancer. It is supported by professional bodies and funded by the Healthcare Commission.

The disease burden of head and neck cancer is significant. Patients require intensive investigation, multi-modality treatments and rehabilitation with long-term support to achieve an adequate recovery.

**Core issues addressed in the first phase of the audit project are:**

- **Delivery of appropriate primary treatment (including adjuvant therapy) in the management of head and neck cancer affecting the larynx and oral cavity by a multi professional team.**
- **Delivery of care to agreed standards.**

## 1.2 What DAHNO adds to existing information

To confirm the quality of care delivered, anonymised data on individual patients needs to be collected and analysed. The head and neck cancer audit, continuously collects data at each patient service contact, and this record is continually updated. Clinical aspects of staging and other casemix factors can be more easily collected.

**In the third annual report the following findings are reported in Trust identifiable format:**

- Participation
- Number of new larynx and oral cavity cancer primaries
- Percentage of those cases submitted with T and N category recorded
- Interval from biopsy to reporting
- Percentage of cases discussed at MDT
- Interval from diagnosis to MDT
- Interval from diagnosis to first definitive treatment (radiotherapy and surgery).

## 1.3 Where head and neck cancer care happens - submission rates

### 1.3.1 Contributing Cancer networks in England and Wales

The third annual report covers the period 1 November 2006 to 31 October 2007. Each of the 36 Cancer Networks in England and Wales have had an opportunity to contribute.

2 networks failed to submit any cases - North London Cancer Network and South East London Cancer Network.

31 English Cancer Networks and all 3 Welsh Cancer Networks have submitted patient records, and the third annual report describes results for over 2,000 patient records – a 50 per cent increase. 13 Cancer Networks have managed to achieve high levels of registration with in excess of 90 per cent of the expected case numbers recorded.

### 1.3.2 Overview of case ascertainment

The data collection period (12 months) showed a rise in case ascertainment to 67 per cent (2,035 of an estimated 3,032 cases in England and Wales). In England, 1,882 cases of an estimated 2,820 cases were submitted (67 per cent) which is a significant rise with improved data completeness particularly on staging.

In Wales, 153 cases of an estimated 212 cases were submitted (72 per cent), which is a high level but with varying data completeness.

Whilst the improved case ascertainment is welcomed, **executive teams in organisations yet to contribute should ensure prioritisation of head and neck cancer in their audit programmes.** Participation in the head and neck cancer audit is part of the Healthcare Commission's Annual Health Check, and the peer review process continuing in 2008.

Complete and comprehensive submission provides a vehicle for assurance to trust boards and patient groups of the quality of care delivered in head and neck cancer. Additionally with complete data submission it will become possible to identify areas where action is required to ensure that care is improved to the highest standards.

## 1.4 Key overall findings

### 1.4.1 The pivotal role of the multi disciplinary (MDT) meeting

**Patient expectations and Improving Outcomes Guidance (IOG) are that all care discussions are made at a MDT, and head and neck cancer teams need to provide assurance to Trust boards on this aspect of care delivery.**

93 per cent of submitted cases were confirmed as having been discussed at a multidisciplinary meeting (this represents 74 per cent of patients submitted).

A small but significant number (5.8 per cent) were recorded as not having been discussed.

A number of providers have higher than average rates of non discussion and the project team will be alerting those organisations where high levels of not discussed are recorded to consider the reasons for this and to develop improvement plans.

20 per cent did not have this important item recorded, from which is not possible to be certain on the overall national discussion rate which could lie in the range 74 to 93 per cent. This still leaves doubt that treatment decisions for patients could be being made outside of MDTs.

### 1.4.2 Speech and language and dietetic provision

Pre-treatment speech and swallowing and dietetic assessment recording has improved but still only for a small percentage of registrations and is likely to reflect poor data quality. Whilst the expert panel members believe that this is not a true reflection of current practice, they are aware of nationwide shortages in allied health professional roles to support cancer MDTs. Patient representatives feel it is imperative that speech and swallowing and dietetic support is available to all patients with head and neck cancer from the point of diagnosis to enhance patient care.

## 1.5 Who receives the care?

1,045 cases of larynx cancer and 986 cases of oral cavity cancer were submitted.

Cancer of the larynx and oral cavity is again shown as a disease of older age groups in the pooled data of 46 months of data collection (90 per cent greater than 50 years old) with males predominating.

### 1.5.1 The patient journey

Consideration of submitted data and informal feedback from expert panels, demonstrates general dental practitioners do not appear to be embracing the two week rule referrals pathway in some networks and in others are not actively involved in the referral process. One in five oral cavity cancer patients are referred via the general dental practitioner/community dental service route, but of these only a quarter are via the two week wait urgent referral pathway. The networks need to examine local pathways and their effective usage.

Understanding is growing of factors responsible for recognition of signs and symptoms in patients that encourage a visit to a doctor or dentist. Furthermore, the variation of the interval from first recognition of suspicious symptoms to diagnosis, as shown by this audit, beg questions of the psychological response to possible malignancy, not only by patients but also care-givers.

There are several methods of obtaining a biopsy in order to reach a diagnosis, and the most appropriate method will be determined by the clinical presentation. The median time from biopsy to its reporting is 3 days for larynx and 4 days for oral cavity, which is an improvement. However, it is noted that 24 per cent of oral cavity cases reported have an interval greater than 10 days. **This is shown by provider trust and confirms this represents both a delay in a small number of organisations and a variation within providers.** To improve the patient pathway process mapping may identify areas where delays in the whole pathway could be reduced (from taking of a biopsy, through to its reporting). Manpower issues within pathology, and in particular head and neck pathology, remain a challenge.

A smaller number of patients show delays in diagnostic imaging, which is an improvement from the first report. **Local teams should assess the timeliness of imaging and seek to reduce delay if applicable.**

The investigation of cancer wait times was expected to reduce patient journey times, whilst median time has reduced in the study period, considerable work remains to achieve these targets for all patients. Booked care and clearly defined patient pathways are key factors to minimise delay. The site specific group should see performance reporting as a routine agenda item, supported by monitored action plans if avoidable delay is evident.

### 1.5.2 Care provided

In the treatment of laryngeal cancer patients, radiotherapy remains the most common first treatment. However, a previously noted trend in treatment via endolaryngeal resection, has not continued this year. The current evidence base does not support the superiority of one treatment over another. DAHNO provides a unique opportunity to track this and other treatment changes in a high quality clinical database containing sufficient information to allow casemix adjusted outcomes.

For surgery, the median interval from diagnosis to first recorded treatment is 25 days but for those undergoing primary radiotherapy a median time of 45 days was found, showing no reduction in comparison to the second annual report. An analysis by provider trust shows wide variation in intervals

within organisations as well as between organisations for radiotherapy.

The majority of oral cavity patients have surgery as a first treatment with a median time to operation of 33 days from diagnosis. For the smaller number who undergo primary radiotherapy the median interval to commencement of treatment is 52 days. An analysis by provider trust shows wide variation in intervals within organisations as well as between organisations for surgery.

**The interval to commencing radiotherapy has remained static, as highlighted in last year's report, this still suggests that head and neck cancer patients continue to have difficulty in accessing radiotherapy services.** Provider organisations for radiotherapy should review patient pathways, as well as the resource committed to head and neck cancer, with the aim of avoiding unnecessary delays.

The Expert Panels noted the importance of collection of actual care delivered along the whole patient pathway and that this is currently inadequate, to allow proper assurance in the complex multi professional management of head and neck cancer.

## 1.6 Recommendations

The third analysis has again demonstrated variability in record completeness between different organisations and between individual records. High levels of submission and completeness of records are required to gain the most value from the audit. NHS Provider Trusts and Cancer Networks should facilitate data collection through the MDT by providing resources, training and direction.

**Trusts, MDTs and site specific groups should review the recommendations below and develop action plans using the soon to be released action planning tool for any deficiencies.**

Trusts, MDTs and Cancer Networks should as a priority:

- **Develop a local action plan based on the findings in the audit using the action planning tool that has been developed by the National Head and Neck Cancer Audit team.**
- **Ensure that Cancer Networks reflect on where variation in access occurs within the network**

as identified in trust identifiable data and seek to examine pathways that underpin it.

- Ensure that tumour staging (TNM) is confirmed and recorded prior to care planning and following surgical procedures.
- Facilitate meeting patient expectations that all care discussions are being made at a MDT, and head and neck cancer teams need to provide assurance around this important aspect of care delivery. This is unanimously supported by the Expert panels.
- Ensure that all Cancer Networks and constituent Provider Trusts not achieving high levels or any level of case submission review their processes and support for submission of data. Best practice supporting data collection can be found at: [www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits).
- Ensure that all MDTs seek to accurately capture resective pathology information including pathological stage for every patient undergoing surgical treatment. This will enable true stage comparison of outcomes.
- Ensure that Provider Trusts uploading information via CSV commence preparation of CSV requirements to meet Phase II as well as attending future workshops.

Full details of all recommendations from the report can be found in Section 6.2. This should be used by organisations when formulating local action plans.

### 1.7 Key aspects for the current collection year November 2007 – October 2008

**Future versions of this annual report will increase reporting of outcomes by contributory provider trust and team, thus the importance of routine collection of factors that contribute to risk adjustment to allow true comparisons to be made (stage, co-morbidity and performance status).**

The index year cohort currently reported will be used to apply casemix adjustment and to develop a casemix adjustment model for the fourth report.

**Phase II has commenced and extends the audit to cover a wider range of anatomic sites (nasopharynx, oropharynx, hypopharynx**

**and major salivary glands) a wider range of pathologies and a more in depth assessment of multi-professional involvement (surgical voice restoration, dietetic and clinical nurse specialist).**

For Phase II a new system infrastructure is available – web DAHNO, and more information can be found at [www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits).

### 1.8 Good Practice

This year it has been possible to capture good practice happening across England and Wales which results in achieving excellent standards of care, case ascertainment and data quality. From this it has been possible to identify key factors which, if present, increase benefits gained by an organisation from participation in the audit.

Key factors influencing improvements in case ascertainment and data quality are:

- A committed clinical team who understand the benefits and requirements of the audit
- Close working between clinical and administrative staff in a supporting environment
- Dedicated administrative staff to capture data and provide data quality checks
- Close working relationships with the information and IT departments to maximise the use of technology in data capture and validation
- Systems and processes to check (ideally by clinicians) data to be entered into DAHNO.

Whilst there is still room for improvement, data completeness, levels of case ascertainment and data quality have improved significantly for a number of performance measures to be shown at trust level and have been incorporated into this report.

This report has included examples of good practice case studies showing how organisations have achieved good results.

### 1.9 Summary report

A summary report is in preparation and will be issued following the publication of this report. Its focus is for wider audience beyond the professional head and neck community. It will be available on line at: [www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits)

## 1.10 Participating Trusts

The data quality calculation can be found in Appendix 9.

The score if all expected cases are submitted with all index events is 100. An allowance is made for diagnostic only centres in comparison to diagnostic and treatment centres. A poor level of data completeness is recorded if a score of less than 26 is achieved, and reflects, for example 50 per cent of estimated cases with 50 per cent completeness. A submission of under five cases automatically records poor data completeness.

Figure 1.10 Participating Trusts

**KEY**

	Good Data Completeness
	Poor Data Completeness
	Not participating in 2006-2007 audit period

<b>3 Counties Cancer Network</b>
Gloucestershire Hospitals NHS Foundation Trust
Hereford Hospitals NHS Trust
Worcestershire Acute Hospitals NHS Trust
<b>Anglia Cancer Network</b>
Bedford Hospital NHS Trust
Cambridge University Hospitals NHS Foundation Trust
Hinchingbrooke Healthcare NHS Trust
Ipswich Hospital NHS Trust
James Paget Healthcare NHS Foundation Trust
Norfolk and Norwich University Hospital NHS Trust
Peterborough and Stamford Hospitals NHS Foundation Trust
The Queen Elizabeth Hospital King's Lynn NHS Trust
West Suffolk Hospitals NHS Trust
<b>Arden Cancer Network</b>
George Eliot Hospital NHS Trust
South Warwickshire General Hospitals NHS Trust
University Hospitals Coventry and Warwickshire NHS Trust
Worcestershire Acute Hospitals NHS Trust
<b>Avon, Somerset and Wiltshire Cancer Network</b>
North Bristol NHS Trust
Royal United Hospital Bath NHS Trust
Taunton and Somerset NHS Foundation Trust
United Bristol Healthcare NHS Trust
Weston Area Health NHS Trust
Yeovil District Hospital NHS Foundation Trust

**Central South Coast Cancer Network**

Basingstoke and North Hampshire NHS Foundation Trust

Isle Of Wight Healthcare NHS Trust

Portsmouth Hospitals NHS Trust

Royal West Sussex NHS Trust

Salisbury NHS Foundation Trust

Southampton University Hospitals NHS Trust

Winchester and Eastleigh Healthcare NHS Trust

**Derby Burton Cancer Network**

Burton Hospitals NHS Trust

Derby Hospitals NHS Foundation Trust

**Dorset Cancer Network**

Dorset County Hospitals NHS Foundation Trust

Poole Hospital NHS Foundation Trust

Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

**Essex Cancer Network**

Basildon and Thurrock University Hospitals NHS Foundation Trust

Essex Rivers Healthcare NHS Trust

Mid Essex Hospital Services NHS Trust

Southend Hospital NHS Trust

**Greater Manchester and Cheshire Cancer Network**

Bolton Hospitals NHS Trust

Central Manchester and Manchester Children's University Hospitals NHS Trust

Christie Hospital NHS Foundation Trust

East Cheshire NHS Trust

Pennine Acute Hospitals NHS Trust

Salford Royal NHS Foundation Trust

Stockport NHS Foundation Trust

Tameside and Glossop Acute Services NHS Trust

The Mid Cheshire Hospitals NHS Trust

Trafford Healthcare NHS Trust

University Hospitals of South Manchester NHS Foundation Trust

Wrightington, Wigan and Leigh NHS Trust

**Greater Midlands Cancer Network**

Dudley Group of Hospitals NHS Trust

Mid Staffordshire General Hospitals NHS Trust

Shrewsbury and Telford Hospital NHS Trust

The Royal Wolverhampton Hospitals NHS Trust

University Hospital of North Staffordshire NHS Trust

Worcestershire Acute Hospitals NHS Trust

**Humber and Yorkshire Coast Cancer Network**

Hull and East Yorkshire Hospitals NHS Trust

Northern Lincolnshire and Goole Hospitals NHS Foundation Trust

Scarborough and North East Yorkshire Healthcare NHS Trust

**Kent and Medway Cancer Network**

Dartford and Gravesham NHS Trust

East Kent Hospitals NHS Trust

Maidstone and Tunbridge Wells NHS Trust

Medway NHS Trust

Queen Victoria Hospital NHS Foundation Trust

**Lancashire and South Cumbria Cancer Network**

Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust

East Lancashire Hospitals NHS Trust

Lancashire Teaching Hospitals NHS Foundation Trust

University Hospitals of Morecambe Bay NHS Trust

**Leicestershire Northamptonshire and Rutland Cancer Network**

Kettering General Hospital NHS Trust

Northampton General Hospital NHS Trust

University Hospitals of Leicester NHS Trust

**Merseyside and Cheshire Cancer Network**

Aintree University Hospitals NHS Foundation Trust

Clatterbridge Centre for Oncology NHS Foundation Trust

Countess of Chester Hospital NHS Foundation Trust

North Cheshire Hospitals NHS Trust

Royal Liverpool and Broadgreen University Hospitals NHS Trust

Southport and Ormskirk Hospital NHS Trust

St Helens and Knowsley Hospitals NHS Trust

Wirral University Teaching Hospital NHS Foundation Trust

**Mid Trent Cancer Network**

Nottingham University Hospitals NHS Trust

Sherwood Forest Hospitals NHS Foundation Trust

United Lincolnshire Hospitals NHS Trust

**Mount Vernon Cancer Network**

East and North Hertfordshire NHS Trust\*

Luton and Dunstable Hospital NHS Foundation Trust

West Hertfordshire Hospitals NHS Trust

**North East London Cancer Network**

Barking, Havering and Redbridge Hospitals NHS Trust

Barts and The London NHS Trust

Homerton University Hospital NHS Foundation Trust

Newham University Hospital NHS Trust

Whipps Cross University Hospital NHS Trust

**North London Cancer Network**

- Barnet and Chase Farm Hospitals NHS Trust
- North Middlesex University Hospital NHS Trust
- Royal Free Hampstead NHS Trust
- The Princess Alexandra Hospital NHS Trust
- The Whittington Hospital NHS Trust
- University College London Hospitals NHS Foundation Trust

**North of England Cancer Network**

- City Hospitals Sunderland NHS Foundation Trust
- County Durham and Darlington NHS Foundation Trust
- Gateshead Health NHS Foundation Trust
- North Cumbria Acute Hospitals NHS Trust
- Northumbria Healthcare NHS Foundation Trust
- South Tees Hospitals NHS Trust
- South Tyneside NHS Foundation Trust
- The Newcastle upon Tyne Hospitals NHS Foundation Trust

**North Trent Cancer Network**

- Barnsley Hospital NHS Foundation Trust
- Chesterfield Royal Hospital NHS Foundation Trust
- Doncaster and Bassetlaw Hospitals NHS Foundation Trust
- Sheffield Teaching Hospitals NHS Foundation Trust
- The Rotherham NHS Foundation Trust

**Pan Birmingham Cancer Network**

- Heart Of England NHS Foundation Trust
- Sandwell and West Birmingham Hospitals NHS Trust
- University Hospital Birmingham NHS Foundation Trust
- Worcestershire Acute Hospitals NHS Trust

**Peninsula Cancer Network**

- Northern Devon Healthcare NHS Trust
- Plymouth Hospitals NHS Trust
- Royal Cornwall Hospitals NHS Trust
- Royal Devon and Exeter NHS Foundation Trust
- South Devon Healthcare NHS Foundation Trust

**South East London Cancer Network**

- Bromley Hospitals NHS Trust
- Guy's and St Thomas' NHS Foundation Trust
- King's College Hospital NHS Foundation Trust
- Queen Mary's Sidcup NHS Trust
- The Lewisham Hospital NHS Trust

**South West London Cancer Network**

Epsom and St Helier University Hospitals NHS Trust

Kingston Hospital NHS Trust

Mayday Healthcare NHS Trust

St George's Healthcare NHS Trust

The Royal Marsden NHS Foundation Trust

**Surrey, West Sussex and Hampshire Cancer Network**

Ashford and St Peter's Hospitals NHS Trust

Frimley Park Hospital NHS Foundation Trust

Royal Surrey County Hospital NHS Trust

Surrey and Sussex Healthcare NHS Trust

**Sussex Cancer Network**

Brighton and Sussex University Hospitals NHS Trust

East Sussex Hospitals NHS Trust

Worthing and Southlands Hospitals NHS Trust

**Thames Valley Cancer Network**

Buckinghamshire Hospitals NHS Trust

Heatherwood and Wexham Park Hospitals NHS Foundation Trust

Milton Keynes Hospital NHS Foundation Trust

Oxford Radcliffe Hospitals NHS Trust

Royal Berkshire NHS Foundation Trust

Swindon and Marlborough NHS Trust

**West London Cancer Network**

Ealing Hospital NHS Trust

Imperial College Healthcare NHS Trust

North West London Hospitals NHS Trust

The Hillingdon Hospital NHS Trust

West Middlesex University Hospital NHS Trust

**Yorkshire Cancer Network**

Airedale NHS Trust

Bradford Teaching Hospitals NHS Foundation Trust

Calderdale and Huddersfield NHS Foundation Trust

Harrogate and District NHS Foundation Trust

Leeds Teaching Hospitals NHS Trust

Mid Yorkshire Hospitals NHS Trust

York Hospitals NHS Foundation Trust

**North Wales Cancer Network**

Conwy and Denbighshire NHS Trust

North East Wales NHS Trust

North West Wales NHS Trust

**South East Wales Cancer Network**

Cardiff and Vale NHS Trust

Gwent Healthcare NHS Trust

North Glamorgan NHS Trust

Velindre NHS Trust

**South West Wales Cancer Network**

Bromorgannwg NHS Trust

Carmarthenshire NHS Trust

Ceredigion and Mid Wales NHS Trust

Pembrokeshire and Derwen NHS Trust

Swansea NHS Trust

Figure 1.11 Routes of Submissions by Trust

SUBMITTING TRUST	SUBMITS FOR
<b>3 Counties Cancer Network</b>	
Gloucestershire Hospitals NHS Foundation Trust	
Hereford Hospitals NHS Trust	
Worcestershire Acute Hospitals NHS Trust	
<b>Anglia Cancer Network</b>	
Bedford Hospital NHS Trust	
Cambridge University Hospitals NHS Foundation Trust	Hinchingbrooke Healthcare NHS Trust
Ipswich Hospital NHS Trust	
Norfolk and Norwich University Hospital NHS Trust	The Queen Elizabeth Hospital King's Lynn NHS Trust / West Suffolk Hospitals NHS Trust, James Paget Healthcare NHS Foundation Trust
Peterborough and Stamford Hospitals NHS Foundation Trust	
<b>Arden Cancer Network</b>	
South Warwickshire General Hospitals NHS Trust	
University Hospitals Coventry and Warwickshire NHS Trust	George Eliot Hospital NHS Trust
Worcestershire Acute Hospitals NHS Trust	
<b>Avon, Somerset and Wiltshire Cancer Network</b>	
North Bristol NHS Trust	United Bristol Healthcare Trust / Weston Area Health NHS Trust / Yeovil District Hospital NHS Foundation Trust
Royal United Hospital Bath NHS Trust	
Taunton and Somerset NHS Trust	
<b>Central South Coast Cancer Network</b>	
Basingstoke and North Hampshire NHS Foundation Trust	
Isle Of Wight Healthcare NHS Trust	

SUBMITTING TRUST	SUBMITS FOR
Portsmouth Hospitals NHS Trust	
Royal West Sussex NHS Trust	
Salisbury NHS Foundation Trust	
Southampton University Hospital's NHS Trust	
Winchester and Eastleigh Healthcare NHS Trust	
<b>Derby Burton Cancer Network</b>	
Derby Hospitals NHS Foundation Trust	Burton Hospitals NHS Trust
<b>Dorset Cancer Network</b>	
Poole Hospital NHS Foundation Trust	Dorset County Hospitals NHS Foundation Trust / Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
<b>Essex Cancer Network</b>	
Basildon and Thurrock University Hospitals NHS Foundation Trust	
Essex Rivers Healthcare NHS Trust	
Mid Essex Hospital Services NHS Trust	
Southend Hospital NHS Trust	
<b>Greater Manchester and Cheshire Cancer Network</b>	
Bolton Hospitals NHS Trust	
Central Manchester and Manchester Children's University Hospitals NHS Trust	
Christie Hospital NHS Foundation Trust	
East Cheshire NHS Trust	
Pennine Acute Hospitals NHS Trust	
Salford Royal Hospitals NHS Trust	
Stockport NHS Foundation Trust	
Tameside and Glossop Acute Services NHS Trust	
The Mid Cheshire Hospitals NHS Trust	
Trafford Healthcare NHS Trust	
University Hospitals of South Manchester NHS Foundation Trust	
Wrightington, Wigan and Leigh NHS Trust	
<b>Greater Midlands Cancer Network</b>	
Mid Staffordshire General Hospitals NHS Trust	
Shrewsbury and Telford Hospital NHS Trust	
The Royal Wolverhampton Hospitals NHS Trust	Dudley Group of Hospitals NHS Trust
University Hospital of North Staffordshire NHS Trust	
Worcestershire Acute Hospitals NHS Trust	
<b>Humber and Yorkshire Coast Cancer Network</b>	
Hull and East Yorkshire Hospitals NHS Trust	Scarborough and North East Yorkshire Healthcare NHS Trust / Northern Lincolnshire and Goole Hospitals NHS Foundation Trust

SUBMITTING TRUST	SUBMITS FOR
<b>Kent and Medway Cancer Network</b>	
East Kent Hospitals NHS Trust	
Maidstone and Tunbridge Wells NHS Trust	
Medway NHS Trust	Dartford and Gravesham NHS Trust
Queen Victoria Hospital NHS Foundation Trust	
<b>Lancashire and South Cumbria Cancer Network</b>	
Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust	
East Lancashire Hospitals NHS Trust	
Lancashire Teaching Hospitals NHS Foundation Trust	
University Hospitals of Morecambe Bay NHS Trust	
<b>Leicestershire, Northamptonshire and Rutland Cancer Network</b>	
Northampton General Hospital NHS Trust	Kettering General Hospital NHS Trust
University Hospitals of Leicester NHS Trust	
<b>Merseyside and Cheshire Cancer Network</b>	
Aintree University NHS Foundation Trust	
Clatterbridge Centre for Oncology NHS Foundation Trust	
Countess of Chester Hospital NHS Foundation Trust	
North Cheshire Hospitals NHS Trust	
Royal Liverpool and Broadgreen University Hospitals NHS Trust	
Southport and Ormskirk Hospital NHS Trust	
St Helens and Knowsley Hospitals NHS Trust	
Wirral University Teaching Hospital NHS Foundation Trust	
<b>Mid Trent Cancer Network</b>	
Nottingham University Hospitals NHS Trust	
Sherwood Forest Hospitals NHS Foundation Trust	
United Lincolnshire Hospitals NHS Trust	
<b>Mount Vernon Cancer Network</b>	
Luton and Dunstable Hospital NHS Foundation Trust	West Hertfordshire Hospitals NHS Trust, Bedford Hospital NHS Trust
East and North Hertfordshire NHS Trust (Mount Vernon Cancer Centre)*	West Hertfordshire Hospitals NHS Trust, North West London Hospitals NHS Trust, The Hillingdon Hospital NHS Trust
<b>North East London Cancer Network</b>	
Barking, Havering and Redbridge Hospitals NHS Trust	
Barts and The London NHS Trust	
Homerton University Hospital NHS Foundation Trust	

SUBMITTING TRUST	SUBMITS FOR
Newham University Hospital NHS Trust	
Whipps Cross University Hospital NHS Trust	
<b>North London Cancer Network</b>	
Barnet and Chase Farm Hospitals NHS Trust	
North Middlesex University Hospital NHS Trust	
Royal Free Hampstead NHS Trust	
The Princess Alexandra Hospital NHS Trust	
The Whittington Hospital NHS Trust	
University College London Hospitals NHS Foundation Trust	
<b>North Of England Cancer Network</b>	
City Hospitals Sunderland NHS Foundation Trust	South Tyneside NHS Foundation Trust / County Durham and Darlington NHS Foundation Trust
County Durham and Darlington NHS Foundation Trust	
North Cumbria Acute Hospitals NHS Trust	
South Tees Hospitals NHS Trust	
The Newcastle upon Tyne Hospitals NHS Foundation Trust	Gateshead Health NHS Foundation Trust, Northumbria Healthcare NHS Foundation Trust
<b>North Trent Cancer Network</b>	
Barnsley Hospital NHS Foundation Trust	
Chesterfield Royal Hospital NHS Foundation Trust	
Doncaster and Bassetlaw Hospitals NHS Foundation Trust	The Rotherham NHS Foundation Trust
Sheffield Teaching Hospitals NHS Foundation Trust	
<b>Pan Birmingham Cancer Network</b>	
Heart of England NHS Foundation Trust	
Sandwell and West Birmingham Hospitals NHS Trust	
University Hospital Birmingham NHS Foundation Trust	
Worcestershire Acute Hospitals NHS Trust	
<b>Peninsula Cancer Network</b>	
Northern Devon Healthcare NHS Trust	
Plymouth Hospitals NHS Trust	
Royal Cornwall Hospitals NHS Trust	
Royal Devon and Exeter NHS Foundation Trust	
South Devon Healthcare NHS Trust	
<b>South East London Cancer Network</b>	
Guy's and St Thomas' NHS Foundation Trust	King's College Hospital NHS Foundation Trust, Bromley Hospitals NHS Trust, Queen Mary's Sidcup NHS Trust
The Lewisham Hospital NHS Trust	

SUBMITTING TRUST	SUBMITS FOR
<b>South West London Cancer Network</b>	
Epsom and St Helier University Hospitals NHS Trust	
Mayday Healthcare NHS Trust	
St George's Healthcare NHS Trust	
The Royal Marsden NHS Foundation Trust	Kingston Hospital NHS Trust
<b>Surrey, West Sussex and Hampshire Cancer Network</b>	
Ashford and St Peter's Hospitals NHS Trust	
Frimley Park Hospital NHS Foundation Trust	
Royal Surrey County Hospital NHS Trust	
Surrey and Sussex Healthcare NHS Trust	
<b>Sussex Cancer Network</b>	
Brighton and Sussex University Hospitals NHS Trust	
East Sussex Hospitals NHS Trust	
Worthing and Southlands Hospitals NHS Trust	
<b>Thames Valley Cancer Network</b>	
Buckinghamshire Hospitals NHS Trust	
Heatherwood and Wexham Park Hospitals NHS Foundation Trust	
Milton Keynes Hospital NHS Foundation Trust	
Oxford Radcliffe Hospitals NHS Trust	
Royal Berkshire NHS Foundation Trust	
Swindon and Marlborough NHS Trust	
<b>West London Cancer Network</b>	
The Hillingdon Hospital NHS Trust	
Ealing Hospital NHS Trust	
Imperial College Healthcare NHS Trust	
West Middlesex University Hospital NHS Trust	
<b>Yorkshire Cancer Network</b>	
Bradford Teaching Hospitals NHS Foundation Trust	Airedale NHS Trust / Calderdale and Huddersfield NHS Foundation Trust
Leeds Teaching Hospitals NHS Trust	
Mid Yorkshire Hospitals NHS Trust	
York Hospitals NHS Foundation Trust	Harrogate and District NHS Foundation Trust
<b>North Wales Cancer Network</b>	
Conwy and Denbighshire NHS Trust	
North East Wales NHS Trust	
North West Wales NHS Trust	

SUBMITTING TRUST	SUBMITS FOR
<b>South East Wales Cancer Network</b>	
Cardiff and Vale NHS Trust	
Gwent Healthcare NHS Trust	
North Glamorgan NHS Trust	
Velindre NHS Trust	
<b>South West Wales Cancer Network</b>	
Bromorgannwg NHS Trust	
Carmarthenshire NHS Trust	
Ceredigion and Mid Wales NHS Trust	
Pembrokeshire and Derwen NHS Trust	
Swansea NHS Trust	

NB: For Figures 1.10 and 1.11 Cancer Networks listed reflect current configuration. Analyses within the body of the report are based on the configuration during the data collection period.

\* Due to an incorrect organisation code being used, data submitted by the East and North Hertfordshire NHS Trust (Mount Vernon Cancer Centre) in the Mount Vernon Cancer Network, is reported under The Hillingdon Hospital NHS Trust (West London Cancer Network)

## 2 Background to head and neck cancer and comparative audit

**For a broader introduction, please refer to the Second Annual report from which the synopsis below is derived.**

### 2.1 What is head and neck cancer?

Head and neck cancer describes a variety of neoplasms in the head and neck region. The definition excludes tumours of the brain and related tissues. Arising principally from the mouth (oral cavity), voice box (larynx) and throat / upper gullet (pharynx), head and neck cancers are amongst a group of the less common cancers, with approximately 6,700 new cases diagnosed in England and Wales each year<sup>12</sup>(ICD Codes C0-C14 and C30-C32).

The most common cancer sites are larynx and oral cavity, and more than 90 percent of all malignant tumours in the head and neck are squamous cell carcinomas (SCC) arising from the lining mucosa.

#### 2.1.1 Cancer sites

The following anatomical cancer sites are covered by the head and neck cancer audit:

- oral cavity: ICD-10 codes C00.3, 4 (mucosa of upper and lower lips) and C02-C06 (buccal mucosa, lower and upper alveolus, lower and upper gingiva, hard palate, dorsal and inferior tongue, floor of mouth)
- larynx: ICD-10 codes C10.1, C32.0, C32.1, C32.2, C32.8, C32.9 (supraglottis (including lingual surface of epiglottis), glottis and subglottis).

#### 2.1.2 Impact of head and neck cancer on patients

The disease burden of head and neck cancer is significant. Patients require intensive investigation, multimodality treatments and prolonged rehabilitation with long term support to achieve an adequate recovery.

The impact of disease on functions such as eating, drinking, speech, swallowing, smell, breathing and normal social interaction and work capabilities is significant.

Second primaries<sup>3, 4</sup> and locoregional recurrence in either the treated field or upper aerodigestive tract, mean that continued long-term surveillance is desirable.

### 2.1.3 Outcome in head and neck cancer

Cancers of the larynx and oral cavity are associated with significant mortality, for example, 5 year survival for larynx cancer is around 50 per cent.

Better prognosis is associated with early detection, while late presentation and neck node metastasis drastically reduce long term survival. The relatively poor survival prognosis for head and neck cancers is linked to lifestyle factors, co-morbidity, late presentation and the high median age of incidence.<sup>5,6</sup>

### 2.2 Measuring clinical care

Measuring clinical care has proven to be notoriously difficult. Establishing a national baseline is the first step in defining existing care delivery. This is a primary function of this national audit.

The core issue addressed in the first phase of the National Head and Neck Cancer Audit is:

- delivery of appropriate primary treatment (including adjuvant therapy) in management of head and neck cancer affecting the larynx and oral cavity by a multi-professional team, and delivery of care to agreed standards.

#### 2.2.1 Sources of existing information and differences that the head and neck cancer audit provides

The limitations of historic sources of head and neck cancer have been previously discussed and the first two reports<sup>7,8</sup> act as a national prospective baseline of information.

The DAHNO system continuously collects data at each patient service contact, and this record is continually updated. Clinical aspects of staging and other casemix factors can be more easily collected. There is a need to collect data to more accurately reflect the healthcare burden imposed by head and neck cancer.

With time this data will allow national assessment of outcomes and provide a tool to improve standards of care, identifying areas of good practice to the wider group of teams delivering head and neck cancer care.

## 2.3 Key partners and drivers in developing clinical audit

### 2.3.1 The National Clinical Audit Support Programme (NCASP) and Patient's Outcomes Programme

Both the National Clinical Audit Support Programme (NCASP) and Patients' Outcomes Programme, (Healthcare Commission), aim to foster high quality audits in which the clinical direction is provided through the appropriate national professional bodies and where management of the process, including project management and provision of IT, is undertaken by appropriate specialists.

The programmes are designed to support clinicians who wish to audit the quality of their care. The national audits provide benchmarking and comparative information via a quality assured approach applying risk adjustment (eg casemix adjustment) where necessary.

The National Clinical Audit Support Programme (NCASP), within The NHS IC, now manages audits in heart disease, diabetes and cancer. The majority of this work is commissioned directly by the Healthcare Commission.

There are three established national clinical audits in cancer, covering head and neck, lung and bowel cancers and two new audits in oesophago-gastric cancer and in mastectomy and breast reconstruction.

In the National Head and Neck Cancer Audit, NCASP works directly with representatives of the British Association of Head and Neck Oncologists (BAHNO) who provide the clinical direction and specialist clinical input.

The Healthcare Commission has contracted to fund this and the other cancer audits until 2009, but will be succeeded by the new commissioner, the Healthcare Quality Improvement Partnership, for the audits in 2008.

As well as providing feedback so that local clinicians and managers can identify where service improvements need to be made, further spurs to improve patient care may come in several ways:

- national reports summarise the key messages, often receiving considerable media attention when published
- since 2005/2006, information about participation in the projects is being used to cross-check Provider Trusts' self-assessments against the Core Standards, as part of the Healthcare Commission's new Annual Health Check
- from 2006/2007, findings from the projects will be used to help cross-check declarations that Provider Trusts make about Developmental Standards.

### 2.3.2: "NHS Plan" in England<sup>9</sup> and "Designed to tackle cancer" in Wales<sup>10</sup>, and cancer audit

The NHS quality agenda requires services to monitor quality of care delivered in a systematic way through clinical governance. Capacity to undertake clinical audit to monitor the quality of clinical care, specifically using national risk-adjusted clinical audit data, is a key component of clinical governance.

The Government is committed to introducing national comparative clinical audit to monitor clinical performance against agreed standards and indicators.

### 2.3.3 National Institute for Clinical Excellence (NICE) Improving Outcomes Guidance (IOG) for head and neck cancer

Clinical guidelines are recommendations by the National Institute for Clinical Excellence (NICE) on appropriate treatment and care of individuals with specific diseases and conditions within the NHS. They are based on best available evidence. Guidelines aim to help health professionals in their work, but they do not replace their knowledge and skills.

NICE commissioned the National Cancer Steering Group to develop service guidance on head and neck cancer for NHS use in England and Wales. The guidance was published in 2005<sup>11</sup> and provides recommendations for good practice that are based on best available evidence of clinical and cost effectiveness. The guidance can be found at: [www.nice.org.uk](http://www.nice.org.uk) and subsequently developed measures at: [www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Cancer](http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Cancer).

The areas addressed, include head and neck Cancer Network and MDTs, referral, diagnosis

and assessment, treatment services, post-treatment follow-up and care, prevention and awareness, patient centred care and palliative care. An active process of peer review of compliance with these measures is ongoing across England.

In Wales,<sup>12</sup> national standards for Head and Neck Cancer Services 2005 define the core aspects of the service that should be provided for cancer patients throughout Wales by March 2009. The standards are to be used in conjunction with other requirements for example, the National Institute for Clinical Excellence (NICE) recommendations.

## 3 DAHNO Application Infrastructure

### 3.1 The DAHNO System

The DAHNO (**D**ata for **H**ead and **N**eck **O**ncology) system which supports the head and neck cancer audit, provides both technical infrastructure for data collection across England as well as facilities for local and central data analysis to deliver continuous comparative audit. Data from Wales is collected within the Cancer Network Information System Cymru (CaNISC)<sup>13</sup> and uploaded to DAHNO.

Each hospital accesses its own local encrypted replica of the DAHNO application database so that the DAHNO application response times are not subject to any network delays.

Opening a database allows users to see all documents to which they have authorised access and in turn allows creation of new documents (either by directly keying in data or by importing data from a third party supplied data file) or editing of existing information.

Once data has been entered into the hospital's local DAHNO application database, the database is then synchronised with the central DAHNO application database so that data can be analysed, and subsequently reported on.

The application requirements and recommendations can be found in Appendix 4.

#### 3.1.1 DAHNO Application

The National Head and Neck Cancer Audit application (known as DAHNO - **D**ata for **H**ead and **N**eck **O**ncology) uses IBM Lotus Notes® and IBM Lotus Domino® as constituents for its software infrastructure. IBM Lotus Notes® and IBM Lotus Domino® are industry leading, client-server, collaborative document-management products incorporating robust security features, and have been widely adopted for use in the commercial sector.

IBM Lotus Notes® allows documents to be defined for data entry and display and treats collections of documents as 'databases'. Each document can be populated with all the design elements familiar to web users.

### 3.1.2 Data submission from Wales

Data from Wales, collected in a summary electronic patient record (CaNISC)<sup>13</sup>, is collated and uploaded to the DAHNO application as a CSV file.

### 3.2 DAHNO application security and patient confidentiality

#### 3.2.1 DAHNO application security

Security mechanisms are designed to ensure only authorised users access information on the DAHNO application database. Users only see records submitted by their own organisation (unless permission is given for them to view other organisations' data from other Provider Trusts / Cancer Networks). Several levels of security are built in to the system:

- ID security: the DAHNO application is accessed through use of an IBM Lotus Notes® ID, and that ID can be set to expire or have its access terminated, thus preventing unauthorised user access. A complex password is required to access the IBM Lotus Notes® ID (and thus, the DAHNO application itself) and that password can be set to expire after a given period forcing the user to change it regularly
- server security: the central (server-based) DAHNO database replica is also protected by server security so that no unauthorised persons can obtain access to it or replicate data to it
- application security: access to the IBM Lotus Notes® database is controlled by a database Access Control List (ACL), ensuring both non-repudiation (a user cannot deny that they have accessed data) and that users / organisations only access their own records. Users may be given 'read only' or editing rights. Users can delete records with correct permissions and if no child documents relate to that record.

The application is encrypted so if any unauthorised person tried to obtain the hard drive upon which the DAHNO application exists, they would also need an authorised ID file (and password knowledge) to access it. All system database accesses are recorded in a system log file that can be audited in event of suspected security threats or data misuse.

### 3.2.2 Patient confidentiality

Audit data is subject to strict rules of confidentiality. The National Clinical Audit Support Programme (NCASP) continues to work with the Healthcare Commission and the Patient Information Advisory Group (PIAG) to ensure that support is provided under Section 60 of the Data Protection Act for the collection and use of patient identifiable data. All current NCASP audits have PIAG support.

Cancer centres send the data to the DAHNO application via a secure connection to the NHS secure network (NHS Net) where it is securely stored on a highly encrypted national computer database. Once captured, the data is only accessible to people who store and analyse the data. Patients can choose to opt out of the audit, such that their details will not be stored or used for any purpose by the audit.

## 4 Methods and approaches

### 4.1 Methodology

A generic methodology in common with other National Clinical Audit Support Programme (NCASP) cancer audits was followed and was described in the Second Annual Report<sup>8</sup>.

### 4.2 Clinical aspects

#### 4.2.1 Inclusions and exclusions in the head and neck cancer audit Phase I

The National Head and Neck Cancer Audit aims to identify and include the following details from contributory centres:

- **new primary cases of squamous cell head and neck carcinoma involving the larynx and oral cavity**

For larynx, this comprises: cancer sites ICD-10 C10.1, C32.0, C32.1, C32.2, C32.8, C32.9 (supraglottis (including lingual surface of epiglottis), glottis and subglottis) and for oral cavity: cancer sites C00.3, 4 (mucosa of upper and lower lips) and C02-C06 (buccal mucosa, upper alveolus and gingiva, lower alveolus and gingiva, hard palate, tongue (lateral, dorsal and inferior) and floor of mouth).

These are identified from a range of sources:

- MDT meetings
- urgent two week wait rule referrals and other clinic booking systems
- pathology reports
- hospital patient administration systems (PAS)
- death certificates (via cancer registries and / or Office of National Statistics (ONS))
- **decompensation from co-morbidity at diagnosis**
- **whether management of cancer patients has been by an identified MDT and to agreed standards with equity of care and without undue delay**
- **the primary treatment modality(ies) received (including adjuvant therapy) for larynx and oral cavity**

- **disease eradication**
- **head and neck cancer specific mortality rate and age specific corrected survival.**

The exclusions in Phase I of the head and neck cancer audit are:

- cancers in anatomical cancer sites outside the larynx and oral cavity
- carcinoma in situ of the larynx and oral cavity
- non-squamous carcinomas and secondary carcinomas to the head and neck
- secondary treatment modalities for recurrent disease
- adverse events.

#### 4.3 Determining cancer centres: Provider Trusts managing head and neck cancer

Throughout the current year each Cancer Network has been invited to attend regional training sessions to both encourage the few yet to submit data, as well as to provide training and feedback to contributory individuals, Provider Trusts and Cancer Networks.

In Wales, submission of data is by upload from the CaNISC system, and a list of organisations providing head and neck cancer care in Wales was provided.

#### 4.4 DAHNO improvements rolled out in 2007

A Web-Accessible Interface (WAI) has recently been implemented in the existing DAHNO application following user feedback. The Web-Accessible Interface for DAHNO is currently running in parallel to the Notes-Client Accessible DAHNO (i.e. we have not yet decommissioned the Notes-Client interface) to give users time to switch over (the Web-Accessible Interface, and the Notes-Client Interface are interfaces to the same underlying DAHNO database, so no transfer of data is required when switching from one interface to the other).

The advantages of switching to the Web-Accessible Interface (WAI) for DAHNO are:

- 1) No more user licences are required - user access is based upon one server licence

- 2) Nearly all data-entry restrictions have been removed
- 3) Users directly access the central DAHNO application, so there is no need for time consuming communication between the central and local (hospital) database replicas
- 4) Because there are no local DAHNO database replicas, the probability of database corruption will be greatly reduced.

The WAI DAHNO application has been designed to accommodate data collection for Phase II of the National Head and Neck Cancer Audit, while NCA DAHNO remains only viable for Phase I data collection. However, a hospital can enter Phase I data using NCA DAHNO, and then switch to WAI DAHNO to compliment that information by entering Phase II data items. However, because of the advantages listed above, users are encouraged to switch from using NCA DAHNO, to WAI DAHNO as soon as they are able.

### 4.5 Priority outputs and rationale

**Refer to Appendix 5.**

### 4.6 Data standards

The audit dataset<sup>14,15</sup> a subset of the National Cancer Dataset (NCDS) received full operation standard approval from the Information Standards Board (ISB) in May 2006.

## 5 Benefits of Participation in the Audit. Why is comparative audit in head and neck cancer important?

**There are a number of key areas relating to head and neck cancer, which, if properly addressed, would be likely to have an impact on the incidence and outcomes of the disease. These can be summarised as follows:**

- i) prevention<sup>16</sup> (e.g. reduction in cigarette smoking and alcohol consumption)
- ii) earlier presentation of patients to secondary care (including screening)
- iii) timely and appropriate referral from the 'diagnostic' team to 'therapy' team (including process of staging)
- iv) management by multi-professional specialist teams
- v) consistent standards and patterns of treatment
- vi) timely access to treatment.

Multi-professional management is recognised as the gold standard, bringing substantial benefits. A previous audit<sup>17</sup> by BAHNO<sup>18</sup> has confirmed variation in management across geographically similar areas, and a variation in outcome. Reasons for this are unclear and could relate to a number of different factors:

- differing standards of clinical practice
- differing levels of co-morbidity
- differences in stage of disease at presentation
- variations in access to specialist treatment services
- artefacts of analysis methods in calculation of the population 'denominator' when deriving the treatment 'proportions'.

If we could match the outcomes from the districts with the lowest rates to those of the highest, we would probably be able to improve long-term survival rates without any therapeutic development.

Initially, the National Head and Neck Cancer Audit has focused on adherence to previously determined process standards<sup>19,20,21</sup>. A group led for BAHNO by Professor Martin Birchall, is currently developing a review of standards applicable to the audit. In time it is intended that the National Head and Neck Cancer Audit will have sufficient power to allow examination

of the relationship between standards of care and patient outcomes, such as mortality.

Wider benefits to the patient, clinical team and the organisation of participation in the audit are significant in supporting those caring for patients with head and neck cancer improve their services. These improvements in organisation of services and care for patients can only be realised if the service's current practice is known. This is what this audit aims to do – providing recommendations of good practice in head and neck cancer care, from an expert panel of MDT professionals, measuring practice against those standards and feeding this back to the organisations.

### 5.1 The Healthcare Commission and Annual Health Check

Participation is used in the Healthcare Commission's Annual Health Check of NHS Provider Trusts in England, to support monitoring quality and performance against agreed clinical standards and benchmarks, whether contained in National Service Framework (NSFs), National Institute for Clinical Excellence (NICE) guidelines or other national guidance.

In Wales, the Healthcare Strategy set out in 'Designed for Life'<sup>10</sup> requires that all cancer teams participate in all Wales clinical audit by March 2008.

### 5.2 England

One of the key commitments of the NHS Cancer Plan<sup>9</sup> and the subsequent Cancer Reform Strategy<sup>22</sup> (which applies to England only), is to bring survival rates up to the best in Europe. Achievement of this objective will depend critically upon:

- ensuring that patients are diagnosed and treated without unnecessary delays
- ensuring that patients receive optimal treatment, especially the initial treatment package given after the diagnosis of cancer.

The Cancer Reform Strategy builds on the progress of the Cancer Plan. It recognises the new challenges and opportunities facing cancer, such as rising incidence, advances in medical technologies, new drugs and

rising expectations amongst the public. An element of the strategy is clinical outcomes measurement.

### 5.3 Wales

One of the key commitments of the Assembly Government is to bring survival rates up to the best in Europe. The Assembly's policy 'Designed to Tackle Cancer in Wales'<sup>10</sup> requires all cancer teams using CaNISC<sup>13</sup> to be participating routinely in national clinical audits and benchmarking with teams in the UK and Europe where possible by March 2008.

### 5.4 Benefits of participation across the healthcare pathway

#### 5.4.1 For Patients

With ever increasing demand from patients to identify well performing services and high quality clinical care this audit can provide information to both patients and patient advocates to facilitate informed patient choice. Published best practice guidance can be used to improve communication between patient, families and carers with health professionals by providing a rationale for treatment options and what to expect in the care pathway.

*"The National Head and Neck Cancer Audit continues to provide a valuable tool for informing both patients and allied health professionals. It is an indicator of centres of clinical performance enabling a better service for patients with head and neck cancer. The DAHNO Team is to be congratulated yet again for their hard work in exploring other avenues and collating even more information for the benefit of both patient and clinician. Well done!"*

#### Christine Piff

Founder and Chief Executive of Let's Face It

#### 5.4.2 For National monitoring bodies

Healthcare organisations are increasingly scrutinised by external agencies seeking assurance on quality of care delivered. Measures of clinical quality are also likely to be used increasingly in the future to monitor the performance of individual doctors. Whilst mortality and other outcomes have traditionally been used as quality measures, confounding variables may mask significant differences in quality of care and correlation between mortality and clinical quality is often low. Measures of clinical process as found within the National Head and Neck Cancer Audit,

have many advantages<sup>23</sup> over outcomes, especially where these are accepted universal components of head and neck care and have a greater potential to reflect team performance. They also have a much shorter audit cycle compared to 5 year survival figures in isolation.

#### 5.4.3 For Commissioners of Services

As for patients, this comparative, continuous, national audit is a tool for commissioners of head and neck cancer services to be assured of the timeliness, quality and performance of local provision. Year on year reporting facilitates benchmarking and adjustment to reflect local differences in disease extent and contributory factors. It can be used to inform investment and development and be used constructively in a dialogue in improving quality of clinical care.

#### 5.4.4 For Clinicians and Clinical Teams

The audit aims to produce a national and local picture of care for patients with head and neck cancer against a number of professionally agreed best practice standards. This baseline measurement and comparator is the starting point in developing and improving clinical practice at a local level. The evidence gained in the audit can be used at both a local and national level as hard evidence for the development of services. The audit is also useful in the education and training of healthcare professionals across the multi-disciplinary team and participation can demonstrate a commitment to quality improvement activities required to meet professional appraisal requirements.

“To have a national database that is of a high standard is mandatory in the modern NHS. It will, with time, not only benefit patients in their outcomes from treatment, but clinicians in delivering evidence based medicine. Due to the low number of cases no one unit / MDT can accumulate enough cases in a short time to get a clear picture of outcome. With the National Head and Neck Cancer audit this is now happening and with full data entry on all cases, this will occur sooner rather than later.

This is starting to alter the way care is delivered even now, and it is answering some of the questions on regional treatment differences within head and neck cancer. With more data a clearer picture will appear resulting in improved patient outcomes. So I appeal to all to contribute and complete all data fields.”

**Simon C Hodder FDS, FRCS, Dip FM**  
Consultant Oral Maxillofacial Head and Neck Surgeon  
Chair All Wales Head and Neck Steering Group

The provision of appropriate professional support throughout the patient pathway should be seen as a priority requirement. Expert Panel members realise this has significant resource implications, but their view is also that speech and language therapists (SALT) and dietetic input is mandatory. They hope all MDTs strive to achieve this input. Resource bids would be supported by accurate data collection, helping to quantify deficit, and its correct capture onto the DAHNO application would identify the national profile of provision.

The accumulated data within DAHNO (now some 5,000 cases) is helping to build a high quality clinical database (HQCD)<sup>24</sup> from consecutive cases which can provide significant research opportunities from anonymised data in the future. This database provides both comprehensive and accurate information, including recording patient details that affect outcome. With sufficient data on confounding variables, answers may be provided to questions comparing treatments that randomised controlled trials will never achieve sufficient power to answer.

#### 5.4.5 For Provider Organisations

As mentioned previously participation is used in the Healthcare Commission's Annual Health Check<sup>25</sup> of NHS Provider Trusts in England, to support monitoring quality and performance against agreed clinical standards and benchmarks. Participating organisations are given information upon which they can judge the performance of their clinical services and target resources to specific areas requiring improvement. Benchmarking of local services against peer organisation is also enabled with a view to driving up the quality of service provision.

#### 5.5 Realising the benefits

The true benefits are realised when clinical teams, supported by their organisations, read, discuss and act on the findings of national audits.

This third report, which has increased the amount of trust identifiable analysis, is providing organisations with evidence of their clinical performance against the national picture and standards of good practice, augmented by local reports given to trusts submitting more than 10 cases. Using the recommendations made in this report, a Local Action Planning toolkit will be issued to all organisations to help facilitate change in practice (where this is required).

# 6 Improvements and Recommendations

Having collected data for 3 years, it is now possible to track improvements over time and to identify areas of practice which still require further attention.

## 6.1 Improvements


### 6.1.1 Case ascertainment

Over the life of the audit it is clear to see that there has been a significant increase in the number of cases entered into the audit. This is a result of more trusts participating and existing organisations improving their processes for capturing patients.

#### Good Practice Standard

All trusts providing head and neck cancer care, whether diagnosing and/or treating should submit data to the National Head and Neck Cancer Audit.

Figure 6.1.1 Percentage of patients submitted against national estimate



#### Good Practice Example

There are a number of different approaches across the country in how trusts ensure maximum case submission. At The Newcastle Upon Tyne Hospitals NHS Foundation Trust, the MDT coordinator captures details of all patients attending the MDT onto a proforma and then enters them into DAHNO. A mid-year local audit is used to check those patients entered onto DAHNO with diagnosed patients entered into the pathology system. This results in a high case ascertainment figure for the trust.

### 6.1.2 Data quality


Data quality has improved significantly over the last year with the average for all trusts increasing from 80 to 139. This calculation was not available in 2005. How the calculation is derived can be found in Appendix 8.

Developments, in both processes at trust level and within the administration of the audit at national level, have resulted in improvements in the overall quality of the data submitted. However, the number of cases where key data is not recorded is still unacceptably high.

#### Good Practice Standard

All trusts providing head and neck cancer care, whether diagnosing and/or treating should submit comprehensive and complete data to the National Head and Neck Cancer Audit.

Figure 6.1.2 Trust score of data quality



#### Good Practice Example

Close collaboration between data in-putter and clinical team has been identified as key to achieving high quality data in DAHNO. At the Royal Devon and Exeter NHS Foundation Trust, data quality is achieved in staging from having the data coordinator work closely with the clinician, this improves the knowledge base of the coordinator and a process is established to ensure good quality data in the system.

**Good Practice Example**

Data quality is seen as a key organisational issue at the North Cumbria Acute Hospitals NHS Trust where they have implemented a trust wide policy to ensure the quality of data produced in-house for national audits as well as other performance monitoring activities. Again a team approach to improving data quality is implemented with the data clerk attending the MDT discussion, capturing the data and reducing errors and increasing completeness of data.

**6.1.2.1 Co-morbidity**

Recording of co-morbidity has risen steadily over the last three years from 18 per cent to 30 per cent, but this is still unacceptably low when the recording of this is so important.


Severity of co-morbidity is associated with survival, selection of initial treatment and the assessment of the quality of care given. In many cases co-morbidity may be more important than tumour site, or TNM staging, in determining the patient's prognosis. It is particularly important in slow growing cancers and those affecting older people such as oral cavity, pharynx and larynx.

The derivation of a co-morbidity score can be achieved with minimum resource by use of a patient self completion questionnaire. A score derivation chart can be found in Appendix 8 and the questionnaire at [www.ic.nhs/canceraudits](http://www.ic.nhs/canceraudits).

**Good Practice Standard**

The influence of factors such as co-morbidity and performance status can have a significant effect upon treatment outcomes. MDTs are encouraged to collect these data items.

Figure 6.1.2.1 Percentage of cases submitted with co-morbidity recorded

**Good Practice Example**

At The Newcastle Upon Tyne Hospitals NHS Foundation Trust, the MDT meeting is the focal point for collecting data for the audit, including co-morbidity. An enthusiastic lead clinician ensures all staff are familiar with the requirements of co-morbidity collation and works closely with other clinical colleagues and administrative staff to record this aspect of care.

**6.1.3 Number of patients seen at MDT**

Of the total cases submitted, the number of patients recorded as seen at the MDT has gradually risen to 74 per cent in 2007 from 68 per cent in 2005, which is encouraging for such an important element of care. Though there is still room for more improvement.


Effective MDT working is critical for treatment planning. All patients should be discussed. Effective coordination of MDT meetings helps to ensure that:

- All relevant information is available
- Decisions are recorded and communicated to all relevant parties
- Waiting times are monitored proactively
- Further steps are planned, booked and coordinated.<sup>26</sup>

**Good Practice Standard**

Patient expectations are that all care discussions are being made at a MDT, and head and neck cancer teams need to provide assurance around this important aspect of care.

Figure 6.1.3a Percentage of cases discussed at MDT



**Good Practice Example**

At Mid Yorkshire NHS Trust the patient pathway coordinator is key to ensuring all patients are seen at the MDT and that the appropriate documentation is available. They also have a MDT alert system for patients referred to Leeds for treatment. As a result of these systems and processes this trust has achieved a high level of patients being seen at the MDT.

Figure 6.1.3b Percentage of cases where discussion at MDT is not recorded



**Good Practice Example**

At Northampton General Hospital NHS Trust excellent MDT attendance is achieved through having an effective process linking the histopathology system into the MDT, by producing a list of all newly diagnosed patients as the agenda for the meeting. This ensures that no patient is missed off the MDT list. A similar approach is also made at The Royal Wolverhampton Hospitals NHS Trust.

Figure 6.2 Issues and recommendations

**KEY RECOMMENDATIONS – high priority in red text**

**N = NETWORK T = PROVIDER TRUST U = USERS P = PROFESSIONS D = DAHNO PROJECT M= Multidisciplinary teams**

<i>Issues</i>	<i>Recommendations (high priority in blue text)</i>	<i>Group to action</i>
<p><b>6.2.1 Developing a local response to the audit findings</b></p>	<ul style="list-style-type: none"> <li>• Each trust should develop an action plan based on the findings in the audit.</li> <li>• An action planning tool will be released to coincide with production of local reports in summer 2008</li> <li>• Networks should facilitate comprehensive introduction of the action planning tool</li> <li>• A local analysis tool has been commissioned by NCASP and will be available in autumn 2008 to support local analysis of a selection of outputs</li> </ul>	<p><b>N</b> <b>T</b> <b>U</b> <b>M</b></p>
<p><b>6.2.2 Developing a network response to the audit findings</b></p>	<ul style="list-style-type: none"> <li>• Each network should liaise with provider trusts to support a comprehensive audit process in head and neck cancer</li> <li>• The network should encourage head and neck tumour site specific groups to regularly discuss comparative audit on their agendas and provider trusts to provide an appropriate infrastructure</li> <li>• Networks should reflect on where variation in access occurs within the network as identified in trust identifiable data and seek to examine pathways that underpin it</li> </ul>	<p><b>N</b> <b>T</b> <b>M</b></p>

N = NETWORK T = PROVIDER TRUST U = USERS P = PROFESSIONS D = DAHNO PROJECT M= Multidisciplinary teams

Issues	Recommendations (high priority in blue text)	Group to action
<p><b>6.2.3 Clinical issues for multi-disciplinary teams</b> A number of issues have been highlighted in the report. The Expert Panel had concerns about the care delivered, based on the data submitted. This may reflect the absence of collection rather true practice. However, the teams should assess their local delivery against the items opposite.</p>	<p><b>MDTs should:</b></p> <ul style="list-style-type: none"> <li>• Ensure the timeliness of pathways to meet national access targets</li> <li>• Ensure the awareness and involvement of general dental practitioners and community dental services in urgent cancer referral processes</li> <li>• Ensure that speech and language therapists and dieticians have active involvement in patient management and their care pathways (see below re Phase II)</li> <li>• <b>Ensure that tumour staging (TNM) is confirmed and recorded prior to care planning and following surgical procedures</b></li> <li>• Ensure that good dental health is maintained throughout treatment</li> <li>• Ensure provision of surgical voice restoration counselling, pre treatment, for all patients having a laryngectomy</li> <li>• Ensure provision of swallowing counselling, pre-treatment, for all patients who are about to undergo oral and oropharyngeal resective and or reconstructive surgery with free tissue transfer or partial laryngo-pharyngeal surgery</li> <li>• Should ensure that delays in commencement of radiotherapy/chemotherapy – either as primary or adjunctive treatment- are minimised</li> <li>• Ensure the recording of all treatments by identifying and documenting any reasons for the provision of chemotherapy in isolation as first line treatment, and where it is used as part of a chemo-radiation regime.</li> <li>• <b>Facilitate meeting patient expectations that all care discussions are being made at a MDT, and head and neck cancer teams need to provide assurance around this important aspect of care delivery. This is unanimously supported by the expert panels.</b></li> <li>• Each MDT should review on a case by case basis as to why decisions are made outside of the MDT, and put steps in place to ensure all cases are discussed</li> <li>• Teams should confirm that chest imaging has occurred in all head and neck cancer patients prior to planning treatment as synchronous malignancies of the chest can occur and have a significant impact on treatment options.</li> <li>• For accurate understanding of care pathways it is important that all components of a surgical procedure are recorded to provide a true reflection of the breadth and complexity of surgical management.</li> <li>• A general theme of the analysis is that the second phase of treatment is not being well captured. This may reflect MDT data capture processes. Teams are encouraged to capture all parts of the patients' careplan.</li> </ul>	<p>N T M U</p>
<p><b>6.2.4 Standards in clinical care</b> Professional bodies, led by the British Association of Head and Neck Oncologists (BAHNO) and facilitated by the National Head and Neck Cancer Audit team, are evolving clinical standards.</p>	<p>Support and comply with evolving clinical standards as they become available in 2008.</p>	<p>N T U P</p>

**N = NETWORK T = PROVIDER TRUST U = USERS P = PROFESSIONS D = DAHNO PROJECT M= Multidisciplinary teams**

<i>Issues</i>	<i>Recommendations (high priority in blue text)</i>	<i>Group to action</i>
<p><b>6.2.5 Data quality and completeness</b> The public should have access to accurate and risk adjusted clinical information.</p> <p>Absence of submission completeness on key fields eg certainty factor, performance status and co-morbidity.</p> <p>67 per cent of potential records submitted. Two Cancer Networks have no submissions to this second annual report.</p> <p>Absence of resective pathology information in submissions.</p>	<ul style="list-style-type: none"> <li>Each provider trust should seek to provide assurance on the quality and timeliness of care delivered to head and neck cancer patients by comprehensive and continuous contribution to the audit.</li> <li>The head and neck cancer audit team will continue to expand the volume of trust identifiable data reported as data becomes more robust.</li> </ul> <p>To provide risk adjustment requires high levels and data quality and completeness. During audit rollout assumptions have been made that poor or missing data did not necessarily represent actual treatment given. Now that the audit is established this assumption is inappropriate and poor or missing data will be reflected as the treatment given:</p> <hr/> <ul style="list-style-type: none"> <li>Networks should increase local awareness and encourage compliance with the audit</li> <li>Provider Trusts should support local provision of data collection not only at commencement of treatment, but through follow up to include data on current treatment and rehabilitation</li> <li>Users and professionals should contribute to both support data collection and maintain consistency and quality of data collected.</li> </ul> <p>Users should familiarise themselves with all the items detailed within the audit, and use opportunities to attend DAHNO workshops. The influence of factors such as co-morbidity and performance status can have a significant effect upon treatment outcomes. Therefore all MDTs should collect these data set items.</p> <hr/> <p>All Cancer Networks and constituent Provider Trusts not achieving high levels or any level of case submission should review their processes and support for submission of data. Best practice supporting data collection can be found at: <a href="http://www.ic.nhs.uk/canceraudits">www.ic.nhs.uk/canceraudits</a></p> <hr/> <p>All MDTs should seek to accurately capture resective pathology information including pathological stage for every patient undergoing surgical treatment. This will enable true stage comparison of outcomes.</p>	<p>T M D</p> <p>N</p> <p>T U P</p> <p>U D</p> <p>N T U P</p> <p>N T U P</p>
<p><b>6.2.6 Data process issues</b> Continued identification of teams delivering cancer care.</p> <p>Absence of data submission on dietetic, speech and language, radiotherapy, palliative care activity.</p>	<p>All networks will be regularly contacted by the Head and Neck cancer audit team to confirm contacts at Provider Trusts/hospitals that deliver head and neck cancer care.</p> <hr/> <p>Organisations should review the data collection process and ensure that it extends across the whole pathway.</p>	<p>D N</p> <p>N T U</p>

**N = NETWORK T = PROVIDER TRUST U = USERS P = PROFESSIONS D = DAHNO PROJECT M= Multidisciplinary teams**

<i>Issues</i>	<i>Recommendations (high priority in blue text)</i>	<i>Group to action</i>
<p><b>6.2.7 Application issues-web DAHNO and Phase II</b> Launch of web DAHNO.</p> <p>Uploading from third party systems.</p> <p>Reporting of import errors.</p>	<p>A web based access to DAHNO has been introduced (January 2008) in response to user requests for a more user friendly environment . Details on this and registration requirements can be found at <a href="http://www.ic.nhs.uk/canceraudits">www.ic.nhs.uk/canceraudits</a></p> <p>The web version contains all the required fields for Phase II.</p> <p>-----</p> <p>The head and neck cancer audit team continue to advise IT providers of requirements to achieve successful upload.</p> <p>Provider trusts uploading information should perform this on a regular basis throughout the index year</p> <p><b>Provider trusts uploading information via csv should commence preparation of csv requirements to meet Phase II as well as attending future workshops</b></p> <p>-----</p> <p>The head and neck cancer audit team to proactively advise users via central import log of issues with import.</p>	<p><b>D U</b></p> <p><b>D</b></p> <p><b>T D U</b></p> <p><b>T D U</b></p>
<p><b>6.2.8 Audit data to support clinical process</b> Contemporaneous data collection</p>	<p>Although DAHNO is an audit process the timely collection of patient pathway data can support and expedite the overall delivery of patient care.</p>	<p><b>N T U</b></p>

## 7 Statistical methods used for data analysis

The presented information is an analysis of a sample of larynx cancer and oral cancer cases from hospital Provider Trusts across England and Wales. Most of the reported measures are either a count of cases or a percentage of total recorded cases. Notes accompanying each measure seek to make the basis of the calculations clear. The interpretation of the results must take into consideration the incomplete ascertainment of the cohort; not all incident cases in England and Wales have been entered onto the system, and many of those cases that are recorded have data items which have not been entered.

- Counts are the totals number of records (usually of patients) in the DAHNO application data extract with a specific record value, or in some cases a count of records with a recorded value.
- The calculation of percentages involves a count and a denominator. The choice of denominator is complicated by incompleteness. For certain measures the selected denominator is the total number of registrations, for others it has been more appropriate to use the number of registrations with any recorded value for a particular data item.

The quality of any data analysis is dependent upon the ascertainment, completeness and accuracy of the data submitted. Analysis is based purely on the data submitted to the DAHNO application by contributing Provider Trusts. It is important to recognise that because some records are incomplete, the published information is based on fewer than the total number of registered cases. Particularly vulnerable are the interval calculations, for instance, the interval from referral to first appointment, broken down by two week wait referrals and others (as in section 8.5.4); if a record has either of the two dates or referral details missing, that record cannot contribute to the chart.

Data is presented as a simple description of data gathered during work-in-progress. As the quality and quantity of data improves, more sophisticated analyses will become possible. The data for analysis was extracted from the DAHNO application as a collection of text files (CSV format).

Analysis was carried out using Stata® 8.1, Microsoft® Access 2000 and Microsoft® Excel 2000.

## 8 Findings

### 8.1 Introduction

The following analysis was performed by the Cancer Registries on data extracted from the DAHNO application database in accordance with the Data Analysis for Annual Report Specification version 0.2 November 2007, supplied to the Cancer Registries by the National Head and Neck Cancer Audit Project Team. Further analyses were performed at the request of the Expert Panels. The data extract period includes patient records with a 'date of diagnosis' between 1 November 2006 and 31 October 2007 inclusive.

### 8.2 Analysed data


Over 2,100 patient diagnoses have been included in the analysis. This has increased by approximately 50 per cent from the first National Head and Neck Cancer Audit Annual Report and 40 per cent from the second annual report. Data has again been included from Wales.

Figure 8.2.a: Submitted diagnoses by year

	04-05	05-06	06-07
<b>Diagnoses submitted</b>	1,042	1,446	2,130
<b>Submissions from</b>	England only	England and Wales	England and Wales
<b>Months of audit</b>	21	13	12
<b>Estimate for period of audit</b>	4,454	2,945	3,032
<b>Corrected annual estimate</b>	2,545( England only)	2,718	3,032
<b>Percent of estimate</b>	23%	49%	67%
<b>Larynx cancer</b>	561	745	1,049
<b>Oral cavity cancer</b>	477	698	986

If all estimated cases had been collected, the total would have exceeded 3,000. The estimated figures have risen year on year (a correction factor to the estimation in the first annual report has been included) to reflect the overall rise in cancer incidence. The information presented in this report is, therefore, a snapshot of the total population. The following chart shows an overview of data collected for larynx and oral cavity cancer for cases with data of diagnosis between 1 November 2006 and 31 October 2007.

Figure 8.2.b: Analysed Data



A considerable improvement in case ascertainment has occurred with 67 per cent of estimated incident cases being recorded within the database, compared with 49 per cent in 2005-2006. Comprehensive case ascertainment remains a goal for future iterations of the audit to ensure a representative reflection of current English and Welsh head and neck cancer management.

95 diagnoses were excluded from the analysis because of inconsistent diagnosis data, 40 had non larynx or oral cavity site codes, 1 was an unresolved case of site of diagnosis and 54 duplicates were removed.

Of the 1,047 patients with larynx cancer, 1,045 had a single tumour and 2 had two tumours in the index year.

Of the 986 patients with oral cavity cancer, 960 had a single tumour in the index year, 11 patients had two tumours and a single patient had four tumours.

As this is a continuous audit with annual reporting years, inevitably some patients will complete the treatment phase of their pathway beyond the reporting year. 58 patients with a date of diagnosis prior to 1 November 2006, subsequently had treatment and the types of first definitive treatment administered are described below:-

**Figure 8.2.c:** Cases of larynx and oral cavity cancer with date of diagnosis included in second annual report but who had treatment after 31 October 2006.

	Larynx	Oral Cavity
<b>Surgery</b>	8	14
<b>Chemotherapy</b>	9	3
<b>Radiotherapy</b>	12	12
<b>TOTAL</b>	<b>29</b>	<b>29</b>

A review of new diagnoses with a diagnosis date prior to 1 November 2006, submitted after the close of the index year for the second annual report, shows that contributors have added a further 394 cases (182 larynx and 212 oral cavity cancers). Future reports will seek to look cumulatively beyond the reporting year. Users are encouraged to provide both diagnostic and treatment data as close as possible to the point of care delivery.

### 8.3 Where head and neck cancer care happens


2,035 cases were presented for analysis, with a date of diagnosis between 1 November 2006 and 31 October 2007. These comprised 1,049 (51.5 per cent) laryngeal cancers and 986 (48.5 per cent) oral cavity cancers. A breakdown of registrations by anatomic sub-site is included in Figure 8.3.1a.

#### 8.3.1 Number of patients registered with new head and neck primaries of the larynx and oral cavity

**Figure 8.3.1.a:** Number of registered new head and neck primaries of the larynx and oral cavity.

Number of patients registered by Site		
	Site	Total
Larynx	Glottis	547
	Supraglottis	258
	Larynx, unspecified	203
	Subglottis	22
	Anterior surface of epiglottis	19
<b>Larynx Total</b>		<b>1,049</b>
Oral cavity	Border of tongue	236
	Anterior floor of mouth	97
	Ventral surface of tongue	88
	Cheek mucosa	84
	Hard palate	69
	Dorsal surface of tongue	67
	Lower gum	59
	Retromolar area	54
	Overlapping lesion of floor of mouth	47
	Lateral floor of mouth	37
	Vestibule of mouth	35
	Upper lip, inner aspect	35
	Upper gum	35
	Overlapping lesion of tongue	33
	Lower lip, inner aspect	6
Mouth, unspecified	4	
<b>Oral Cavity Total</b>		<b>986</b>
<b>Total</b>		<b>2,035</b>

Figure 8.3.1.b: Number of patients registered with new head and neck primaries of the larynx and oral cavity.



In larynx, as expected, glottic cancers predominate, (52 per cent), with 25 per cent occurring in the supraglottis. This was a similar distribution to that seen previously. 'Larynx NOS' (not otherwise specified) represents those cancers which involve cartilage, multiple sub-sites, and are also referred to as transglottic tumours, or it reflects failure to delineate the site of tumour origin.

The number of subglottic tumours previously, in 2005-2006, appeared higher than expected (2.7 per cent compared to 1.7 per cent of all ONS registrations) but was thought likely to reflect a sampling bias. The finding this year of 1.8 per cent is more directly comparable to the ONS expected figure.

In oral cavity, tumours of the lateral border of the tongue are the most common cancer site, (24 per cent), with a more even distribution amongst the remaining sub-sites. The hard palate (7 per cent compared to 2 per cent of all ONS registrations) appears to be, again, over represented as in 2005-2006. The expert panels reflected that this figure may be increased by difficulties in determining the boundary between hard and soft palate and the alveolar process. The inclusion of oropharynx in the 2007-2008 collection year will help define this further. 4 records included in 'unspecified oral cavity' have no specific cancer site code record. This was less than that seen previously.

### 8.3.2 Estimate of total number of patients with new head and neck primaries of the larynx and oral cavity in the index period

The following figure includes an estimate of the expected number of cases of larynx and oral cavity cancers per year in England and Wales. The estimate of new head and neck primaries of the larynx and oral cavity for England were taken from the CIS for the diagnosis year 2004. The estimates by Cancer Network in England were adjusted by the overall percentage increase in England as a whole, compared with the previous estimates for Cancer Networks in England from the first and second report. The corresponding figure for Wales (and Cancer Networks) was taken from the Welsh Cancer Intelligence and Surveillance Unit for the diagnosis year 2004<sup>2</sup>.

The estimate consists of 2,820 cases in England, comprises 1,691 larynx cancers and 1,129 oral cavity cancers. In Wales, there were 209 cases, of which 114 cases were larynx and 95 cases were oral cavity.

Cancer registry data provides a good estimate of new cases, which allows for incident cases not attending at hospital. It includes a wider selection of tumour sites than oral cavity and larynx. The ONS all registrations data<sup>1</sup> was used to calculate the proportion of all head and neck cancers that are categorised as oral cavity or larynx. Although Cancer Networks serve a geographically defined population, they may also see cross border referrals.

Figure 8.3.2.a: Estimate of total number of patients with new head and neck primaries of the larynx and oral cavity in the index period.

Cancer Network	DAHNO registrations	Estimate for 12 months	DAHNO registrations as % of estimate
Yorkshire Cancer Network	201	145	139
Northern Cancer Network	147	144	102
Pan Birmingham Cancer Network	135	112	121
Peninsula Cancer Network	127	106	120
Mid Trent Cancer Network	112	95	118
Cancer Care Alliance of Teesside, South Durham and North Yorkshire	96	59	162
Leicestershire, Northamptonshire and Rutland Cancer Network	89	71	125
Merseyside and Cheshire Cancer Network	80	146	55
Avon, Somerset and Wiltshire Cancer Network	78	99	79
Derby/Burton Cancer Network	67	39	172
North Trent Cancer Network	63	96	66
Greater Midlands Cancer Network	59	107	55
Sussex Cancer Network	56	56	100
Three Counties Cancer Network	48	58	83
Dorset Cancer Network	48	47	102
Arden Cancer Network	47	47	100
Humber and Yorkshire Coast Cancer Network	47	58	81
West Anglia Cancer Network	45	85	53
Norfolk and Waveney Cancer Network	44	40	110
Thames Valley Cancer Network	43	113	38
Mid Anglia Cancer Network	34	47	73
South Essex Cancer Network	30	31	96
Greater Manchester and Cheshire Cancer Network	27	208	13
Mount Vernon Cancer Network	26	51	51
Kent and Medway Cancer Network	24	96	25
Surrey, West Sussex and Hampshire Cancer Network	23	52	44
West London Cancer Network	22	85	26
Lancashire and South Cumbria Cancer Network	20	104	19
North East London Cancer Network	20	60	33
South West London Cancer Network	14	87	16
Central South Coast Cancer Network	10	123	8
North London Cancer Network	0	77	0
South East London Cancer Network	0	76	0
<b>ENGLAND</b>	<b>1,882</b>	<b>2,820</b>	<b>67</b>
North Wales	26	46	57
South West Wales	43	67	64
South East Wales	84	96	88
<b>WALES</b>	<b>153</b>	<b>209</b>	<b>73</b>
<b>TOTAL</b>	<b>2,035</b>	<b>3,032</b>	<b>67</b>

Networks are shown as defined at the start of the index period November 2006.

Figure for Wales taken as total larynx and oral cavity registrations from Welsh Cancer Intelligence and Surveillance Unit for 2004.

Figure for England taken as total larynx and oral cavity registrations from CIS for 2004.

Figures for English Cancer Networks use previous report figures and adjusted by the percentage increase for England as a whole for each network.

### 8.3.3 Submission by Network and Provider Trust of patients with new head and neck primaries of the larynx and oral cavity in the index period

Figure 8.3.3.a: Submission by Network and Provider Trust of patients with new head and neck primaries of the larynx and oral cavity in the index period.

Cancer Network	Submitting Provider Trust to DAHNO	Larynx	Oral Cavity	Total
3 Counties	Gloucestershire Hospitals NHS Foundation Trust	17	23	40
	Hereford Hospitals NHS Trust	3	5	8
	Worcestershire Acute Hospitals NHS Trust	0	0	0
<b>Total</b>		<b>20</b>	<b>28</b>	<b>48</b>
Arden	South Warwickshire General Hospitals NHS Trust	0	0	0
	University Hospitals Coventry and Warwickshire NHS Trust	23	24	47
	Worcestershire Acute Hospitals NHS Trust	0	0	0
<b>Total</b>		<b>23</b>	<b>24</b>	<b>47</b>
Avon Somerset and Wiltshire	North Bristol NHS Trust	45	13	58
	Royal United Hospital Bath NHS Trust	1	0	1
	Taunton and Somerset NHS Foundation Trust	11	8	19
<b>Total</b>		<b>57</b>	<b>21</b>	<b>78</b>
Central South Coast	Isle of Wight Healthcare NHS Trust	1	0	1
	Basingstoke and North Hampshire NHS Foundation Trust	1	0	1
	Portsmouth Hospitals NHS Trust	0	0	0
	Royal West Sussex NHS Trust	0	8	8
	Salisbury NHS Foundation Trust	0	0	0
	Southampton University Hospital's NHS Trust	0	0	0
Winchester and Eastleigh Healthcare NHS Trust	0	0	0	
<b>Total</b>		<b>2</b>	<b>8</b>	<b>10</b>
Derby Burton	Derby Hospitals NHS Foundation Trust	37	30	67
<b>Total</b>		<b>37</b>	<b>30</b>	<b>67</b>
Dorset	Dorset County Hospital NHS Foundation Trust	0	1	1
	Poole Hospital NHS Foundation Trust	19	28	47
<b>Total</b>		<b>19</b>	<b>29</b>	<b>48</b>
Greater Manchester and Cheshire	Bolton Hospitals NHS Trust	1	0	1
	Central Manchester and Manchester Children's University Hospitals NHS Trust	0	0	0
	Christie Hospital NHS Foundation Trust	*	*	*
	Pennine Acute Hospitals NHS Trust	0	0	0
	Salford Royal NHS Foundation Trust	0	0	0
	Stockport NHS Foundation Trust	0	0	0
	Tameside and Glossop Acute Services NHS Trust	13	13	26
	The Mid Cheshire Hospitals NHS Trust	0	0	0
	Trafford Healthcare NHS Trust	0	0	0
	University Hospital of South Manchester NHS Foundation Trust	0	0	0
Wrightington, Wigan and Leigh NHS Trust	0	0	0	
<b>Total</b>		<b>14</b>	<b>13</b>	<b>27</b>
Greater Midlands	Mid Staffordshire General Hospitals NHS Trust	1	0	1
	Shrewsbury and Telford Hospital NHS Trust	13	16	29
	The Royal Wolverhampton Hospitals NHS Trust	14	15	29
	University Hospital of North Staffordshire NHS Trust	0	0	0
	Worcestershire Acute Hospitals NHS Trust	0	0	0
<b>Total</b>		<b>28</b>	<b>31</b>	<b>59</b>
Humber and Yorkshire Coast	Hull and East Yorkshire Hospitals NHS Trust	31	16	47

Cancer Network	Submitting Provider Trust to DAHNO	Larynx	Oral Cavity	Total
<b>Total</b>		<b>31</b>	<b>16</b>	<b>47</b>
<b>Kent and Medway</b>	East Kent Hospitals NHS Trust	0	0	0
	Medway NHS Trust	4	5	9
	Maidstone and Tunbridge Wells NHS Trust	13	2	15
	Queen Victoria Hospital NHS Foundation Trust	0	0	0
<b>Total</b>		<b>17</b>	<b>7</b>	<b>24</b>
<b>Lancashire and South Cumbria</b>	Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust	9	2	11
	East Lancashire Hospitals NHS Trust	5	3	8
	Lancashire Teaching Hospitals NHS Foundation Trust	0	0	0
	University Hospitals of Morecombe Bay NHS Trust	1	0	1
<b>Total</b>		<b>15</b>	<b>5</b>	<b>20</b>
<b>Leicestershire, Northamptonshire and Rutland</b>	Northampton General Hospital NHS Trust	17	18	35
	University Hospitals of Leicester NHS Trust	21	33	54
<b>Total</b>		<b>38</b>	<b>51</b>	<b>89</b>
<b>Merseyside and Cheshire</b>	Aintree University Hospitals NHS Foundation Trust	7	21	28
	Clatterbridge Centre for Oncology NHS Foundation Trust	0	0	0
	Countess of Chester NHS Trust	4	7	11
	North Cheshire Hospitals NHS Trust	0	0	0
	Royal Liverpool and Broadgreen University Hospitals NHS Trust	18	8	26
	Southport and Ormskirk Hospitals NHS Trust	0	4	4
	St Helens and Knowsley Hospitals NHS Trust	7	0	7
	Wirral University Teaching Hospital NHS Foundation Trust	2	2	4
<b>Total</b>		<b>38</b>	<b>42</b>	<b>80</b>
<b>Mid Anglia</b>	Essex Rivers Healthcare NHS Trust	4	10	14
	Ipswich Hospital NHS Trust	3	1	4
	Mid Essex Hospital Services NHS Trust	1	15	16
<b>Total</b>		<b>8</b>	<b>26</b>	<b>34</b>
<b>Mid Trent</b>	Nottingham University Hospitals NHS Trust	31	36	67
	Sherwood Forest Hospitals NHS Foundation Trust	3	5	8
	United Lincolnshire Hospitals NHS Trust	14	23	37
<b>Total</b>		<b>48</b>	<b>64</b>	<b>112</b>
<b>Mount Vernon</b>	Luton and Dunstable Hospital NHS Foundation Trust	22	4	26
<b>Total</b>		<b>22</b>	<b>4</b>	<b>26</b>
<b>Norfolk and Waveney</b>	Norfolk and Norwich University Hospital NHS Trust	23	21	44
<b>Total</b>		<b>23</b>	<b>21</b>	<b>44</b>
<b>North East London</b>	Barking, Havering and Redbridge Hospitals NHS Trust	9	11	20
	Barts and The London NHS Trust	0	0	0
	Homerton University Hospital NHS Foundation Trust	0	0	0
	Newham University Hospital NHS Trust	0	0	0
	Whipps Cross University Hospital NHS Trust	0	0	0
<b>Total</b>		<b>9</b>	<b>11</b>	<b>20</b>
<b>North London</b>	North Middlesex University Hospitals NHS Trust	0	0	0
	Barnet and Chase Farm Hospitals NHS Trust	0	0	0
	The Princess Alexandra Hospital NHS Trust	0	0	0
	Royal Free Hampstead NHS Trust	0	0	0
	The Whittington Hospital NHS Trust	0	0	0
	University College London Hospitals NHS Foundation Trust	0	0	0
<b>Total</b>		<b>0</b>	<b>0</b>	<b>0</b>

Cancer Network	Submitting Provider Trust to DAHNO	Larynx	Oral Cavity	Total
North Trent	Barnsley Hospitals NHS Foundation Trust	0	0	0
	Chesterfield Royal Hospital NHS Foundation Trust	3	4	7
	Doncaster and Bassetlaw Hospitals NHS Foundation Trust	17	9	26
	Sheffield Teaching Hospitals NHS Foundation Trust	28	2	30
<b>Total</b>		<b>48</b>	<b>15</b>	<b>63</b>
Northern	City Hospitals Sunderland NHS Foundation Trust	16	1	17
	North Cumbria Acute Hospitals NHS Trust	17	13	30
	The Newcastle Upon Tyne Hospitals NHS Foundation Trust	44	56	100
<b>Total</b>		<b>77</b>	<b>70</b>	<b>147</b>
Pan Birmingham	Heart of England NHS Foundation Trust	28	7	35
	Sandwell and West Birmingham Hospitals NHS Trust	5	0	5
	University Hospital Birmingham NHS Foundation Trust	39	56	95
	Worcestershire Acute Hospitals NHS Trust	0	0	0
<b>Total</b>		<b>72</b>	<b>63</b>	<b>135</b>
Peninsula	Northern Devon Healthcare NHS Trust	1	0	1
	Plymouth Hospitals NHS Trust	19	15	34
	Royal Cornwall Hospitals NHS Trust	17	7	24
	Royal Devon and Exeter Healthcare NHS Foundation Trust	11	25	36
	South Devon Healthcare NHS Foundation Trust	16	16	32
<b>Total</b>		<b>64</b>	<b>63</b>	<b>127</b>
South East London	Guy's and St Thomas' NHS Foundation Trust	0	0	0
	King's College Hospital NHS Foundation Trust	0	0	0
	The Lewisham Hospital NHS Trust	0	0	0
<b>Total</b>		<b>0</b>	<b>0</b>	<b>0</b>
South Essex	Basildon and Thurrock General Hospitals NHS Foundation Trust	2	0	2
	Southend Hospital NHS Trust	14	14	28
<b>Total</b>		<b>16</b>	<b>14</b>	<b>30</b>
South West London	Epsom and St Hellier University Hospital NHS Trust	0	0	0
	Mayday Healthcare NHS Trust	0	0	0
	St George's Healthcare NHS Trust	0	1	1
	The Royal Marsden NHS Foundation Trust	8	5	13
<b>Total</b>		<b>8</b>	<b>6</b>	<b>14</b>
Surrey, West Sussex and Hants	Royal Surrey County Hospital NHS Trust	7	16	23
<b>Total</b>		<b>7</b>	<b>16</b>	<b>23</b>
Sussex	Brighton and Sussex University Hospitals NHS Trust	10	16	26
	East Sussex Hospitals NHS Trust	13	14	27
	Worthing and Southlands Hospitals NHS Trust	0	3	3
<b>Total</b>		<b>23</b>	<b>33</b>	<b>56</b>
Teesside, South Durham and North Yorkshire	County Durham and Darlington NHS Foundation Trust	11	12	23
	South Tees Hospitals NHS Trust	40	33	73
<b>Total</b>		<b>51</b>	<b>45</b>	<b>96</b>
Thames Valley	Buckinghamshire Hospitals NHS Trust	0	0	0
	Heatherwood and Wexham Park Hospitals NHS Foundation Trust	6	1	7
	Milton Keynes Hospital NHS Foundation Trust	0	0	0
	Oxford Radcliffe Hospitals NHS Trust	19	17	36
	Royal Berkshire NHS Foundation Trust	0	0	0
	Swindon and Marlborough NHS Trust	0	0	0
<b>Total</b>		<b>25</b>	<b>18</b>	<b>43</b>

Cancer Network	Submitting Provider Trust to DAHNO	Larynx	Oral Cavity	Total
West Anglia	Bedford Hospital NHS Trust	0	0	0
	Cambridge University Hospitals NHS Foundation Trust	18	27	45
	Peterborough and Stamford Hospitals NHS Foundation Trust	0	0	0
<b>Total</b>		<b>18</b>	<b>27</b>	<b>45</b>
West London	The Hillingdon Hospital NHS Trust ( Mount Vernon Cancer Centre)	5	17	22
	Ealing Hospital NHS Trust	0	0	0
	West Middlesex University Hospital NHS Trust	0	0	0
	Imperial College Healthcare NHS Trust	0	0	0
<b>Total</b>		<b>5</b>	<b>17</b>	<b>22</b>
Yorkshire	Bradford Teaching Hospitals NHS Foundation Trust	18	30	48
	Mid Yorkshire Hospitals NHS Trust	17	29	46
	Leeds Teaching Hospitals NHS Trust	28	32	60
	York Hospitals NHS Foundation Trust	15	32	47
<b>Total</b>		<b>78</b>	<b>123</b>	<b>201</b>
<b>England Total</b>		<b>941</b>	<b>941</b>	<b>1,882</b>
North Wales	Conwy and Denbighshire NHS Trust	6	1	7
	North East Wales NHS Trust	7	4	11
	North West Wales NHS Trust	5	3	8
<b>Total</b>		<b>18</b>	<b>8</b>	<b>26</b>
South East Wales	Cardiff and Vale NHS Trust	9	3	12
	Gwent Healthcare NHS Trust	27	9	36
	North Glamorgan NHS Trust	9	6	15
	Velindre NHS Trust	17	4	21
<b>Total</b>		<b>62</b>	<b>22</b>	<b>84</b>
South West Wales	BroMorgannwg NHS Trust	8	1	9
	Carmarthenshire NHS Trust	4	2	6
	Ceredigion and Mid Wales NHS Trust	2	0	2
	Pembrokeshire and Derwen NHS Trust	4	0	4
	Swansea NHS Trust	10	12	22
<b>Total</b>		<b>28</b>	<b>15</b>	<b>43</b>
<b>Wales Total</b>		<b>108</b>	<b>45</b>	<b>153</b>
<b>England and Wales</b>		<b>1,049</b>	<b>986</b>	<b>2,035</b>

\* Treating Trust only – data are allocated to location entering demographic data, usually diagnosing Trust

Networks are shown as defined at the start of the index period November 2006.

The following have merged during the period of this audit; Northern and the Cancer Care Alliance Cancer Networks have merged to become the North of England Cancer Network, Mid Anglia, Norfolk and Waveney, and South Essex Cancer Networks are now Anglia Cancer Network and Essex Cancer Network.

- 2,035 cancers, of a theoretical maximum total of 3,032 cancers have been registered (67 per cent) to the audit.
- 34 out of 36 Cancer Networks in England and Wales have entered at least one patient into the DAHNO system. The minimum contribution from any submitting network was 7 cases.
- No submissions were received from the North London Cancer Network and South East London Cancer Network.

Figure 8.3.3.b: Submission by Cancer Network where over 90 per cent of estimated new head and neck primaries of the larynx and oral cavity in the index period, were made in 2005-2006 and 2006-2007.

Cancer Network	Over 90% of estimate in 2005-2006 DAHNO registrations	Over 90% of estimate in 2006-2007 DAHNO registrations
Derby/Burton Cancer Network	118	172
Cancer Care Alliance of Teesside, South Durham and North Yorkshire	112	162
Yorkshire Cancer Network		139
Leicestershire, Northamptonshire and Rutland Cancer Network		125
Pan Birmingham Cancer Network	92	121
Peninsula Cancer Network	110	120
Mid Trent Cancer Network	151	118
Norfolk and Waveney Cancer Network	100	110
Dorset Cancer Network		102
Northern Cancer Network		102
Sussex Cancer Network	124	100
Arden Cancer Network		100
South Essex Cancer Network		96

- 25 networks achieved more than 50 per cent of expected cases and 13 achieved more than 90 per cent compared to 7 out of 34 in 2005-2006.
- At individual Provider Trust level 4 organisations who had previously contributed high levels of registration were unable to achieve this in 2006-2007. These were:
  - Lancashire Teaching Hospitals NHS Trust
  - Salford Royal Hospitals NHS Trust
  - Pennine Acute Hospitals NHS Trust
  - South Warwickshire General Hospitals NHS Trust
- The best performing Cancer Networks have managed to achieve high levels of registration. These have benefited from good organisation, shared learning and the investment by hospital Provider Trusts in data collection personnel.
- The MDT meeting is a key focal point for data collection as the correct members of the team are assembled.

#### 8.3.4 Submission by Cancer Network and Provider Trust of patients with new head and neck primaries of the larynx and oral cavity in the index period, where cases had pre treatment recorded T and N staging category

For some this was due to a loss of data entry resource and others technical reasons in, for example, the upload of information from third party systems.

- The DAHNO application can receive data by either direct data entry (2/3 of submissions) or by the use of a CSV upload facility (1/3 of submissions). A number of organisations that collect data on in-house / third party systems have not taken the opportunity to contribute as yet. The DAHNO helpdesk is available to help users contribute by this means, with both technical and practical advice. The audit development team continue to try and simplify the upload process.
  - Data from Wales was initially collected in the National Summary Electronic Cancer Patient Report (CaNISC) system and uploaded via a CSV export into DAHNO.
- Counts and percentage of cases with recorded pre treatment T and N staging by provider trust. Trusts have been colour banded to represent completeness of staging information:
- of 2,035 patients, who have been registered to the audit, 1,550 (76.2 per cent) contained T and N pre treatment staging category information
  - this year there has been an improvement in staging and organisations are to be encouraged to improve this further

Figure 8.3.4a: Submitted diagnoses by year where T and N recorded

	2004-2005	2005-2006	2006-2007
<b>Diagnoses submitted</b>	1,042	1,443	2,035
<b>Submissions from</b>	England only	England and Wales	England and Wales
<b>Cases with T and N staging recorded</b>	673	776	1,550
<b>Percent of staging</b>	64.8	53.8	76.2

- there is a variation between and within Cancer Networks and between England (79.2 per cent) and Wales (39.2 per cent) in the quantity of staging information submitted.

### Good Practice Standard

Recording cancer site and accurate stage is a key medical responsibility, with best practice suggesting that this should be clearly documented and captured at the MDT. Staging remains a key influence on outcome. It is important that this improves to achieve 100 per cent of cases staged in any high quality database collection, to allow valid comparisons to be made.

Figure 8.3.4.b: Submission by Cancer Network and Provider Trust of patients with new head and neck primaries of the larynx and oral cavity in the index period, where cases had recorded T and N staging category.

**Key:** **Green** = 75 per cent or more **T** and **N** recorded **Amber** = 25 per cent to 75 per cent **T** and **N** recorded **Red** = Less than 25 per cent **T** and **N** recorded

Cancer Network	Submitting Provider Trust to DAHNO	Cases submitted where T and N recorded	Total	Percentage of those with T and N recorded
<b>3 Counties</b>	Gloucestershire Hospitals NHS Foundation Trust	38	40	95.0
	Hereford Hospitals NHS Trust	2	8	25.0
<b>Total</b>		<b>40</b>	<b>48</b>	<b>83.3</b>
<b>Arden</b>	University Hospitals Coventry and Warwickshire NHS Trust	15	47	31.9
<b>Total</b>		<b>15</b>	<b>47</b>	<b>31.9</b>
<b>Avon Somerset and Wiltshire</b>	North Bristol NHS Trust	58	58	100.0
	Royal United Hospital Bath NHS Trust	0	1	0.0
	Taunton and Somerset NHS Foundation Trust	19	19	100.0
<b>Total</b>		<b>77</b>	<b>78</b>	<b>98.7</b>
<b>Central South Coast</b>	Basingstoke and North Hampshire Hospital NHS Foundation Trust	1	1	100.0
	Isle of Wight Healthcare NHS Trust	1	1	100.0
	Royal West Sussex NHS Trust	6	8	75.0
<b>Total</b>		<b>8</b>	<b>10</b>	<b>80.0</b>
<b>Derby Burton</b>	Derby Hospitals NHS Foundation Trust	66	67	98.5
<b>Total</b>		<b>66</b>	<b>67</b>	<b>98.5</b>
<b>Dorset</b>	Dorset County Hospital NHS Foundation Trust	1	1	100.0
	Poole Hospital NHS Foundation Trust	45	47	95.7
<b>Total</b>		<b>46</b>	<b>48</b>	<b>95.8</b>
<b>Greater Manchester and Cheshire</b>	Bolton Hospitals NHS Trust	0	1	0.0
	Tameside and Glossop Acute Services NHS Trust	8	26	30.8
<b>Total</b>		<b>8</b>	<b>27</b>	<b>29.6</b>
<b>Greater Midlands</b>	Mid Staffordshire General Hospitals NHS Trust	0	1	0.0
	Shrewsbury and Telford Hospital NHS Trust	12	29	41.4
	The Royal Wolverhampton Hospitals NHS Trust	0	29	0.0
<b>Total</b>		<b>12</b>	<b>59</b>	<b>20.3</b>

**Key:** **Green** = 75 per cent or more **T** and **N** recorded **Amber** = 25 per cent to 75 per cent **T** and **N** recorded  
**Red** = Less than 25 per cent **T** and **N** recorded

Cancer Network	Submitting Provider Trust to DAHNO	Cases submitted where T and N recorded	Total	Percentage of those with T and N recorded
<b>Humber and Yorkshire Coast</b>	Hull and East Yorkshire Hospitals NHS Trust	44	47	93.6
	<b>Total</b>	<b>44</b>	<b>47</b>	<b>93.6</b>
<b>Kent and Medway</b>	Maidstone and Tunbridge Wells NHS Trust	0	15	0.0
	Medway NHS Trust	4	9	44.4
<b>Total</b>		<b>4</b>	<b>24</b>	<b>16.7</b>
<b>Lancashire and South Cumbria</b>	Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust	11	11	100.0
	East Lancashire Hospitals NHS Trust	8	8	100.0
	University Hospitals of Morecombe Bay NHS Trust	1	1	100.0
<b>Total</b>		<b>20</b>	<b>20</b>	<b>100.0</b>
<b>Leicestershire, Northamptonshire and Rutland</b>	Northampton General Hospital NHS Trust	21	35	60.0
	University Hospitals of Leicester NHS Trust	52	54	96.3
<b>Total</b>		<b>73</b>	<b>89</b>	<b>82.0</b>
<b>Merseyside and Cheshire</b>	Aintree University Hospitals NHS Foundation Trust	27	28	96.4
	Countess of Chester NHS Foundation Trust	2	11	18.2
	Royal Liverpool and Broadgreen University Hospitals NHS Trust	4	26	15.4
	Southport and Ormskirk Hospital NHS Trust	0	4	0.0
	St Helens and Knowsley Hospitals NHS Trust	4	7	57.1
	Wirral University Teaching Hospital NHS Foundation Trust	2	4	50.0
<b>Total</b>		<b>39</b>	<b>80</b>	<b>48.8</b>
<b>Mid Anglia</b>	Essex Rivers Healthcare NHS Trust	11	14	78.6
	Ipswich Hospital NHS Trust	2	4	50.0
	Mid Essex Hospital Services NHS Trust	0	16	0.0
<b>Total</b>		<b>13</b>	<b>34</b>	<b>38.2</b>
<b>Mid Trent</b>	Nottingham University Hospitals NHS Trust	63	67	94.0
	Sherwood Forest Hospitals NHS Foundation Trust	8	8	100.0
	United Lincolnshire Hospitals NHS Trust	26	37	70.3
<b>Total</b>		<b>97</b>	<b>112</b>	<b>86.6</b>
<b>Mount Vernon</b>	Luton and Dunstable Hospital NHS Foundation Trust	19	26	73.1
<b>Total</b>		<b>19</b>	<b>26</b>	<b>73.1</b>
<b>Norfolk and Waveney</b>	Norfolk and Norwich University Hospital NHS Trust	44	44	100.0
<b>Total</b>		<b>44</b>	<b>44</b>	<b>100.0</b>
<b>North East London</b>	Barking, Havering and Redbridge Hospitals NHS Trust	16	20	80.0
<b>Total</b>		<b>16</b>	<b>20</b>	<b>80.0</b>
<b>North Trent</b>	Chesterfield Royal Hospital NHS Foundation Trust	5	7	71.4
	Doncaster and Bassetlaw Hospitals NHS Foundation Trust	25	26	96.2
	Sheffield Teaching Hospitals NHS Foundation Trust	22	30	73.3
<b>Total</b>		<b>52</b>	<b>63</b>	<b>82.5</b>
<b>Northern</b>	City Hospitals Sunderland NHS Foundation Trust	17	17	100.0
	North Cumbria Acute Hospitals NHS Trust	25	30	83.3
	The Newcastle Upon Tyne Hospitals NHS Foundation Trust	98	100	98.0
<b>Total</b>		<b>140</b>	<b>147</b>	<b>95.2</b>
<b>Pan Birmingham</b>	Heart of England NHS Foundation Trust	25	35	71.4
	Sandwell and West Birmingham Hospitals NHS Trust	1	5	20.0
	University Hospital Birmingham NHS Foundation Trust	93	95	97.9
<b>Total</b>		<b>119</b>	<b>135</b>	<b>88.1</b>

Cancer Network	Submitting Provider Trust to DAHNO	Cases submitted where T and N recorded	Total	Percentage of those with T and N recorded
Peninsula	Northern Devon Healthcare NHS Trust	1	1	100.0
	Plymouth Hospitals NHS Trust	34	34	100.0
	Royal Cornwall Hospitals NHS Trust	20	24	83.3
	Royal Devon and Exeter NHS Foundation Trust	36	36	100.0
	South Devon Healthcare NHS Foundation Trust	31	32	96.9
<b>Total</b>		<b>122</b>	<b>127</b>	<b>96.1</b>
South Essex	Basildon and Thurrock University Hospitals NHS Foundation Trust	2	2	100.0
	Southend University Hospital NHS Foundation Trust	28	28	100.0
<b>Total</b>		<b>30</b>	<b>30</b>	<b>100.0</b>
South West London	St George's Healthcare NHS Trust	1	1	100.0
	The Royal Marsden NHS Foundation Trust	10	13	76.9
<b>Total</b>		<b>11</b>	<b>14</b>	<b>78.6</b>
Surrey, West Sussex and Hants	Royal Surrey County Hospital NHS Trust	21	23	91.3
<b>Total</b>		<b>21</b>	<b>23</b>	<b>91.3</b>
Sussex	Brighton and Sussex University Hospitals NHS Trust	13	26	50.0
	East Sussex Hospitals NHS Trust	14	27	51.9
	Worthing and Southlands Hospitals NHS Trust	0	3	0.0
<b>Total</b>		<b>27</b>	<b>56</b>	<b>48.2</b>
Teesside, South Durham and North Yorkshire	County Durham and Darlington NHS Foundation Trust	13	23	56.5
	South Tees Hospitals NHS Trust	69	73	94.5
<b>Total</b>		<b>82</b>	<b>96</b>	<b>85.4</b>
Thames Valley	Heatherwood and Wexham Park Hospitals NHS Foundation Trust	0	7	0.0
	Oxford Radcliffe Hospitals NHS Trust	19	36	52.8
<b>Total</b>		<b>19</b>	<b>43</b>	<b>44.2</b>
West Anglia	Cambridge University Hospitals NHS Foundation Trust	41	45	91.1
<b>Total</b>		<b>41</b>	<b>45</b>	<b>91.1</b>
West London	The Hillingdon Hospital NHS Trust (Mount Vernon Cancer Centre)	20	22	90.9
<b>Total</b>		<b>20</b>	<b>22</b>	<b>90.9</b>
Yorkshire	Bradford Teaching Hospitals NHS Foundation Trust	36	48	75.0
	Mid Yorkshire Hospitals NHS Trust	31	46	67.4
	United Leeds Teaching Hospitals NHS Trust	54	60	90.0
	York Hospitals NHS Foundation Trust	44	47	93.6
<b>Total</b>		<b>165</b>	<b>201</b>	<b>82.1</b>
<b>England</b>		<b>1,490</b>	<b>1,882</b>	<b>79.2</b>
North Wales	Conwy and Denbighshire NHS Trust	1	7	14.3
	North East Wales NHS Trust	0	11	0.0
	North West Wales NHS Trust	1	8	12.5
<b>Total</b>		<b>2</b>	<b>26</b>	<b>7.7</b>
South East Wales	Cardiff and Vale NHS Trust	2	12	16.7
	Gwent Healthcare NHS Trust	28	36	77.8
	North Glamorgan NHS Trust	7	15	46.7
	Velindre NHS Trust	8	21	38.1
<b>Total</b>		<b>45</b>	<b>84</b>	<b>53.6</b>

**Key:** **Green** = 75 per cent or more **T** and **N** recorded **Amber** = 25 per cent to 75 per cent **T** and **N** recorded  
**Red** = Less than 25 per cent **T** and **N** recorded

Cancer Network	Submitting Provider Trust to DAHNO	Cases submitted where T and N recorded	Total	Percentage of those with T and N recorded
South West Wales	BroMorgannwg NHS Trust	4	9	44.4
	Carmarthenshire NHS Trust	3	6	50.0
	Ceredigion and Mid Wales NHS Trust	0	2	0.0
	Pembrokeshire and Derwen NHS Trust	1	4	25.0
	Swansea NHS Trust	5	22	22.7
<b>Total</b>		<b>13</b>	<b>43</b>	<b>30.2</b>
<b>Wales Total</b>		<b>60</b>	<b>153</b>	<b>39.2</b>
<b>England and Wales Total</b>		<b>1,550</b>	<b>2,035</b>	<b>76.2</b>


- Where trusts only contribute to the diagnostic part of the pathway, final pre-treatment staging may only be confirmed at the MDT led by the treatment centre. Technical difficulties may hinder the reconciliation of data from different sources in some cancer Cancer Networks

## 8.4 Who receives the care – demography, casemix and socio economic status

### 8.4.1 Age and sex distributions of registrations

#### Larynx

Figure 8.4.1.a: Larynx Cancer; Registration counts by age and sex.



There were 7 cases with unknown sex;


- 1 case aged 30-34 years
- 4 cases aged 60-64 years
- 1 case aged 65-69 years
- 1 case aged 75-59 years.

There was also one male case with a diagnosis date preceding his birth date.

- 82 per cent of larynx cancer patients were male.
- 7.8 per cent were under 50 years of age.
- The median ages were; for males 67 years and females 64 years.

- 7 per cent of male cases were under the age of 50. 25 per cent were aged over 75.
- 10 per cent of female cases were under the age of 50. 23 per cent were aged over 75.
- 3 cases (all female) were under the age of 30. Of these (one case was aged between 0-4 years (which was subsequently confirmed as a data entry error) and the other two cases were aged between 20-24 years).
- National Head and Neck Cancer Audit registrations are broadly in line with ONS which reports the rate of laryngeal cancer peaking in the 75 to 79 age group for both males and females.


Figure 8.4.1.b: Ratio of male to female registrations larynx cancer compared with ratio of males to females in England and Wales.



- The ratio of male to female laryngeal cancers exceeds the ratio of males to females in England and Wales by a factor of approximately 4 beyond the age of 45 years.
- The risk of laryngeal cancer is approximately 4 times greater in males than in females over 45 years of age.

### Larynx Cancer Registration Counts by age and sex January 2004-October 2006


Figure 8.4.1.c: Larynx Cancer Registration Counts by age and sex January 2004-October 2007 (2,619 cases).



- Cumulative data of over 2,600 male and female cases from the inception of the audit shows similar distributions by age band supporting the findings above and again confirming contribution from a homogenous population.
- A sub analysis showed no significant difference in age distribution between England and Wales.
- A peak of incidence of laryngeal cancers occurs between the ages of 55 and 79, and future proposals in relation to screening (as proposed in the Cancer Reform Strategy <sup>22</sup>) if applied to larynx cancer would gain greatest return within these age groupings.


Oral Cavity

Figure 8.4.1.d: Oral Cavity Cancer; Registration counts by age and sex.




- There were two cases aged less than 20 years of age (one male case aged 15-19 years and one female case aged 0-4 years). (Subsequent enquiry confirmed as an error in data submission with the latter patient being 78 years of age).
- Three male cases could not be given an age due to two cases having the diagnosis date preceding the birth date and one case with a missing diagnosis date.
- Sex was recorded as unknown in one case (65-69 years of age) and one case in the diagnosis file was not in the patient file so could not be allocated an age or sex.
- 58 per cent of cases of oral cavity cancer were male.
- 14 per cent of patients were aged under 50 years.
- The median ages were; for males 62 years and females 68 years.
- 14 per cent of male cases were under the age of 50, 17 per cent were aged over.
- 13 per cent of female cases were under the age of 50. 46 per cent were aged over 75.
- The apparent trend seen in last year's report of a second peak of registrations in elderly females is again seen in this year's data, and in the combined data from the audit's inception. However, further analysis of this trend is discussed below.
- National Head and Neck Cancer Audit registrations are broadly in line with ONS which reports rates of oral cancer in men approximately double that in women at the age of 50, but approximately equal over the age of 80.
- The fact that more cancer cases have been recorded in older females than older males is accounted for by the greater life expectancy of females, and consequently there is a larger population of women over the age of 80 than of men.

Figure 8.4.1.e: Ratio of male to female registrations oral cavity cancer compared with ratio of males to females in England and Wales.



- The ratio of male to female oral cavity cancers exceeds the ratio of males to females in England and Wales by a factor of approximately 2 between the ages of 40 and 80. This suggests that the risk of oral cavity cancer in males is approximately double than in females between the ages of 40 and 80; beyond this age risk is approximately equal. Using national age-sex distribution in each age band, a better comparison of true incidence can be made.

Figure 8.4.1.f: Oral Cavity Cancer Registration Counts by age and sex January 2004-October 2007 (2,535 cases)



- Cumulative data of over 2,500 cases from the inception of the audit shows similar distributions by age band supporting the findings above and confirming contribution from a homogenous population.
- A sub analysis showed no significant difference in age distribution between England and Wales.
- The incidence of oral cavity cancers occurs over a broader age range (compared to laryngeal cancer) between the ages of 45 and 85, and any future proposals in relation to screening (as proposed in the Cancer Reform Strategy) if applied to oral cavity cancer would need to screen a wide age group.

A number of recent publications have demonstrated an increasing incidence of oral squamous cell carcinoma (particularly of the tongue) occurring in younger patients (under 40 years<sup>27</sup>). Three consecutive year's data have failed to demonstrate this phenomenon in England and Wales. Registrations again do not appear to confirm the trend of a rising occurrence in young people. However, not all cases have been registered in this time frame particularly in the South of England where figures support a higher incidence in London and the South East for 13 to 24 year olds across non thyroid head and neck anatomic sites <sup>28</sup>.

## 8.4.2 Distribution of stage

### 8.4.2.1 Larynx

#### 8.4.2.1.1 Stage at diagnosis


Figure 8.4.2.1.1.a: Larynx; Stage at diagnosis.

N Category	T category						Total
	T1	T2	T3	T4	TX	Not Recorded	
<b>N0</b>	25.1	13.2	11.3	4.6	0.1	1.0	<b>55.3</b>
<b>N+</b>	1.1	3.2	3.8	6.3			<b>14.5</b>
<b>NX</b>	0.8	0.2	0.3	0.5	4.9		<b>6.6</b>
<b>Not recorded</b>	0.2	0.5	0.1	0.4		22.5	<b>23.6</b>
<b>Total</b>	<b>27.2</b>	<b>17.1</b>	<b>15.5</b>	<b>11.7</b>	<b>5.0</b>	<b>23.5</b>	<b>100</b>

Percentage of 1,049 recorded cases

- Recording of staging continues to improve.
- Over 76.5 per cent had T and N category recorded.
- Overall 14.5 per cent of larynx cancers were node positive at presentation.
- Analysis by sub-site of primary showed, for glottic cancers, 35 of 547 cases to be node positive at diagnosis, compared to 99 of 258 cases of supraglottic cancer, with 18 larynx NOS (not specified). This demonstrates the greater propensity of supraglottic cancer compared to glottic cancer to involve regional nodes.
- 1.6 cent were M1, confirming the low propensity of laryngeal carcinomas of presenting with distant metastatic disease.

Figure 8.4.2.1.1.b: Larynx; Stage at diagnosis.



65.5 per cent of laryngeal cancers have stage at diagnosis recorded to allow categorisation into low stage and high stage disease (thus excluding Tx and Nx).

34.5 per cent of laryngeal cancers have no staging recorded, or insufficient information to categorise stage. The figures show an improvement on the previous year (2005-2006 44.5 per cent) which is encouraging, but considerable further work is required to meet universal stage recording.

In laryngeal cancer, as previously found, early stage disease predominates <sup>7,8</sup>

**Good Practice Standard**

Recording cancer site and accurate stage is a key medical responsibility, with best practice suggesting that this should be clearly documented and captured at the MDT. Staging remains a key influence on outcome. It is important that this improves to achieve 100 per cent of cases staged in any high quality database collection, to allow valid comparisons to be made.

**8.4.2.1.2 Comparison of stage at diagnosis and post-surgery staging**

Of the 255 patients recorded as undergoing surgery (202 with curative intent), information on stage at diagnosis, with post surgical staging (ie based on resective pathology), was available for T category in 185 patients and N category in 179 patients.

Of the 185 patients where staging was recorded 72 underwent laser surgery.

Figure 8.4.2.1.2.a: Comparison of stage at diagnosis and post-surgery staging.

	T	Diagnosis					Total
		T1	T2	T3	T4	TX	
Post-surgery	T1	65	2			1	67
	T2	1	18		1	1	21
	T3			30	2	0	32
	T4	1	1	5	49	1	57
	TX		1		1	5	7
	<b>Total</b>	<b>67</b>	<b>22</b>	<b>35</b>	<b>53</b>	<b>8</b>	<b>184</b>

- In T category, 8 patients were upstaged following surgery, and 5 downstaged.

Figure 8.4.2.1.2.b: Comparison of stage at diagnosis and post-surgery staging.

	N	Diagnosis					Total
		N0	N1	N2	N3	NX	
Post-surgery	N0	119	1			2	122
	N1	1	11	1			13
	N2	2	1	28	1		32
	N3				1		1
	NX	2				9	11
	<b>Total</b>	<b>124</b>	<b>13</b>	<b>29</b>	<b>2</b>	<b>11</b>	<b>179</b>

- 4 patients were upstaged and 3 patients were downstaged, which shows a level of correlation expected rather than the previous absence of any change in N category. The sample size, however, is too small and incomplete at this stage to draw any definitive conclusions.
- As expected only a small number of patients with very advanced neck disease staging recorded (N3) underwent surgical treatment.

**8.4.2.1.3 Summary of recorded stage certainty**

Percentage of cases with recorded T N M category (452 T category recorded; 434 N category recorded; 410 M category recorded).

Figure 8.4.2.1.3.a: Summary of recorded stage certainty.

Stage Category	Stage Certainty				
	C1	C2	C3	C4	Not Recorded
Cases with recorded T	10.5	14.7	14.8	3.1	56.9
Cases with recorded N	12.8	22.1	4.3	2.2	58.6
Cases with recorded M	16.8	18.2	3.6	0.5	60.9

- 43.1 per cent had T stage certainty factor recorded, 41.4 per cent had N stage certainty factor recorded and 39.1 per cent had M stage certainty factor recorded.
- This is a significant decline this year in the recording of this item and the relevance of this item will be raised in future workshops.
- At key points in the patient pathway, staging is a defining parameter which allows for more interpretation of outcome, which facilitates grouping a description of disease extent in a uniform manner, to allow valid comparison.

Figure 8.4.2.1.3.b: Summary of recorded stage certainty.

Certainty factor	
C1	Evidence from standard diagnostic means (eg inspection, palpation, and standard radiography, intraluminal endoscopy for tumours of certain organs)
C2	Evidence obtained by special diagnostic means (eg radiographic imaging in special projections, tomography, computerised tomography(CT), ultrasonography, lymphography, angiography, scintigraphy, magnetic resonance imaging (MRI), endoscopy, biopsy and cytology)
C3	Evidence from surgical exploration, including biopsy and cytology
C4	Evidence of the extent of disease following definitive surgery and pathological examination of the resected specimen
C5	Evidence from autopsy

Stage certainty is a relatively new concept to clinicians and links to the category (TNM) recorded, the means by which this was established and the degree of confidence associated with the diagnosis.<sup>29</sup>

- Less than half of laryngeal cases had certainty factor completed, which is a reverse of previous progress. It would be expected that the numbers with C4 should be greater based on the number of resective procedures performed.

#### Good Practice Standard

For those cases undergoing surgical management it is important that resective pathology is accurately recorded to allow true stage comparison. Surgical teams should develop responsibilities in this key area.

## 8.4.2.2 Oral cavity


### 8.4.2.2.1 Stage at diagnosis

Figure 8.4.2.2.1.a: Oral Cavity; Stage at diagnosis.

N Category	T Category						Total
	T1	T2	T3	T4	TX	Not Recorded	
N0	25.5	14.8	2.2	8.2	0.1	0.3	51.1
N+	2.5	6.3	2.7	10.0		0.2	21.8
NX	0.8	0.4	0.4	0.5	2.5		4.7
Not recorded	0.4	0.1	0.1	0.3		21.5	22.4
Total	29.2	21.6	5.5	19.1	2.6	22.0	100

- 78 per cent had T and N category recorded.
- 22 per cent were N positive at diagnosis.
- Analysis by sub-site of primary showed, for glottic cancers, 35 of 547 cases to be node positive at diagnosis, compared to 99 of 258 cases of supraglottic cancer, with 18 larynx NOS (not specified). This demonstrates the greater propensity of supraglottic cancer compared to glottic cancer to involve regional nodes.
- Of the 215 cases of oral cavity cancer which were node positive at diagnosis, there was a more even distribution of associated primary site. However, the most common primary sites associated with regional metastasis were floor of mouth and retromolar trigone.
- 1.0 per cent were M1, confirming the low propensity of oral cavity carcinomas to present with distant metastatic disease.

Figure 8.4.2.2.1.b: Oral Cavity; Stage at diagnosis.



64.8 per cent of oral cavity cancers have stage at diagnosis recorded to allow categorisation into low and high stage disease (thus excluding Tx and Nx).

35.2 per cent of oral cancers have no staging recorded, or insufficient information to categorise stage. The figures show an improvement on the previous year (2005-2006, 41.5 per cent) which is encouraging.

#### Good Practice Standard

Recording cancer site and accurate stage is a key medical responsibility, with best practice suggesting that this should be clearly documented and captured at the MDT. Staging remains a key influence on outcome. It is important that this improves to achieve 100 per cent of cases staged in any high quality database collection, to allow valid comparisons to be made.

The previously noted dominance of late stage cancer (2004-2005 report<sup>7</sup>) is not evident again in this year's data. As the level of staging rises the finding of a predominance of early stage cancer is supported. However, no firm conclusion can be drawn due to the level of no stage recorded or insufficient TNM to categorise.

#### 8.4.2.2.2 Comparison of stage at diagnosis and post-surgery staging

Of the 531 patients recorded as undergoing surgery, information on stage at diagnosis, with post surgical staging (ie based on resective pathology), was available for T category in 362 patients and N category in 358 patients.

- 68 per cent of patients undergoing surgery had post resective surgery staging details recorded.

Figure 8.4.2.2.2.a: Comparison of stage at diagnosis and post-surgery staging.

T	Diagnosis					Total	
	T1	T2	T3	T4	TX		
Post-surgery	T1	138	12	1	4	2	157
	T2	5	90	4	1	1	101
	T3	1	1	12	1	0	15
	T4	2	3	2	71	3	81
	TX	1	2			5	8
<b>Total</b>	<b>147</b>	<b>108</b>	<b>19</b>	<b>77</b>	<b>11</b>	<b>362</b>	

- In T category, 14 patients were upstaged following surgery and 23 were downstaged (10 per cent change in stage).

Figure 8.4.2.2.2.b: Comparison of stage at diagnosis and post-surgery staging.

N	Diagnosis					Total	
	N0	N1	N2	N3	NX		
Post-surgery	N0	224	3	3		2	232
	N1	10	32	1		2	45
	N2	7	10	41	1	2	61
	N3				2		2
	NX	4		1		13	18
	<b>Total</b>	<b>245</b>	<b>45</b>	<b>46</b>	<b>3</b>	<b>19</b>	<b>358</b>

- 27 patients were upstaged and 8 patients were downstaged (10 per cent change in stage). This is consistent with last year's data. The sample size, however, is too small and incomplete at this stage to draw any definitive conclusions.
- The number of patients upstaged following surgery seems low compared to published estimates of occult metastasis in squamous cell carcinoma of the oral cavity. Given the predominance of cancer of the tongue in the cases submitted it might be expected that higher percentage of upstaging would be seen.

### 8.4.2.2.3 Summary of recorded stage certainty

Percentages of cases with recorded T N M (519 T category recorded; 508 N category recorded and 487 M category recorded).

Figure 8.4.2.2.3.a: Summary of recorded stage certainty.

Stage Category	Stage Certainty					Total
	C1	C2	C3	C4	Not Recorded	
Cases with recorded T	14.7	16.1	16.4	5.4	47.4	100
Cases with recorded N	16.2	27.2	5.0	3.1	48.5	100
Cases with recorded M	24.7	19.5	4.8	0.4	50.6	100

- 52.6 per cent had T stage certainty factor recorded, 51.5 per cent had N stage certainty factor recorded and 49.4 per cent had M stage certainty factor recorded.
- This is a significant decline this year in the recording of this item and the relevance of this item will be raised in future workshops.
- At key points in the patient pathway, staging is a defining parameter which allows for more interpretation of outcome, which facilitates grouping a description of disease extent in a uniform manner, to allow valid comparison.
- Just over a half of oral cases had certainty factor completed, which represents a reverse of previous progress. It would be expected that the numbers with C4 should be greater based on the number of resective procedures performed.

#### Good Practice Standard

For those cases undergoing surgical management, it is important that resective pathological staging is accurately recorded to allow true stage comparison. Surgical teams should take responsibility in this area and, in particular, should ensure that the certainty factor is also accurately recorded.

Figure 8.4.2.2.3.b: Summary of recorded stage certainty.

Certainty factor	
C1	Evidence from standard diagnostic means (eg inspection, palpation, and standard radiography, intraluminal endoscopy for tumours of certain organs)
C2	Evidence obtained by special diagnostic means (eg radiographic imaging in special projections, tomography, computerised tomography (CT), ultrasonography, lymphography, angiography, scintigraphy, magnetic resonance imaging (MRI), endoscopy, biopsy and cytology)
C3	Evidence from surgical exploration, including biopsy and cytology
C4	Evidence of the extent of disease following definitive surgery and pathological examination of the resected specimen
C5	Evidence from autopsy

### 8.4.2.3 Comparison of low to high stage disease by tumour site

The rise in the level of staging submission allows a comparison of early versus late disease by site for this year's data.

Figure 8.4.2.3: Distribution of low and high stage disease by anatomic sub site. Low stage disease is Stage I and Stage II and high stage disease is Stage III and Stage IV (see UICC manual for contributory T and N categories)

	Site	Low Stage	High Stage	Stage Unknown	Total
Larynx	Glottis	291	116	140	547
	Supraglottis	59	132	67	258
	Larynx, unspecified	46	54	103	203
	Anterior surface of epiglottis	2	5	15	22
	Subglottis	10	4	5	19
<b>Total</b>		<b>408</b>	<b>311</b>	<b>330</b>	<b>1,049</b>
Oral Cavity	Border of tongue	134	50	52	236
	Anterior floor of mouth	45	21	31	97
	Ventral surface of tongue	38	20	30	88
	Cheek mucosa	34	26	24	84
	Hard palate	21	23	25	69
	Dorsal surface of tongue	23	18	26	67
	Lower gum	11	41	7	59
	Retromolar area	14	26	14	54
	Overlapping lesion of floor of mouth	17	15	15	47
	Lateral floor of mouth	18	9	10	37
	Upper lip, inner aspect	12	6	17	35
	Upper gum	13	17	5	35
	Vestibule of mouth	7	18	10	35
	Overlapping lesion of tongue	5	12	16	33
	Lower lip, inner aspect	3	0	3	6
	Mouth unspecified	0	1	3	4
<b>Oral Cavity Total</b>		<b>395</b>	<b>303</b>	<b>288</b>	<b>986</b>
<b>Total</b>		<b>803</b>	<b>614</b>	<b>618</b>	<b>2,035</b>

- In larynx cancer for glottic cancer low stage disease predominates (2.5 to 1), whilst in supraglottic cancer high stage disease is the commoner (2.2 to 1).
- However, no firm conclusion can be drawn due to the level of no stage recorded or insufficient TNM to categorise.
- In oral cavity cancer for the tongue and anterior/lateral floor of mouth and inner aspect of lip low stage disease predominates, whilst in the remaining sites high stage disease is more frequent.

#### 8.4.2.4 Submission by Cancer Network of patients with new head and neck primaries of the larynx and oral cavity by ratio of low to high stage disease January 2004-October 2007

Figure 8.4.2.4: Submission by Cancer Network of patients with new head and neck primaries of the larynx and oral cavity by ratio of low to high stage disease January 2004-October 2007

Cancer Network	Low Stage	High Stage	Unknown Stage	Total	Low:High ratio
3 Counties	27	12	23	62	2.3
Arden	11	15	86	112	0.7
Avon Somerset and Wiltshire	41	29	87	157	1.4
Central South Coast	3	3	3	9	1.0
Derby Burton	80	84	10	174	1.0
Dorset	71	35	11	117	2.0
Greater Manchester and Cheshire	28	20	92	140	1.4
Greater Midlands	8	7	50	65	1.1
Humber and Yorkshire Coast	21	24	28	73	0.9
Kent and Medway	7	5	35	47	1.4
Lancashire and South Cumbria	10	5	35	50	2.0
Leicestershire, Northamptonshire and Rutland	85	87	65	237	1.0
Merseyside and Cheshire	184	112	106	402	1.6
Mid Anglia	30	40	53	123	0.8
Mid Trent	108	85	93	286	1.3
Mount Vernon	16	19	17	52	0.8
Norfolk and Waveney	44	33	36	113	1.3
North East London	12	6	4	22	2.0
North London	2	5	0	7	0.4
North Trent	73	53	41	167	1.4
Northern	154	151	57	362	1.0
Pan Birmingham	177	148	42	367	1.2
Peninsula	122	93	85	300	1.3
South East London	0	1	0	1	0.0
South Essex	32	18	0	50	1.8
South West London	85	66	16	167	1.3
Surrey, West Sussex and Hants	28	23	12	63	1.2
Sussex	36	29	61	126	1.2
Teesside, South Durham and North Yorkshire	51	42	181	274	1.2
Thames Valley	23	29	84	136	0.8
West Anglia	67	34	28	129	2.0
West London	18	7	2	27	2.6
Yorkshire	210	186	118	514	1.1
<b>England Total</b>	<b>1,864</b>	<b>1,506</b>	<b>1,561</b>	<b>4,931</b>	<b>1.2</b>

Figure 8.4.2.4: Continued

Cancer Network	Low Stage	High Stage	Unknown Stage	Total	Low:High ratio
North Wales	3	4	60	67	0.8
South East Wales	41	45	75	161	0.9
South West Wales	15	10	60	85	1.5
<b>Wales Total</b>	<b>59</b>	<b>59</b>	<b>195</b>	<b>313</b>	<b>1.0</b>
<b>England and Wales Total</b>	<b>1,923</b>	<b>1,565</b>	<b>1,756</b>	<b>5,244</b>	<b>1.2</b>

In preparation for future risk adjustment, a comparison of pooled submission since the inception of the audit by network of the ratio of low to high stage disease was made to understand variation in presentation of the stage of disease.

The higher the ratio, the greater the predominance of low stage disease.

The ratio varied between 2.6:1 and 0.4:1, with an average in England of 1.2:1 and in Wales of 1.0:1. This supports the initial presumption of a geographic variation in the stage of disease in presentation across England and Wales.

Caution should be made in interpreting data from networks whose submission rates or level of recording stage are poor.

#### 8.4.2.5 Submission by Cancer Network of patients who underwent surgery of the larynx and oral cavity where recording of pre treatment and post resective pathological staging is identified in the index period

Figure 8.4.2.5: Submission by Cancer Network of patients who underwent surgery of the larynx and oral cavity where recording of pre treatment and post resective pathological staging is identified in the index period

Cancer Network	T and N recorded pre-treatment	Number with surgery	T and N recorded post-surgery
3 Counties	40	16	16
Arden	15	27	7
Avon Somerset and Wiltshire	77	20	20
Central South Coast	7	3	2
Derby Burton	66	53	42
Dorset	46	24	23
Greater Manchester and Cheshire	8	1	0
Greater Midlands	12	27	3
Humber and Yorkshire Coast	44	17	16
Kent and Medway	4	4	0
Lancashire and South Cumbria	20	1	1
Leicestershire, Northamptonshire and Rutland	73	41	38
Merseyside and Cheshire	39	0	0
Mid Anglia	13	23	7
Mid Trent	97	52	40
Mount Vernon	19	6	6
Norfolk and Waveney	44	5	5
North East London	16	7	5
North Trent	52	26	21

Figure 8.4.2.5: Continued

Cancer Network	T and N recorded pre-treatment	Number with surgery	T and N recorded post-surgery
Northern	140	66	42
Pan Birmingham	119	54	53
Peninsula	122	57	40
South Essex	30	13	13
South West London	11	3	2
Surrey, West Sussex and Hants	22	18	18
Sussex	27	25	16
Teesside, South Durham and North Yorkshire	82	28	13
Thames Valley	19	19	9
West Anglia	41	21	0
West London	20	13	12
Yorkshire	165	80	74
<b>England Total</b>	<b>1,490</b>	<b>750</b>	<b>544</b>
North Wales	2	1	0
South East Wales	45	14	5
South West Wales	13	22	1
<b>Wales Total</b>	<b>60</b>	<b>37</b>	<b>6</b>
<b>England and Wales Total</b>	<b>1,550</b>	<b>787</b>	<b>544</b>

Cancer Networks are shown as defined at the start of the index period November 2006.

Note pre-surgery data is by provider hospital whereas post surgery data is by treating hospital.

- Of the 1,550 diagnoses where T and N staging category were recorded, 787 underwent surgery. Of the 787 surgical cases, all of which would be expected to have resective pathological staging (pTNM<sup>29</sup>), 544 had post surgery T and N category recorded. This represents 69 per cent of the surgical treatment group.
- pTNM remains the gold standard in the staging of cancer and networks should encourage collection of this important item in the analysis of survival and treatment effectiveness
- 12 networks show high levels of post surgery T and N category and are to be congratulated.

### 8.4.3 Distribution of performance status at point of treatment decision

#### Larynx

Figure 8.4.2.5: Submission by Cancer Network of patients with new head and neck primaries of the larynx and oral cavity by ratio of low to high stage disease January 2004-October 2007

Performance status	Percentage of 474 recorded values
0. Able to carry out all normal activity without restriction	43.7
1. Restricted in physically strenuous activity	17.1
2. Able to walk and capable of all self care but unable to carry out any work	9.1
3. Capable of only limited self care	3.6
4. Completely disabled	0.6
5. Not recorded	25.9
<b>Total</b>	<b>100.0</b>

## Oral cavity

Figure 8.4.3.b: Oral Cavity; Distribution of performance status at point of treatment decision.

Performance status	Percentage of 477 recorded values
0. Able to carry out all normal activity without restriction	55.7
1. Restricted in physically strenuous activity	16.4
2. Able to walk and capable of all self care but unable to carry out any work	9.0
3. Capable of only limited self care	5.0
4. Completely disabled	0.2
5. Not recorded	13.7
<b>Total</b>	<b>100.0</b>

- 1,732 patients had at least one careplan (a careplan represents the point in the patient pathway where a plan of treatment is proposed and thus an appropriate point to assess and record a patient's fitness).
- 951 patients had performance status recorded, which is 46.7 per cent of the total registrations. This equates to 55 per cent of patients with a recorded careplan.
- The completion of performance status remains poor.
- To facilitate risk adjustment further training on performance status and completeness is required. The figures for the first two annual reports suggest that the majority of patients have a normal performance status and there appears to be equivalence between the oral cavity and laryngeal groups.

### 8.4.4 Presence or absence of significant co-morbidity at index point of diagnosis (ACE-27)

A description of the Adult Comorbidity index (ACE-27 <sup>30,31</sup>) can be found in Appendix 7

#### Larynx

- 891 patients had at least one careplan.
- 302 patients had co-morbidity index recorded. This is 34 per cent of patients with a recorded careplan, which is 28 per cent of total registrations.

#### 8.4.4.1 Summary of recorded co-morbidity

Figure 8.4.4.1.a: Larynx; Summary of recorded co-morbidity

Grade	Percentage of 302 recorded values
Grade 0 - No co-morbidity	43.0
Grade 1 - Mild decompensation	33.1
Grade 2 - Moderate decompensation	14.2
Grade 3 - Severe decompensation	9.6
<b>Total</b>	<b>100.0</b>

## Oral Cavity

- 841 patients had at least one careplan.
- 352 patients had co-morbidity index recorded. This is 42 per cent of patients with a recorded careplan, which is 36 per cent of total registrations.

Figure 8.4.4.1.b: Oral Cavity; Summary of recorded co-morbidity.

Co-morbidity index	Percentage of 350 recorded values
Grade 0 - No co-morbidity	52.6
Grade 1 - Mild decompensation	23.4
Grade 2 - Moderate decompensation	14.0
Grade 3 - Severe decompensation	10.0
<b>Total</b>	<b>100</b>

Co-morbidity has been shown to have an important impact in assessing risk and to be an important predictor of outcome. Further effort will be put into training workshops to encourage completeness. All MDT's are encouraged to collect co-morbidity data.

- The figures in this year's report do not show the previously noted greater frequency of moderate and severe decompensation. The figures are closer to those of a previous UK population of larynx only cancer patients studied <sup>32,33</sup>.
- The figures for co-morbidity suggest that 48 per cent of the total population (larynx and oral cavity) patients had no co-morbidity. This appears to tally with the normal performance status in the previous output (8.4.3) and the reported figure last year.

### Good Practice Standard

The influence of factors such as co-morbidity and performance status can have a significant effect upon treatment outcomes. Therefore all MDT's are to be encouraged to collect these data set items to facilitate future risk adjustment.

## 8.4.5 Deprivation analysis: Distribution of diagnosis, treatment and outcome by socio-economic Lower Super Output Areas, derived from the postcode in England and Wales

The Index of Multiple Deprivation 2004 (IMD 2004) was used as a measure of socio-economic deprivation and is applicable in England <sup>34,35</sup>. The Welsh Index of Multiple Deprivation (WIMD 2005) was used as a measure of socio-economic deprivation and is applicable to Wales. Both indices are not directly comparable due to the differing proportion of the domains that make up the index for each country.

The lower the index score the greater the level of deprivation for each Lower Super Output Area (LSOA). For each country, these LSOAs were split into quintiles based on the same number of LSOAs (or as close to as possible) being in each quintile, thus the first quintile represents those who are most deprived. Each registration was assigned a quintile of deprivation.

100 English and 9 Welsh registrations did not have a valid postcode attributable to an LSOA therefore, a deprivation score could not be calculated.

To investigate any bias that may be caused by the partial coverage of the National Head and Neck Cancer Audit, the registrations have been totalled by the average deprivation of their PCT of residence. A deprivation score is attributed to (English) PCTs according to the population weighted mean score of the Lower Super Output Areas that make up that PCT. PCTs were then ranked and categorised into quintiles. The total registrations by PCT deprivation are below, and show no particular bias.

Figure 8.4.5.a: Deprivation quintile of PCT


Deprivation quintile of PCT	Total
Least deprived	264
4	309
3	316
2	388
Most Deprived	496
Blank	109
<b>Total</b>	<b>1882</b>

Figure 8.4.5.b: Deprivation quintile of PCT- Percentage of PCTs with some cases in DAHNO

Deprivation quintile of PCT	Percentage of PCTs with some cases in DAHNO
Least Deprived	83
4	77
3	73
2	84
Most Deprived	63

### 8.4.5.1 Summary of registrations by deprivation in England


Figure 8.4.5.1.a: Summary of registrations by deprivation in England.



- As previously the distribution of cases is more even across the deprivation quintiles for both larynx and oral cavity, though a greater number of larynx registrations reside in areas of relative deprivation (quintiles 1 and 2).


### 8.4.5.2 Deprivation and stage in England

Figure 8.4.5.2.a: Deprivation and stage in England.



### 8.4.5.2 Proportion of registrations with sufficient stage data to categorise as low stage or high stage

Figure 8.4.5.2.b: Proportion of registrations with sufficient stage data to categorise as low stage or high stage.



The lower chart (Figure 8.4.5.2.b) demonstrates for each quintile the percentage of registrants who have staging information recorded, this demonstrates


similar proportions across the quintiles showing the upper graph (Figure 8.4.5.2.a) is not biased by incomplete staging.

Of the overall 2,035 patients, 1,773 had a postcode that could be classified into a LSOA and had staging recorded to allow classification early or late stage disease (885 larynx cancer and 888 oral cavity cancer). The rise in the percentage of staging reinforces the

indication (seen in last years report) that at diagnosis late stage cancer is more likely in the most deprived, while amongst the least deprived low stage cancer is more common. Across all quintiles however low stage disease is numerically greater.

### 8.4.5.3 Deprivation and interval from onset of first symptom to referral in England


Figure 8.4.5.3.a: Larynx and Oral Cavity - Interval from first symptom to referral by socio-economic deprivation in England (765 cases had date of first symptom recorded).



- It has been previously proposed that deprivation has a bearing on delayed presentation and delayed onward referral <sup>8</sup>.
- The interval to first symptom has reduced significantly for oral cavity cancer in the last year, where in all deprivation quintiles it now appears as a shorter interval than in larynx cancer.
- The reasons for the above are not clear but may reflect a larger sample size or an improvement in patient access or pathway intervals.
- No clear relationship is shown between the interval from onset of first symptom to referral and deprivation for larynx or oral cavity cancer.


#### 8.4.5.4 Deprivation and interval from referral to treatment in England

Figure 8.4.5.4.a: Larynx - Interval from referral to first recorded treatment by socio-economic deprivation in England.



- The interval from referral to first recorded treatment by deprivation quintile shows near identical median values between the most deprived and least, which is comparable to last years sample.

Figure 8.4.5.4.b: Oral Cavity - Interval from referral to first recorded treatment by socio-economic deprivation in England.




- The interval from referral to first recorded treatment by deprivation quintile shows a 6 day difference in median value (least deprived 54 days compared to 60 days for the most deprived). This is in contrast to a 20 day difference between the most deprived and least deprived evident in the first annual report, and equivalence last year. This item will continue to be evaluated, but is encouraging that delayed access seen in the first annual report appears to be reducing.
- This item will continue to be evaluated, but is encouraging that delayed access seen in the first annual report appears to be reducing.

#### 8.4.5.5 Proportion of registrations in each Cancer Network in England and Wales by quintile of deprivation January 2004-October 2007


- A comparison between networks in England since the inception of the audit who have submitted greater than 20 larynx or oral cavity cases are shown in the rainbow charts. The total number of cases submitted is shown at the top of the column.
- The small numbers in some networks mean that selection bias may influence the comparison.
- Differences in deprivation will be utilised in calculating risk adjustment in future reports.
- Differences in deprivation may influence the level of support particularly for social care required by each network for its head and neck services.

Figure 8.4.5.5.1.a: Larynx cancer registrations in England  
 Proportion of laryngeal registrations in each Cancer Network in England by quintile of deprivation, January 2004–October 2007




- In larynx cancer, the most deprived have a greater prevalence in the North of England, being 20 per cent above the England average in some networks.
- In larynx cancer, the least deprived have a greater prevalence in the South of England, being 15 to 30 per cent below the England average in some networks.

Figure 8.4.5.1.b: Oral cavity cancer registrations in England  
Proportion of oral cavity registrations in each Cancer Network in England by quintile of deprivation, January 2004–October 2007



- In oral cavity cancer, the most deprived have a greater prevalence again in the North of England, being 10 to 15 per cent above the England average in some networks.
- In oral cavity cancer, the least deprived have a greater prevalence in the South of England, being 15 to 30 per cent below the England average in some networks.

Figure 8.4.5.5.2: Larynx and oral cavity cancer registrations in Wales



- In larynx and oral cavity in Wales, the most deprived have a greater prevalence in the South East of Wales, being 5 per cent above the Wales average however this has the greatest area of population density.

## 8.5 The patient journey - diagnostic and staging process, waiting intervals

### 8.5.1 Source of referral to specialist team in England

#### 8.5.1.1 Larynx

Figure 8.5.1.1.a: Larynx; Source of referral to specialist team in England. (990 cases)

Primary referral source	2ww from GP or dentist	Other	Not recorded	Total
GP	451	250	7	708
Emergency / A&E	1	36	1	38
Consultant referral	2	212	6	220
Self / Other		37	2	39
Unknown	2	33	1	36
<b>Total</b>	<b>456</b>	<b>568</b>	<b>17</b>	<b>1,041</b>

*The two week wait target for urgent cancer referral applies to England and figures above only include patients from England.*

- There is a ratio of 1.75:1 in referral via the two week wait urgent referral pathway compared to other referral priorities, in referrals from general practitioners in those with diagnosed cancer. Other network based reviews have also shown that the non two week referral pathway remains the commonest route in those diagnosed with head and neck cancer <sup>36</sup>. However, the audit has not sampled the total number of referrals from which these derived.
- This compares in 2006 to 1.49:1, and 1.7:1 in 2005 suggesting that two week wait referrals from GPs as a source for diagnosed cancers have returned to levels seen in 2005.

#### 8.5.1.2 Oral cavity

Figure 8.5.1.1.b: Oral Cavity; Source of referral to specialist team in England (912 cases)

Primary referral source	Two week wait from GP or dentist	Other	Not recorded	Total
GP	332	150	4	486
GDP / CDS	39	127	1	167
Emergency / A&E	1	16		17
Consultant referral	4	188	1	193
Self / Other		56		56
Unknown		36	12	48
<b>Total</b>	<b>376</b>	<b>573</b>	<b>18</b>	<b>567</b>

*The two week wait target for urgent cancer referral applies to England and figures above only include patients from England.*

- There is a ratio of 2.16:1 in referral via the two week wait urgent referral pathway compared to other referral priorities, in referrals from general medical practitioners in those with diagnosed cancer, and a ratio of 0.30:1 for those referred under the two week wait from general dental practitioners (GDP) / Community Dental Services (CDS). From consideration of the submitted data and informal feedback from the Expert Panels, general dental practitioners do not appear to be embracing the two week wait referrals pathway in some networks and in others are not actively involved in the process. Cancer Networks should consider a strategy to enhance the role of the GDP in the cancer referral process. The audit, however, has not sampled the total number of referrals from which these derived.
- In 2006 the ratio was 2.02:1, suggesting a similar proportion of patients with cancer are being referred via the two week wait rule from general practitioners. Further education is required to enable practitioners to recognise alarm symptoms and utilise the two week wait referral pathway.

## 8.5.2 Summary as percentage of cases with both 'primary referral priority' and 'primary referral source' completed in England

### 8.5.2.1 Larynx

Figure 8.5.2.1a: Larynx; Summary as percentage of cases with both 'primary referral priority' and 'primary referral source' completed (percentage of 990 cases)

Primary referral source	Two week wait from GP or dentist	Other priority	Total
GP	45.6	25.3	70.9
GDP / CDS			
Emergency / A&E	0.1	3.6	3.7
Consultant referral	0.2	21.4	21.6
Self / Other		3.7	3.7
<b>Total</b>	<b>45.9</b>	<b>54.1</b>	<b>100.0</b>

*The two week wait target for urgent cancer referral applies to England and figures above only include patients from England.*

- 70.9 per cent of those diagnosed with laryngeal cancer are referred by their general practitioner, whilst of the remaining 29.1 per cent, 21.6 per cent are referred from another consultant.

## 8.5.2.2 Oral cavity

Figure 8.5.2.2 a: Oral Cavity; Summary as percentage of cases with both 'primary referral priority' and 'primary referral source' completed (percentage of 912 cases)


Primary referral source	Two week wait from GP or dentist	Other priority	Total
GP	36.4	16.4	52.8
GDP / CDS	4.3	13.9	18.2
Emergency/A&E	0.1	1.8	1.9
Consultant referral	0.4	20.6	21.0
Self/Other		6.1	6.1
<b>Total</b>	<b>41.2</b>	<b>58.8</b>	<b>100.0</b>

*The two week wait target for urgent cancer referral applies to England and figures above only include patients from England.*

- 52.8 per cent of those diagnosed with oral cavity cancer are referred by their general practitioner. Of the remaining 47.2 per cent, 21 per cent are referred from another consultant and 18 per cent from a general dental practitioner or the Community Dental Service. However, 14 per cent of these were not referred using an urgent referral pathway. The important role of general dental services in screening for oral cavity cancer is recognised, but further work is required to ensure referral urgency is appropriately applied.


### 8.5.3 Interval from first symptom to referral to specialist team

Figure 8.5.3.a: Interval from first symptom to referral to specialist team for index year November 2006 to October 2007.



- Patient recall of the onset of their first symptom to their point of referral is a crude indicator of patient awareness. The figures presented continue to suggest earlier presentation of oral cavity cancer (median interval 54 days) compared to laryngeal cancer (median interval 76 days). This shows a similar difference to the first and second annual reports confirming a trend. This may be because within the oral cavity, cancers are more visible.


Figure 8.5.3.b: Interval from first symptom to referral to specialist team; January 2004-October 2007.



- The second chart shows data from the inception of the audit from 2,146 patients. The cumulative findings confirm consistency of median times from first symptom to referral for both larynx and oral cavity cancer, in cases from 2004 to 2007.
- The significance of delay in outcome and stage at presentation remains controversial <sup>37,38,39,40,41,42,43</sup>.
- Increasing patient and practitioner awareness of suspicious symptoms should yield an early diagnosis, particularly in larynx cancer.
- Practitioners should be encouraged to familiarise themselves with and utilise national referral guidelines. National referral guidelines (Referral Guidelines for Suspected Cancers) can be found at: [www.dh.gov.uk](http://www.dh.gov.uk)

### 8.5.4 Interval from referral to first appointment in England

Figure 8.5.4.a: Interval from referral to first appointment in England.



The two week wait target for urgent cancer referral applies to England and figures above only include patients from England.

- The figure shows that for non two week wait referrals, 30 per cent have an interval from referral to first appointment of 0 days. This reflects self referrals, referrals to an Accident and Emergency Service and those seen on the day of phone or fax request.
- The two week wait rule for referral to first appointment was introduced in England in December 2000<sup>44</sup>. This is designed to speed up the patient's entry into the cancer care pathway and improve outcomes, though this has not been demonstrated in other cancers<sup>45</sup>. The median for both larynx and oral cavity two week wait and other referrals is comfortably within the standard, showing that patients with suspicious symptoms independent of route of referral are seen promptly. Again, however 20 per cent of other referrals in the sample are waiting over one month for their first appointment, and would imply 10 per cent of 2 week wait patients are waiting over 14 days. The latter are not adjusted times and therefore do not take into account patients choosing to wait over 14 days and those not attending first appointments. National cancer waiting times, which take account of adjustments, show 100 per cent of those received within 24 hours and 93 per cent of those not received within 24 hours being seen within 14 days for two week wait patients.
- With the implementation of national referral guidelines in England, (Guidance on Cancer Services - Improving Outcomes in Head and Neck Cancers and Referral Guidelines for Suspected Cancers<sup>11</sup>), it would be expected that an ever increasing proportion of patients will be referred via the two-week wait pathway but this is not borne out in this third period of data collection.

The introduction of Choose and Book has placed upon the referrer the responsibility of requesting urgent priority for symptoms not falling into the two week wait criteria rather than a reliance upon triage. Further reductions in cancer waiting times have been announced in the Cancer Reform Strategy<sup>22</sup> to be implemented by December 2008.

- The importance of alarm symptoms and their usage by general practitioners has again been made with

the recognition that the diagnosis of cancer by an individual GP is still rare<sup>46,47</sup>.

- Understanding is growing of factors responsible for recognition of signs and symptoms in patients that encourage a visit to a doctor and dentist. Furthermore, the variation of the interval from first recognition of suspicious symptoms to diagnosis, as shown by this audit, begs questions of the psychological response to possible malignancy, not only by patients but also care-givers.

### 8.5.5 Interval from referral to diagnosis in England and Wales


A number of key events occur in the cancer care pathway, and the following three graphs reflect time intervals along that path.

The point of diagnosis reflects the date upon which a biopsy was taken rather than the date histology was reported. The date of the MDT meeting where care options were discussed is reflected in the date MDT management was planned. The careplan agreed date is the date upon which the treating clinician and patient agree that care pathway. The date of 'primary

care notification' is the date that communication was sent to the primary care practitioner.

Anxiety promoted by uncertainty is acknowledged as the major psychological distress experience by patients following referral to specialist services for diagnostic investigation. This anxiety often reaches levels where clinical intervention is indicated. Reducing the interval between referral and diagnosis will attenuate 'case' level anxiety.

Figure 8.5.5.a: Interval from referral to diagnosis in England and Wales.




- The apparent more rapid diagnosis of oral cavity cancers may be explained by the fact that many of these diagnoses can be achieved via local anaesthetic out-patient biopsy, whereas for laryngeal cancer the requirement for general anaesthesia may induce additional delays. There have been small decreases for both larynx and oral cavity cancers in the time taken from referral to diagnosis in this period of data collection.
- In both larynx and oral cavity cancer, patients may present initially with precancerous lesions that are carefully followed up over extended periods. This can, therefore, mean that their ultimate diagnosis of cancer from referral may not occur until a significant time has elapsed. This is likely to explain why the graph shows that only 95 per cent of patients reach a diagnosis by 100 days and then plateau.

### 8.5.5.1 Time from biopsy to reporting

This item represents the time from the biopsy being taken to its reporting.

Figure 8.5.5.1a: Time from biopsy



- The median time from biopsy to its reporting is 3 days for larynx.
- There has been a general shift to the left in the graphical appearance ie same day reporting is significantly higher. The Head and Neck Clinical Reference Group noted the latter and considered this may reflect same day cytology reporting, frozen section (in a small number of patients) or data quality as fixing and staining of specimens takes more than 24 hours.
- The chart below reports, by trust, a breakdown for larynx of the interval from biopsy to reporting of 10 days or less and greater than 10 days. Only those organisations contributing data on over 5 cases are presented. These organisations are to be congratulated in this area and it should be acknowledged that non-submitters' interval to reporting could be considerably poorer than the organisations presented.

- The chart is colour coded to show quartiles as follows;

**Key:** **Green** = trusts where less than 25 per cent of cases have taken more than 10 days

**Amber** = trusts with less than 50 per cent but greater than or equal to 25 per cent which have taken more than 10 days

**Red** = trusts with greater than or equal to 50 per cent of cases which have taken more than 10 days

Figure 8.5.5.1.b: Time from biopsy to reporting by trust, for those trusts reporting greater than 5 larynx cases

Larynx					
Hospital Trust	Number <=10 days	% <=10 days	Number > 10 days	% > 10 days	Total
Barking Havering and Redbridge Hospitals NHS Trust	7	77.8	2	22.2	9
Bradford Hospitals NHS Trust	13	72.2	5	27.8	18
Brighton and Sussex University Hospitals NHS Trust	10	100.0	0	0.0	10
City Hospitals Sunderland NHS Trust	15	93.8	1	6.3	16
East Sussex Hospitals NHS Trust	10	83.3	2	16.7	12
Gloucestershire Hospitals NHS Trust	7	63.6	4	36.4	11
Hull and East Yorkshire Hospitals NHS Trust	7	77.8	2	22.2	9
Newcastle Upon Tyne Hospitals NHS Foundation Trust	39	92.9	3	7.1	42
North Cumbria Acute Hospitals NHS Trust	5	41.7	7	58.3	12
Nottingham University Hospitals NHS Trust	30	100.0	0	0.0	30
Poole Hospital NHS Foundation Trust	16	84.2	3	15.8	19
Royal Cornwall Hospitals NHS Trust	13	92.9	1	7.1	14
Royal Devon & Exeter Healthcare NHS Foundation Trust	5	83.3	1	16.7	6
Royal Shrewsbury Hospital's NHS Trust	11	84.6	2	15.4	13
Southend Hospital NHS Trust	12	100.0	0	0.0	12
Southern Derbyshire Acute Hospitals NHS Trust	27	84.4	5	15.6	32
South Devon Health Care NHS Foundation Trust	15	93.8	1	6.3	16
South Tees Acute Hospitals NHS Trust	19	100.0	0	0.0	19
University Hospitals of Leicester NHS Trust	16	80.0	4	20.0	20
University Hospital Birmingham NHS Foundation Trust	13	54.2	11	45.8	24
United Lincolnshire Hospitals NHS Trust	6	85.7	1	14.3	7
York Health Services NHS Trust	14	93.3	1	6.7	15
WELSH NETWORK	18	90.0	2	10.0	20
<b>Total</b>	<b>328</b>	<b>85.0</b>	<b>58</b>	<b>15.0</b>	<b>386</b>

Figure 8.5.5.1.c: Time from biopsy to reporting by trust, for those trusts reporting greater than 5 oral cavity cases

Due to data quality issues, it has not been possible to produce a breakdown by trust, for those of the time from biopsy to reporting for oral cavity.

- To improve the patient pathway process mapping may identify areas where delays in the whole pathway could be reduced (from taking of a biopsy, through to its reporting).
- There are several methods of obtaining a biopsy in order to reach a diagnosis. The most appropriate method will be determined by the clinical presentation. This figure is a combination of data from cytological and histological specimens; these specimen types have different implications in terms of the complexity of interpretation and the types of diagnoses that can be made. Organisations should consider this complexity when reviewing pathways.
- Local MDTs should review regularly performance in the patient pathway.
- Manpower issues within pathology and in particularly head and neck pathology remain a challenge.

## 8.5.6 The multi-disciplinary team (MDT) and its functions

### 8.5.6.a Summated analysis of multi-disciplinary discussion for index year

Figure 8.5.6.a: The multi-disciplinary team (MDT) and its functions.

Discussed	Larynx	Oral Cavity	All
Yes	71.6	76.9	74.2
No	6.6	4.9	5.8
Not recorded	21.8	18.2	20.1

- Overall 74 per cent of patients were confirmed as having been discussed at an MDT meeting. The expected standard (proposed in the SWAHN audit 1997-1999<sup>49</sup>) suggested this should reach 100 per cent.
- It is a standard in the Improving Outcomes Guidance<sup>11</sup> that all patients are discussed in an MDT.
- These results show that there has been a small increase in the number of patients whose management has been planned outside of an MDT. (3.8 per cent last year has risen to 5.8 per cent this year). Recorded as not discussed at MDT.

A number of providers have rates above the average and the project team will be alerting those organisations where high levels of not discussed are recorded to consider the reasons for this and to develop improvement plans.

- The absence of this key data in 22 per cent of larynx cancer and 18 per cent of oral cavity cancer cases is of concern as this may reflect a non ideal pathway with more treatment decisions being made outside of MDTs and the true overall rate of MDT discussion lies between 74 and 93 per cent.

- The Expert Panels considered whether the figures above were falsely low, as they were likely to contain some individuals who had not reached the point in the pathway for an MDT discussion to occur. A more detailed analysis of the cohort with a date of diagnosis before 1 October 2007, and those after this date was made.
- This showed little difference ie 75 per cent being recorded as having been discussed at an MDT in those with a date of diagnosis prior to 1 October 2007, whilst for those with a date of diagnosis after 1 October 2007 the rate of not recorded doubled and a significant fall in discussed occurred.
- The MDT is a key point of registration of a cancer diagnosis.

#### Good Practice Standard

100 per cent of diagnoses should be discussed at a MDT, currently in England and Wales only 74 per cent are recorded as having been discussed.

- The Expert Panels considered whether the figures reported above were a reflection on a number of organisations failing to record information, or partial recording across a wider range of providers.
- The chart below reports by provider the information supplied to the audit on MDT discussion. Care should be taken in assessing percentages where only small case numbers were submitted.

## 8.5.6.b Analysis of multi-disciplinary discussion for index year by provider trust

Figure 8.5.6.b: Analysis of multi-disciplinary discussion for index year by provider trust

Larynx and Oral Cavity							
Hospital Trust	Yes MDT	% Yes MDT	No MDT	% No MDT	MDT Not Recorded	% MDT Not Recorded	Total
Aintree University Hospitals NHS Foundation Trust	0	0	0	0	27	100	27
Barking Havering and Redbridge Hospitals NHS Trust	20	100	0	0	0	0	20
Basildon and Thurrock University Hospitals NHS Foundation Trust	1	50	0	0	1	50	2
Basingstoke and North Hampshire NHS Foundation Trust	1	100	0	0	0	0	1
Birmingham Heartlands and Solihull NHS Trust	21	60	0	0	14	40	35
Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust	7	63.6	1	9.1	3	27.3	11
Bolton Hospitals NHS Trust	0	0	0	0	1	100	1
Bradford Teaching Hospitals NHS Foundation Trust	43	89.6	0	0	5	10.4	48
Brighton and Sussex University Hospitals NHS Trust	25	96.2	0	0	1	3.8	26
Cambridge University Hospitals NHS Trust	43	100	0	0	0	0	43
Chesterfield Royal Hospitals NHS Foundation Trust	7	100	0	0	0	0	7
City Hospitals Sunderland NHS Foundation Trust	8	47.1	0	0	9	52.9	17
Countess of Chester NHS Trust	0	0	0	0	11	100	11
County Durham and Darlington NHS Foundation Trust	0	0	0	0	23	100	23
Doncaster and Bassetlaw Hospitals NHS Foundation Trust	23	88.5	1	3.8	2	7.7	26
Dorset County Hospital NHS Foundation Trust	1	100	0	0	0	0	1
East Lancashire Hospitals NHS Trust	2	25	4	50	2	25	8
East Sussex Hospitals NHS Trust	16	61.5	1	3.8	9	34.6	26
Essex Rivers Healthcare NHS Trust	12	85.7	2	14.3	0	0	14
Gloucestershire Hospitals NHS Trust	37	86	6	14	0	0	43
Heatherwood and Wexham Park Hospitals NHS Foundation Trust	6	85.7	0	0	1	14.3	7
Hereford Hospitals NHS Trust	0	0	0	0	5	100	5
Hull and East Yorkshire Hospitals NHS Trust	40	85.1	0	0	7	14.9	47
Ipswich Hospital NHS Trust	1	25	0	0	3	75	4
Isle of Wight Healthcare NHS Trust	1	100	0	0	0	0	1
Luton and Dunstable Hospital NHS Foundation Trust	15	57.7	0	0	11	42.3	26
Maidstone and Tunbridge Wells NHS Trust	0	0	0	0	15	100	15
Medway NHS Trust	9	100	0	0	0	0	9
Mid Yorkshire Hospitals NHS Trust	38	82.6	1	2.2	7	15.2	46
Mid Essex Hospital Services NHS Trust	2	12.5	0	0	14	87.5	16

Larynx and Oral Cavity							
Hospital Trust	Yes MDT	% Yes MDT	No MDT	% No MDT	MDT Not Recorded	% MDT Not Recorded	Total
Mid Staffordshire General Hospitals NHS Trust	0	0	0	0	1	100	1
University Hospitals of Morecambe Bay NHS Trust	0	0	1	100	0	0	1
Newcastle Upon Tyne Hospitals NHS Foundation Trust	98	100	0	0	0	0	98
Norfolk and Norwich University Hospital NHS Trust	24	54.5	0	0	20	45.5	44
North Bristol NHS Trust	34	58.6	20	34.5	4	6.9	58
North Cumbria Acute Hospitals NHS Trust	28	93.3	0	0	2	6.7	30
Northampton General Hospital NHS Trust	32	91.4	0	0	3	8.6	35
Northern Devon Healthcare NHS Trust	0	0	0	0	1	100	1
Nottingham University Hospitals NHS Trust	56	83.6	5	7.5	6	9	67
Oxford Radcliffe Hospitals NHS Trust	32	100	0	0	0	0	32
Plymouth Hospitals NHS Trust	30	90.9	0	0	3	9.1	33
Poole Hospital NHS Foundation Trust	43	93.5	3	6.5	0	0	46
Royal Cornwall Hospitals NHS Trust	19	82.6	1	4.3	3	13	23
Royal Devon and Exeter NHS Foundation Trust	29	80.6	5	13.9	2	5.6	36
Royal Liverpool and Boadgreen University Hospitals NHS Trust	0	0	0	0	25	100	25
Shrewsbury and Telford Hospital NHS Trust	29	100	0	0	0	0	29
Royal Surrey County Hospital NHS Trust	21	95.5	1	4.5	0	0	22
Royal United Hospital Bath NHS Trust	0	0	0	0	1	100	1
Royal West Sussex NHS Trust	7	87.5	0	0	1	12.5	8
Sandwell and West Birmingham Hospitals NHS Trust	1	20	0	0	4	80	5
Sheffield Teaching Hospitals NHS Foundation Trust	30	100	0	0	0	0	30
Sherwood Forest Hospitals NHS Trust	4	57.1	2	28.6	1	14.3	7
South Devon Healthcare NHS Foundation Trust	31	96.9	0	0	1	3.1	32
South Tees Hospitals NHS Trust	71	98.6	1	1.4	0	0	72
Southend Hospital NHS Trust	27	96.4	0	0	1	3.6	28
Derby Hospitals NHS Foundation Trust	44	67.7	17	26.2	4	6.2	65
Southport and Ormskirk Hospital NHS Trust	0	0	0	0	4	100	4
St George's Healthcare NHS Trust	1	100	0	0	0	0	1
St Helens and Knowsley Hospitals NHS Trust	0	0	0	0	7	100	7
Tameside and Glossop Acute Services NHS Trust	2	7.7	19	73.1	5	19.2	26
Taunton and Somerset NHS Foundation Trust	0	0	4	21.1	15	78.9	19
The Hillingdon Hospital NHS Trust (Mount Vernon Cancer Centre)	20	90.9	0	0	2	9.1	22
The Royal Marsden Hospital NHS Trust	11	84.6	0	0	2	15.4	13

Larynx and Oral Cavity							
Hospital Trust	Yes MDT	% Yes MDT	No MDT	% No MDT	MDT Not Recorded	% MDT Not Recorded	Total
The Royal Wolverhampton Hospitals NHS	26	89.7	3	10.3	0	0	29
The United Leeds Teaching Hospitals NHS Trust	18	32.1	2	3.6	36	64.3	56
United Lincolnshire Hospitals NHS Trust	34	91.9	0	0	3	8.1	37
University Hospital Birmingham NHS Trust	92	97.9	0	0	2	2.1	94
University Hospitals Coventry and Warwickshire NHS Trust	44	93.6	0	0	3	6.4	47
University Hospitals of Leicester NHS Trust	46	86.8	0	0	7	13.2	53
Wirral University Teaching Hospital NHS Foundation Trust	3	75	0	0	1	25	4
Worthing and Southlands Hospitals NHS	0	0	0	0	3	100	3
York Hospitals NHS Foundation Trust	45	97.8	0	0	1	2.2	46
<b>WELSH NETWORKS</b>	<b>78</b>	<b>51.3</b>	<b>16</b>	<b>10.5</b>	<b>58</b>	<b>38.2</b>	<b>152</b>
<b>Total:</b>	<b>1489</b>	<b>74.2</b>	<b>116</b>	<b>5.8</b>	<b>403</b>	<b>20.1</b>	<b>2008</b>

- 29 organisations who submitted over 10 cases to the audit discussed over 85 per cent of cases (unadjusted for dates of diagnosis after 1 October 2007) at MDT providing assurance of an aspect of their patient care and should be commended.
- 5 organisations who submitted over 10 diagnoses stated significant numbers of patients as not having being discussed at MDT. Cancer leads may wish to consider whether this reflects poor data quality or issues about the function and availability of the MDT. Whilst it is possible that for a small tumour, excision


biopsy may be curative, it would still be expected that these cases would be discussed at MDT.

- Analysis by trust of MDT discussion will be a regular feature of future reports being a universally accepted best practice in head and neck cancer care.

#### Good Practice Standard


Patient expectations are that all care discussions are being made at a MDT, and head and neck cancer teams need to provide assurance around this important aspect of care delivery. 29 organisations have provided this.

### 8.5.7 Interval from diagnosis to decision to treat



- The median interval from diagnosis to MDT for larynx patients is 14 days and for oral cavity patients it is 18 days. Both of these times show a small decline from the first and second annual reports. Within the 62 day target for the two week wait referral to treatment (effective in England, from 1 January 2006)<sup>9</sup> it would be expected that this interval may have reduced significantly.
- The interval from diagnosis to MDT reflects transfer of the biopsy to the laboratory, processing of the specimen and its reporting, receipt of the report and booking to the next MDT. An interim step can be a return to out patients when an unexpected diagnosis arises.
- 12 per cent of patients with laryngeal cancer and 20 per cent with oral cavity cancer have their MDT management planned in more than 30 days from the biopsy being taken. This may represent for oral cavity cancer a contribution from the delay to biopsy reporting seen in Figure 8.5.5.1.
- To examine whether there is variation in interval within organisations or variation in different providers the chart below compares those diagnoses where the interval from diagnosis is less than 30 days and those of 30 days or longer.

Figure 8.5.7.1.b: Percentage of patients with interval from diagnosis to MDT of less than 30 days




- In a minority of organisations all patients have an interval from diagnosis to MDT of less than 30 days, whilst in a quarter over 20 per cent of patients exceed 30 days.
- Local teams should regularly monitor patients' pathway intervals and work with service improvement leads where regular delay is seen for both two week wait patients and those of other priorities.

The interval between diagnosis and treatment is critical for patients' psychological response, especially the hope of a possible cure against the burden of the treatment process. Sensitive access of information by the health care team to patients may assist their response.

### 8.5.7.2 Interval from diagnosis to date care plan agreed


Figure 8.5.7.2a Interval from diagnosis to date care plan agreed



- The median interval from diagnosis to date careplan agreed for larynx patients is 15 days, for oral cavity patients it is 19 days.
- It is an accepted standard that all patients are discussed in an MDT. This may reflect a non ideal pathway or may be a reflection of poor data quality.
- This chart appears to demonstrate that the majority of careplans are agreed within a short interval of the MDT meeting.

### 8.5.7.3 Interval from date care plan agreed to sending communication to primary care

Figure: 8.5.7.3a Interval from date care plan agreed to sending communication to primary care



- Where this information is recorded, in over 75 per cent of cases, primary care notification occurred on the same day. However, again only a third of cases had this information recorded. Best practice would be supported by confirmation that this standard is being achieved for all patients.

### 8.5.8 Number and percentage with histological confirmation prior to cancer careplan

Figure 8.5.8.a: Number of cases with histological confirmation prior to cancer careplan

No. of cases	Larynx	Oral cavity	All
Yes	758	746	1504
No	36	35	71
<b>Total</b>	<b>794</b>	<b>781</b>	<b>1575</b>

Figure 8.5.8.b: Percentage with histological confirmation prior to cancer careplan

As % of cases with both dates recorded	Larynx	Oral cavity	All
Yes	95.5	95.5	95.5
No	4.5	4.5	4.5
<b>Total</b>	<b>100</b>	<b>100</b>	<b>100</b>

- 1,815 patients can be associated with a diagnostic pathology date, and 1,575 of these patients have a careplan date (794 larynx, 781 oral cavity).
- Of these, 758 larynx (96 per cent) and 781 oral cavity (96 per cent) patients have histological confirmation recorded before the careplan.

- In head and neck cancer, it would be expected that all patients would have histological confirmation of a tumour prior to the agreement of a careplan. It is encouraging to see that a major improvement in confirmation that histological confirmation is available ahead of a care plan (80 per cent previously) and the results seem likely due to a significant improvement in data quality.
- There is a significant risk in proceeding to a cancer careplan without written histological confirmation of diagnosis, as rarely other conditions such as tuberculosis can mimic cancer.

### 8.5.9 Number and percentage with staging information recorded at time of cancer careplan

The percentage with staging information recorded at the time of cancer careplan reflects the percentage of patients with a careplan (indicated by record of 'management planned date' or non-blank 'careplan agreed date') with some recorded T, N or M diagnostic staging.

1,685 patients have a careplan date (recorded entry in careplan agreed date, or recorded entry in management planned date) (860 Larynx, 825 Oral Cavity).

1,407 have some diagnostic T, N or M staging recorded (724 Larynx, 683 Oral Cavity)

The tables summarise those 1,685 records with a careplan date:

Figure 8.5.9.a: Number of cases with staging information recorded at time of cancer careplan

Number	Larynx	Oral Cavity	Total
Yes	724	683	1407
No	136	142	278
<b>Total</b>	<b>860</b>	<b>825</b>	<b>1685</b>

Figure 8.5.9.b: Percentage with staging information recorded at time of cancer careplan

Percentage	Larynx	Oral Cavity	Total
Yes	84.2	82.8	83.5
No	15.8	17.2	16.5
<b>Total</b>	<b>100</b>	<b>100</b>	<b>100</b>

- Overall, of those patients with a recorded careplan, 83.5 per cent had recorded staging information. This figure is again encouraging with a 10 per cent rise in staging recorded. Historically this proved a difficult area in which to develop improvement as noted in the previous SWAHN audits <sup>49,50,51</sup>
- Staging of tumours is a critical part of the treatment pathway as well as being a key determinant of outcome, and is a key medical responsibility.
- All MDTs should continue to be encouraged to complete and validate staging information and validate outcome.

#### Good Practice Standard

The Expert Panels are unanimous that all MDTs must ensure the recording of accurate staging information in 100 per cent of patients.

### 8.5.10 Percentage having chest imaging by chest x-ray (CXR) or chest computerised tomography (CT) prior to cancer careplan


- Imaging of the chest (by CXR or CT) is recorded in 536 patients of the 1,681 who have a careplan date.
- This appears to represent that only 32 percent of patients with a recorded careplan had chest imaging.
- Whilst the level of completeness superficially appears poor for this item, it needs to be recognised that on further discussion with a number of reporting centres (as preparation for reporting this item by named trust) there appeared a marked discrepancy between the frequency of chest imaging delivered and that reported. Where a combined CT of neck and thorax was performed the imaging of the thorax was not always recorded. Therefore results need to be interpreted with caution.
- This output was intended to reflect best practice where, due to the recognised incidence of second primary lung cancers<sup>52</sup>, chest imaging should occur prior to a cancer careplan in all patients.
- Further training and consultation needs to occur to ensure accurate reflection of practice by this item.

#### Good Practice Standard

Synchronous malignancies of the chest can occur and have a significant impact on treatment options. Teams are encouraged to confirm that chest imaging has occurred in all head and neck cancer patients prior to planning treatment.

### 8.5.11 Interval from imaging request to date imaging performed (CT/MRI) contributory to pre-treatment staging complying with the Royal College of Radiologists' guidelines

Figure 8.5.11: Interval from imaging request to date imaging performed (CT/MRI) contributory to pre-treatment staging complying with the Royal College of Radiologists' guidelines



- Progression of a patient along the cancer care pathway requires prompt imaging. Most of the 871 patients with recorded imaging had their imaging in less than 14 days from request. A much reduced (54 patients 2005-2006) but still relevant number of patients' pathways, from the evidence collected, show delays. The figure below demonstrates the

imaging requests where a delay greater than 4 weeks occurred.

- However, a substantial number of organisations have not provided imaging data and therefore no firm conclusions can be made on the timeliness of imaging.

### 8.5.11.1 Imaging types where interval from imaging requests from data imaging is performed is 4 weeks or more

Figure 8.5.11.1.a: Imaging types where interval is 4 weeks or more


Imaging type	Larynx	Oral cavity	Total
X-ray	2		2
CT scan	3	4	7
MRI scan		4	4
Ultrasound		1	1
Other	3	1	4
<b>Total</b>	<b>8</b>	<b>10</b>	<b>18</b>

- In examining delays to CT/MRI scan this was found to apply to 7 organisations. Feedback will be provided in the local reports.

- No delays to barium studies were found this year.
- Considerable effort has occurred in the NHS in England to reduce 'delays to test' and this has been studied by the Healthcare Commission<sup>53</sup>. Cancer patients may have benefited from general improvements.
- A radiologist should be a core member of an MDT and this integration process should accelerate access to imaging.
- This information will continue to be looked at robustly in the future and organisations are encouraged to submit data to allow true comparison and assurance of timely pathways for patients.


### 8.5.12 Interval from diagnosis to first definitive treatment

Figure 8.5.12.a: Larynx; Interval from diagnosis to first definitive treatment



- The majority of laryngeal cancer patients' first treatment is primary radiotherapy, with a median interval of 45 days from the point of diagnosis. For the smaller number who undergo surgery the median interval from diagnosis to first recorded treatment is 25 days. These show little change.

Figure 8.5.12.b: Oral Cavity; Interval from diagnosis to first definitive treatment



- The majority of oral cavity cancer patient's first treatment is surgery, with a median interval of 33 days from the point of diagnosis. For the smaller numbers who undergo primary radiotherapy, the median interval from diagnosis to first recorded treatment is 52 days.
- The results shown above, highlight that laryngeal and oral cavity cancer patients wait a similar interval for radiotherapy. The median time of 45 to 52 days is of concern for the ability to reach the 62 day target (England only).
- Also, of concern, is that 50 per cent of patients are waiting for more than 45 to 52 days to commence radiotherapy, which may reflect resource limitations. This conclusion, that resource limitations particularly apply to radiotherapy, is supported by shorter access times for surgery in comparison for both sub-sites which share the initial common pathway to treatment decision.
- Best practice suggests that primary radiotherapy should commence within 28 days of diagnosis <sup>54,55</sup>.

### 8.5.12.1 Interval from diagnosis to first definitive treatment by trust and by type of treatment

The following chart examines by trust the interval from diagnosis to first definitive treatment and the intent of treatment. Only providers reporting to the audit 5 or more cases in a category are presented in order to assure patient confidentiality. Small numbers skew the pathway.

Figure 8.5.12.1a: Interval from diagnosis to first definitive treatment by trust and by type of treatment (for those providers submitting 5 or more larynx cases).

Larynx						
Treatment	Trust	Treatment intent	No. of cases	Min. No. days	Max. No. days	Median No. days
Radiotherapy	All Hospitals	Curative	225	14	107	46.5
	Barking Havering & Redbridge Hospitals NHS Trust	Curative	6	27	38	34.5
	Bradford Teaching Hospitals NHS Foundation Trust	Curative	9	35	50	45
	Brighton and Sussex University Hospitals NHS Trust	Curative	6	32	55	50.5
	Gloucestershire Hospitals NHS Foundation Trust	Curative	7	27	59	47
	Hull and East Yorkshire Hospitals NHS Trust	Curative	21	16	107	36
	Luton and Dunstable Hospital NHS Foundation Trust	Curative	5	41	80	45
	Maidstone & Tunbridge Wells NHS Trust	Curative	9	27	99	49
	The Newcastle Upon Tyne Hospitals NHS Foundation Trust	Curative	11	33	96	49
	Norfolk and Norwich University Hospital NHS Trust	Curative	7	39	104	61
	North Bristol NHS Trust	Curative	8	40	75	50
	Plymouth Hospitals NHS Trust	Curative	5	14	49	39
	Poole Hospital NHS Foundation Trust	Curative	6	21	62	46.5
	Royal Devon and Exeter Healthcare NHS Foundation Trust	Curative	9	21	63	38
	Shrewsbury and Telford Hospital NHS Trust	Curative	9	32	90	47
	South Devon Healthcare NHS Foundation Trust	Curative	8	28	56	39
	South Tees Hospitals NHS Trust	Curative	22	27	68	46.5
	The Royal Wolverhampton Hospitals NHS Trust	Curative	6	26	52	35.5
	United Lincolnshire Hospitals NHS Trust	Curative	9	41	85	42
	University Hospital Birmingham NHS Foundation Trust	Curative	18	31	77	53.5
University Hospitals of Leicester NHS Trust	Curative	9	26	67	41	
	<b>WELSH NETWORK</b>	<b>Curative</b>	<b>35</b>	<b>28</b>	<b>91</b>	<b>56</b>

Larynx							
Treatment	Trust	Treatment intent	No. of cases	Min. No. days	Max. No. days	Median No. days	
Radiotherapy	All Hospitals	Not known	72	2	234	45.5	
	Cambridge University Hospitals NHS Foundation Trust	Not known	14	5	47	19	
	North Bristol NHS Trust	Not known	12	27	96	45.5	
	Nottingham University Hospitals NHS Trust	Not known	16	2	56	37	
	University Hospitals Coventry and Warwickshire NHS Trust	Not known	7	34	70	46	
	<b>WELSH NETWORK</b>	<b>Not known</b>	<b>23</b>	<b>7</b>	<b>234</b>	<b>59</b>	
Surgery	All Hospitals	Curative	153	0	114	25.5	
	Bradford Teaching Hospitals NHS Foundation Trust	Curative	7	9	82	38	
	Gloucestershire Hospitals NHS Foundation Trust	Curative	5	0	111	57	
	Hull & East Yorkshire Hospitals NHS Trust	Curative	7	6	34	24	
	The Newcastle Upon Tyne Hospitals NHS Foundation Trust	Curative	10	16	50	40.5	
	North Cumbria Acute Hospitals NHS Trust	Curative	8	16	66	26	
	Northampton General Hospital NHS Trust	Curative	7	21	44	32	
	Oxford Radcliffe Hospitals NHS Trust	Curative	7	5	35	21	
	Royal Cornwall Hospitals NHS Trust	Curative	13	0	55	19	
	Sheffield Teaching Hospitals NHS Trust	Curative	14	6	114	35	
	South Devon Healthcare NHS Foundation Trust	Curative	5	3	44	21	
	South Tees Hospitals NHS Trust	Curative	10	20	60	34	
	Derby Hospitals NHS Foundation Trust	Curative	25	0	75	21	
	University Hospital Birmingham NHS Foundation Trust	Curative	8	18	49	29.5	
	University Hospitals of Leicester NHS Trust	Curative	5	9	64	25	
	York Hospitals NHS Foundation Trust	Curative	11	0	41	25	
	<b>WELSH NETWORK</b>	<b>Curative</b>	<b>11</b>	<b>0</b>	<b>75</b>	<b>21</b>	
	Surgery	All Hospitals	Not known	22	0	63	13.5
		North Bristol NHS Trust	Not known	9	0	56	35
		Nottingham University Hospitals NHS Trust	Not known	8	0	23	13.5
University Hospitals Coventry and Warwickshire NHS Trust		Not known	5	0	63	35	

Figure 8.5.12.1.b: Interval from diagnosis to first definitive treatment by trust and by type of treatment (for those providers submitting 5 or more oral cavity cases)

Oral Cavity						
Treatment	Trust	Treatment intent	No. of cases	Min. No. days	Max. No. days	Median No. days
Radiotherapy	All Hospitals	Curative	24	31	161	59.5
	Newcastle Upon Tyne Hospitals NHS Foundation Trust	Curative	5	31	47	37
	South Tees Acute Hospitals NHS Trust	Curative	9	38	87	61
	United Lincolnshire Hospitals NHS Trust	Curative	5	38	70	58
	<b>WELSH NETWORK</b>	<b>Curative</b>	<b>5</b>	<b>68</b>	<b>161</b>	<b>97</b>
Surgery	All Hospitals	Curative	385	0	106	33.5
	Barking Havering and Redbridge Hospitals NHS Trust	Curative	6	13	55	28
	Bradford Hospitals NHS Trust	Curative	16	20	62	37.5
	Brighton and Sussex University Hospitals NHS Trust	Curative	8	15	57	32
	Cambridge University Hospitals NHS Foundation Trust	Curative	12	4	61	15
	East Sussex Hospitals NHS Trust	Curative	7	14	50	41
	Gloucestershire Hospitals NHS Trust	Curative	10	21	77	51.5
	Hull and East Yorkshire Hospitals NHS Trust	Curative	10	20	57	31.5
	Mid Yorkshire Hospitals NHS Trust	Curative	13	11	60	43
	Newcastle Upon Tyne Hospitals NHS Foundation Trust	Curative	28	16	101	33.5
	North Cumbria Acute Hospitals NHS Trust	Curative	9	40	106	53
	Northampton General Hospital NHS Trust	Curative	10	14	69	33.5
	Oxford Radcliffe Hospitals NHS Trust	Curative	9	0	64	30
	Poole Hospital NHS Foundation Trust	Curative	20	0	53	31.5
	Royal Devon and Exeter Healthcare NHS Foundation Trust	Curative	18	3	87	34.5
	Shrewsbury and Telford Hospital NHS Trust	Curative	12	16	43	25
	Royal Surrey County Hospital NHS Trust	Curative	15	6	69	23
	South Devon Health Care NHS Foundation Trust	Curative	10	16	56	41.5
	South Tees Hospitals NHS Trust	Curative	11	0	105	52
	Southend Hospital NHS Trust	Curative	12	10	71	32.5
Derby Hospitals NHS Foundation Trust	Curative	25	0	61	20	

Oral Cavity						
Treatment	Trust	Treatment intent	No. of cases	Min. No. days	Max. No. days	Median No. days
	The Hillingdon Hospital NHS Trust (Mount Vernon Cancer Centre)	Curative	11	19	61	34
	The Royal Wolverhampton Hospitals NHS Trust	Curative	11	0	49	29
	United Lincolnshire Hospitals NHS Trust	Curative	12	0	61	38
	University Hospital Birmingham NHS Foundation Trust	Curative	34	15	73	39.5
	University Hospitals of Leicester NHS Trust	Curative	18	0	62	33.5
	York Hospitals NHS Foundation Trust	Curative	24	0	63	39.5
	<b>WELSH NETWORK</b>	<b>Curative</b>	<b>14</b>	<b>0</b>	<b>77</b>	<b>38</b>
<b>Surgery</b>	All Hospitals	Not known	50	2	85	30.75
	Mid Yorkshire Hospitals NHS Trust	Not known	5	34	85	43
	Mid Essex Hospital Services NHS Trust	Not known	12	2	41	14.5
	Nottingham University Hospitals NHS Trust	Not known	21	12	47	30
	University Hospitals Coventry and Warwickshire NHS Trust	Not known	12	13	48	31.5

### Larynx

- For patients undergoing surgery with stated curative intent the median interval from diagnosis to first treatment was 25.5 days with a range from 0 to 114 days.
- For patients undergoing radiotherapy with curative intent was 46.5 days, with a range of 14 to 107.


### Oral cavity

- For patients undergoing surgery with stated curative intent the median interval from diagnosis to first treatment was 33.5 days with a range from 0 to 106 days.
- For patients undergoing radiotherapy with curative intent was 59.5 days, with a range of 31 to 161.

- The results demonstrate significant variation within organisations, but confirms the previously identified problem in accessing radiotherapy services.
- For surgery considerable variation is again seen, and MDTs should be encouraged to process map the pathway to minimise access times.
- MDTs may benefit from monitoring this interval prospectively between audits, and considering both patients on two week wait paths and those on non two week wait paths. The 31 day treatment target is from care plan agreed to start of definitive treatment but does not include the interval from diagnosis to care plan agreed.
- The fourth annual report will examine time intervals for treatment in recurrence.

### 8.5.13 Interval from referral to first definitive treatment in England

Figure 8.5.13.a: Interval from referral to first definitive treatment in England



The two week wait target for urgent cancer referral applies to England and figures above only include patients from England.


The 62 day target came into effect in England on 1 January 2006 and sets an expectation that patients referred under the two week wait will commence treatment in under 62 days.

- The median interval for larynx patients not referred via the two week rule was 69 days, but for two week wait patients it was 60 days.
- The median interval for oral cavity patients not referred via the two week rule was 54 days, but for two week wait patients it was 55 days.

- Whilst the median now falls less than 62 days for both larynx and oral cavity patients, considerable work remains to achieve this standard for all patients from date of referral to start of treatment. It should be noted that the intervals reported for two week rule patients are unadjusted (for cancellations, did not attend and deferred treatments etc).

## 8.5.14 Interval from surgical resection to reporting on resective specimen

Figure 8.5.14.a: Interval from surgical resection to reporting on resective specimen




- The median interval to reporting for larynx is 8 days and oral cavity is 11 days.
- In oral cavity, a consideration may be those specimens with composite bone resection which may require decalcification for complete assessment. In some circumstances it may be appropriate to consider issuing a preliminary report on the margins and neck status so that the further management of the patient can be decided without delay. Trusts should discuss with pathology colleagues if and when this approach might be possible, and also whether more rapid decalcification protocols could be introduced without sacrificing the quality of the final pathology report.
- However, the curves for larynx and oral cavity are very similar suggesting that this may be a resource issue. Further work is required to define this part of the treatment pathway.

### 8.5.15 Interval from date of surgery to post-operative radiotherapy

The first recorded surgery date was considered. The first recorded radiotherapy after the surgery date was then compared to it, and the interval derived.

Figure 8.5.15.a: Interval from date of surgery to post-operative radiotherapy



The two week wait target for urgent cancer referral applies to England and figures above only include patients from England.

- The median interval to post-operative radiotherapy was 56 days for larynx and 58 days for oral cavity. It should be noted the sample size is small.
- This part of the pathway reflects completion of post surgical healing, confirmation of resective pathology and preparation to proceed to start radiotherapy including production of a mould and planning.
- Tumour biology and previous work suggest that there should be less than 6 weeks (42 days) to commencement of radiotherapy following surgery<sup>55</sup>. The results presented suggest considerable delay to commencing radiotherapy following both oral and laryngeal surgery.
- Further work is required to assess the contributory elements to this process.
- Pre-booking of adjuvant radiotherapy at the time of decision to treat may assist in reducing this interval.

### 8.6 Care provided - squamous cell carcinoma larynx

- 1,049 cases of larynx cancer were registered onto the DAHNO application.
- 891 cases have a careplan of which 698 (78.3 per cent) of these cases have a careplan with recorded treatment. This indicates either recorded treatment or a recorded careplan indicating palliative or supportive care.

Figure 8.6.a: Care provided - squamous cell carcinoma larynx

First recorded treatment	Early stage	Late stage	Not staged*	Total
Surgery	98	99	61	258
Radiotherapy	182	81	102	365
Chemotherapy	4	24	11	39
Chemoradiotherapy	4	16	6	26
Specialist palliative care	0	5	5	10
Not recorded				351
<b>Total</b>	<b>288</b>	<b>225</b>	<b>185</b>	<b>1,049</b>

\*Not staged – insufficient T, N, M for categorising early / late

- The data quality for this item has improved significantly.
- The established treatment for the majority of patients with laryngeal cancer in England and Wales is radiotherapy and this matches the results shown above.
- The previously noted increased number of early staged patients having received surgery as their first definitive treatment, matching to a rising popularity of endolaryngeal resection is not so evident with this years increased submission. Only one third of early laryngeal lesions were treated surgically.
- In advanced disease where appropriate, radical surgery (laryngectomy) with adjuvant radiotherapy is the curative treatment of choice. In those not suitable for surgery organ sparing protocols are being utilised.

#### 8.6.1 Percentage having surgical resection with curative intent

- The intent was curative for 202 of the 255 cases with recorded surgery (79 per cent).
- Those with curative intent for surgery make up 29 per cent of the 698 with some recorded treatment, and 19.2 per cent of the total 1,049 cases.
- The 53 cases with intent other than curative show that: four are with palliative intent, 10 are with diagnostic intent, 12 are 'not known' and 25 have no intent recorded. 2 cases have incompatible codes from csv uploaded records.

#### 8.6.2 Percentage by category of clearance for surgical resection margins

- Of the 202 records with curative intent, 58 per cent of records contained this information, a marked improvement in recording.
- In the 109 cases where laser excision of early lesions has occurred, a similar percentage had not had margins recorded (compared to open surgery) but as expected fewer cases had margins greater than 5 mm. Margins may be much narrower than for open surgery<sup>56</sup> and thus obviate the classification used in data collection.
- Where open surgery was performed, one third of cases had margins over 1 mm clear, and a quarter more than 5 mm clear. However, the number not recorded obviates any significant conclusion.

### 8.6.3 Percentage having pre-treatment dental assessment

- A pre-treatment dental assessment is recorded for less than 6 per cent of the 1,049 larynx registrations (62 patients) and is a similar figure to last year (7 per cent). This is likely to reflect poor data quality.
- This is 9 per cent of the 688 cases with some record of treatment.
- An additional 64 larynx and oral cavity patients had a dental assessment but no date of treatment was recorded.

It is disappointing that the volume of data has not increased and MDTs are recommended to collect this data.

The Expert Panel members would hope that this is not an accurate reflection of practice as it is extremely important to maintain good dental health throughout treatment <sup>57,58</sup>.

#### Good Practice Standard

Dental health during and after treatment for head and neck cancer is a significant contributor to patient well being. MDTs are strongly encouraged to provide information to confirm that care is being provided.

### 8.6.4 Percentage having pre-operative / pre-treatment speech and swallowing assessment (includes for laser cordectomy) and percentage having pre-operative / pre-treatment (includes radio and chemotherapy) dietetic assessment

- A pre-treatment speech and swallowing assessment is recorded for 8 per cent of the 1,049 larynx registrations (81 patients).
- This is 12 per cent of the 688 cases with some record of treatment.
- The submission of this item has improved.
- 15 per cent of the 255 cases undergoing surgery.
- Of the 92 patients reported as having a laryngectomy, 35 (38 per cent) are recorded as having a speech and language assessment. It would be expected this would be over 80 per cent.
- A further 25 of those having a speech and swallowing assessment had this after treatment had commenced.
- Patient representatives feel it is imperative that speech and swallowing and dietetic support is available to all patients with laryngeal cancer from diagnosis. The lack of appropriate professional support should be seen as a priority requirement. For those undergoing laryngectomy the speech therapist plays an important role in supporting choice in the method of restored speech <sup>59,60</sup>.
- An additional 50 larynx and oral cavity patients had a speech and language assessment but no date of treatment was recorded (18 larynx and 32 oral cavity).

#### Good Practice Standard

The absence of demonstration of appropriate speech and language support being provided to patients with laryngeal cancer remains a cause for concern, particularly in those undergoing laryngectomy.

Active involvement of speech and language colleagues in the audit process is to be encouraged by all MDTs.

- A pre-treatment dietetic assessment is recorded for 3 per cent of the 1,049 larynx registrations (27 patients) and is likely to reflect poor data quality.
- This is 4 per cent of the 688 cases with some record of treatment.
- Over 39 per cent of those having a dietetic assessment had this prior to treatment.
- 41 larynx patients had a post treatment dietetic assessment.

**Good Practice Standard**

Dietetic support is important through all parts of the patient pathway, particularly in those undergoing any form of treatment where the morbidity of the treatment can be reduced by appropriate support. MDTs are encouraged to confirm the dietetic care provided.

Whilst the Expert Panel members believe that this is not a true reflection of current practice, they are aware of countrywide shortages in allied health professional posts to support cancer MDTs. The Expert Panel members realise this has significant resource implications, but their view is that speech and language therapists (SALT) and dietetic input is mandatory in all stages of laryngeal cancer <sup>61</sup>.

They hope all MDTs strive to achieve this input. Resource bids would be supported by accurate data collection to quantify deficit and its correct capture onto the DAHNO application would identify the national profile of provision.

**Good Practice Standard**

Phase II of DAHNO has extended sections on surgical voice restoration and dietetic information. It is hoped that active involvement of all health professionals who care for head and neck cancer patients will be encouraged by MDTs to provide a comprehensive record of the multi-professional care provided.

**8.6.5.a: Percentage receiving each category of surgical procedure (including surgery to neck, surgical voice restoration)**

- 255 patients have at least one surgical procedure recorded.

Main categories of operation (patients may be counted in more than one category):

Figure 8.6.5.a: Percentage receiving each category of surgical procedure (including surgery to neck, surgical voice restoration)

Larynx patients – surgery summary	Number	Percentage of 255 with surgery
Micro-laryngeal resection	112	43.9
• of these 112 patients the number having neck dissection	0	
Laryngectomy	92	36.1
• of these 92 the number having supraglottic laryngectomy	4	
• of these 92, the number having neck dissection	11	
• of these 92, number having primary surgical voice restoration	15	
More extensive resection	8	
Neck dissections (including those mentioned with laryngectomy and more extensive resection)*	66	25.9
Comprehensive neck dissection	31	12.2
Modified neck dissection	14	5.5
Selective neck dissection	27	10.6

\*More extensive resection describes where a portion of the hypopharynx or oropharynx is removed beyond that normally included in a total laryngectomy.

- Endolaryngeal microsurgical resection accounted for 44 per cent of surgical procedures and its frequency is rising (compared to 39 per cent last year, and 30 per cent in 2004-2005) as an alternative to radical radiotherapy in early laryngeal cancer. The audit will continue to monitor this trend with interest.
- 36.1 per cent of surgical procedures were laryngectomies, with 95 per cent of these being total laryngectomies with only 17 per cent recorded as having primary surgical voice restoration. The expert panels felt again that this was not representative of current clinical practice.
- The Expert Panel members would expect that the majority of patients (in excess of 80 per cent) undergoing this procedure would be counselled by a speech and language therapist pre-operatively and be offered primary surgical voice restoration. The availability of speech and language therapists may be a confounding factor but the absence of full data collection above (Figure 8.6.5.a) limits the ability to resolve this.
- The fourth annual collection period includes an extensive section on surgical voice restoration which is hoped will encourage speech and language colleagues to more actively participate in the audit.
- A small number of more extensive procedures are identified for very advanced tumours.
- 317 cases have recorded radical (curative or adjuvant) radiotherapy. This is 74 per cent of the 426 with recorded radiotherapy.
- Those with radical radiotherapy make up 62 per cent of the 688 with some recorded treatment, and 40.6 per cent of the total 1,049 cases.
- The 71 other cases with recorded radiotherapy break down as 14 with palliative intent and 67 with no intent recorded.
- The majority of patients have radiotherapy as primary treatment or as a planned adjuvant treatment within their initial cancer care plan. However, some patients, having undergone primary surgery, may be advised to proceed to post-operative radiotherapy based on adverse features evident in their resective histology report. Of the 32 patients having post surgical radiotherapy, 6 had undergone microlaryngeal resection, and 20 total laryngectomy. The former would suggest that margins at laser excision were close or incomplete and the latter could be influenced by both poor prognostic indicators in the primary specimen or neck.
- The Expert Panel members have concern that there may be deficiencies in capturing radiotherapy data. This still accounts for a small number of patients and thus will be looked at in future reports when sufficient cases have been captured.
- The availability of Radiotherapy Episode Statistics (RES) data from 2009, will be an opportunity for DAHNO to acquire radiotherapy data more readily.

### Good Practice Standard

It is important that all components of a surgical procedure are recorded to provide a true reflection of the breadth and complexity of surgical management. Surgical voice restoration appears currently under-represented in the surgical procedures submitted.

### 8.6.6 Percentage having radical radiotherapy with curative intent

The established treatment for the majority of patients with laryngeal cancer in England is radiotherapy, and this matches to the results shown above.

### 8.6.7 Percentage having palliative treatment by type (ie radiotherapy, chemotherapy and surgery)

Of those presenting with advanced disease only small numbers would be expected to get true palliative treatment. It will be of interest in the future to assess what benefit they accrue, and whether they have received this as part of a clinical trial.

- 21 patients have recorded palliative treatment, 2 per cent of the total 1,049 registrations, 3 per cent of the 688 with recorded treatment.
- The 21 cases break down as: 4 cases of palliative surgery, 14 cases of palliative radiotherapy and 4

cases with palliative chemotherapy. (one patient had two palliative radiotherapy treatments).

### 8.6.8 Percentage having chemotherapy (including categories such as 'adjuvant' and 'neo-adjuvant')

The previous view of the Expert Panel members, was that there was no available evidence supporting the notion that chemotherapy in isolation improves long term survival in laryngeal cancer<sup>62</sup>. However, there has been renewed interest in organ preservation using chemotherapy with some evidence suggesting the benefits of concurrent chemoradiation<sup>63</sup> and another, suggesting induction chemotherapy<sup>64</sup> can be used to predict complete clinical responders. Again it will be of interest to assess the benefits as they accrue with time.

- The intent was curative, adjuvant or neo-adjuvant for 62 of the 85 cases with recorded chemotherapy (73 per cent).
- These 62 cases are 9 per cent of the 688 with some recorded treatment, and 8 per cent of the total 1,049 cases.
- The 62 cases with a chemotherapy record break down by intent as: 41 curative, 12 adjuvant, 9 neo-adjuvant and 4 palliative. 19 cases had unknown intent or were uncoded.
- A review where it appeared that patients had chemotherapy as sole treatment in laryngeal cancer, identified that the majority were given as part of a chemo radiotherapy regimen, but there were deficiencies in capturing the complete patient pathway.

### 8.6.9 Percentage referred to specialist palliative care team

There was only data in 10 cases of referral to a specialist palliative care team.

Specialist palliative care practitioners should be essential members of the core MDT team. Current processes of data capture may not pick up this activity as the provision can occur in a variety of non hospital organisations eg community and hospice care. The National Head and Neck Cancer Audit Project Team will be interested to hear about successful methodology to integrate this element of data capture from Cancer Networks.

### Good Practice Standard

Data collection of care delivered along the whole patient pathway is a key requirement to understand the whole package of care. Cancer Networks are encouraged to facilitate this data collection.

### 8.6.10 Percentage receiving no specific treatment (including active monitoring category)

- 395 larynx cases have no recorded surgery, chemotherapy or radiotherapy.
- None of these cases have 'supportive' as their careplan intent.
- 14 of the other cases have 'active monitoring' as the careplan intent.

### 8.6.11 Percentage of patients where careplan agreed matches careplan delivered

- 891 of the 1,049 registrations have a recorded careplan (84.9 per cent).
- 532 of 891 patients have a treatment record matching the careplan (59.7 per cent), of which 559 careplans matched.
- Where the careplan was not matched the commonest occurrence was a proposed combined therapy, where only one of the treatments was recorded. This most likely reflects poor data quality but could reflect changes to planned management in surgery patients due to resective pathology findings or morbidity from therapy.
- MDTs are encouraged to record all treatments provided.

Note: Each patient can have more than one careplan. Agreement between careplan and delivery was taken to require a match of every planned treatment in all recorded careplans with a recorded treatment.

## 8.7 Care provided - squamous cell carcinoma oral cavity

- 986 cases of oral cavity cancer were registered onto the DAHNO application.
- 841 cases have a careplan of which 649 (77.1 per cent) of these cases have a careplan with recorded

treatment. This indicates either recorded treatment or a recorded careplan indicating palliative or supportive care.

Note: 649 cases have been used as 'the number of cases with recorded treatment' in the calculation of percentages in this section.

Figure 8.7.a: Care provided – squamous cell carcinoma oral cavity

First recorded treatment	Early stage	Late stage	Not staged*	Total
Surgery	250	144	138	532
Radiotherapy	22	31	13	66
Chemotherapy	1	14	8	23
Chemotherapy and radiotherapy (same day)	0	10	3	13
Specialist palliative care	0	9	6	15
Not recorded				337
<b>Total</b>	<b>273</b>	<b>208</b>	<b>168</b>	<b>986</b>

\*Not staged – insufficient T, N, M for categorising as early/late

- The established treatment for the majority of patients with oral cavity cancer in England and Wales is primary surgery, and this matches the results shown above.
- Of the 649 with recorded treatment, 74 per cent have sufficient staging data to allow categorisation into early and late disease. Chemotherapy and chemoradiotherapy although in small numbers are almost exclusively found in the treatment of late stage disease.

### 8.7.1 Percentage having pre-treatment dental assessment

- A pre-treatment dental assessment is recorded for 20 per cent of the 841 oral cavity registrations with care plans (170 patients).
- This is 27 per cent of the 620 cases with some record of treatment.

The Expert Panel members would hope that this is not a true reflection of practice as it is extremely important to maintain good dental health throughout treatment <sup>57,58</sup>.

### Good Practice Standard

Dental health, during and after treatment for head and neck cancer, is a significant contributor to patient well being. In oral cavity cancer proximity to the mandible or its direct involvement and the risks of ingress of infection following therapy, keep dental health as a high priority. MDTs are strongly encouraged to provide information to confirm that care is being provided.

### 8.7.2 Percentage having surgical resection with curative intent

- The intent was curative surgery for 441 of the 531 cases with recorded surgery (83 per cent).
- Those with curative surgery make up 71 per cent of the 620 with some recorded treatment, and 52 per cent of the total 841 cases with recorded care plans.
- The 90 cases with intent other than curative break down as; 1 with palliative intent, 9 with diagnostic intent, 1 with staging intent, 28 with intent not known and 51 with intent not recorded.

### 8.7.3 Percentage by category of clearance for surgical resection margins

Percentages of 441 cases recorded as surgery with curative intent.

Figure 8.7.3.a: Care provided - squamous cell carcinoma oral cavity

Category	per cent
Not recorded	38.3
1. Margin involved	6.1
2. <1 mm clear	6.6
3. 1-5 mm clear	24.3
4. > 5 mm clear	20.2
5. Uncertain	2.0
8. Not applicable	2.5

- Using the Royal College of Pathologists guidelines<sup>65</sup>, there was evidence in only 20 per cent of cases, of an acceptable clear margin.
- Only 58 per cent of resective pathology records show details on margins of normal tissue around the tumour, which limits the conclusions that can be drawn.
- Adequate resective margins are a predictor of both local recurrence and surgical adequacy<sup>66,67</sup>.
- Of the records completed, a quarter of them demonstrate margins greater than 5mm.

### 8.7.4 Percentage having pre-operative speech and swallowing assessment and percentage having pre-operative / pre-treatment dietetic assessment

- A pre-operative speech and swallowing assessment is recorded for 13 per cent of the 841 oral cavity registrations with care plans (108 patients).
- This is 17 per cent of 634 cases with some record of treatment.
- Patients undergoing major surgery require extensive swallowing rehabilitation support.
- An additional 56 patients had speech and language assessment after the date of the first treatment.

#### Good Practice Standard

The absence of demonstration of appropriate speech and language and swallowing support, being provided to patients with oral cavity cancer, remains a cause for concern, particularly in those undergoing major surgery.

Active involvement of speech and language colleagues in the audit process is to be encouraged by all MDTs.

- A pre-treatment dietetic assessment is recorded for 6 per cent of the 841 oral cavity registrations with care plans (54 patients).
- This is 9 per cent of the 634 cases with some treatment.
- An additional 46 patients had a dietetic assessment after the date of the first treatment.

#### Good Practice Standard

Dietetic support is important through all parts of the patient pathway, particularly in those undergoing any form of treatment where the morbidity of the treatment can be reduced by appropriate support. MDTs are encouraged to confirm the dietetic care provided.

Whilst the Expert Panel members believe that this is not a true reflection of current practice, they are aware of countrywide shortages in allied health professional posts to support cancer MDTs. The Expert Panel members realise this has significant resource implications, but their view is that speech and language therapists (SALT) and dietetic input is mandatory. They hope all MDTs strive to achieve this input. Resource bids would be supported by accurate data collection to quantify deficit and its correct capture onto the DAHNO application would identify the national profile of provision.

### 8.7.5 Percentage receiving each category of surgical procedure (including surgery to neck, and flap repair)

Figure 8.7.5.a: Percentage receiving each category of surgical procedure (including surgery to neck, and flap repair)

Oral cavity patients - surgery summary	Count	Percentage of 531 patients with surgery
Floor of mouth excision	79	14.9
of these 79, the number having neck dissection	39	
Buccal mucosa excision	53	10
of these 53, the number having neck dissection	17	
Patients having tongue procedures	180	
of these 180, the number having neck dissection	89	
patients having total glossectomy	5	
patients having partial glossectomy	107	
patients having excision lesion of tongue	76	
Patients having mandible procedures	84	15.8
of these 84, the number having neck dissection	62	
patients having extensive mandibulectomy	5	
patients having hemimandibulectomy	22	
patients having marginal mandibulectomy	36	
patients having mandibulectomy or excision lesion	21	
Total maxillectomy	2	0.4
Partial maxillectomy	23	4.3
Comprehensive neck dissection (includes those listed previously)	31	5.8
Modified neck dissection (includes those listed previously)	32	6.0
Selective neck dissection (includes those listed previously)	139	26.2
All neck dissections	210	39.5
Reconstruction mouth	94	17.7
with flap	36	
with primary closure	5	
with buccal flap	12	
with pectoralis major	1	
with radial forearm	38	
With SSG	6	
Reconstruction mouth by cancer site		
tongue	23	
lip	1	
gum	15	
mouth floor	22	
palate	6	
cheek mucosa	14	
mouth vestibule	5	
retromolar trigone	6	
Mouth unspecified	2	

- Surgery followed by adjuvant radiotherapy – determined by histological findings is the commonest treatment modality for oral squamous cell carcinoma.
- Management of the N0 neck remains a contentious issue, but may be influenced by the requirement to enter the neck for reconstructive options.
- Of those patients undergoing floor of mouth excision only 50 per cent are recorded as having a neck dissection. The Expert Panels felt that this was a low figure compared to expected practice, but may reflect data quality issues.
- The number of reconstructions seems low, but may reflect that the method of data capture by multiple fields within the application, makes data capture difficult, and that the number of fields available is inadequate. A revision of the application has increased the number of procedural elements that can be recorded. Further review will be carried out in next year's report. Surgical teams are encouraged to record all aspects of surgical care provided.
- The majority of patients have radiotherapy as primary treatment or as a planned adjuvant treatment within their initial cancer careplan. Some patients, having undergone primary surgery, may be advised to proceed to post-operative radiotherapy based on adverse features in their resective histology report. The Expert Panel members have concern that there may be deficiencies in capturing radiotherapy data. This accounts for a small number of patients and thus will be looked at in future reports when sufficient cases have been captured.

#### Good Practice Standard

It is important that all components of a surgical procedure are recorded to provide a true reflection of the breadth and complexity of surgical management.

#### 8.7.6 Percentage having radical radiotherapy (including brachytherapy, post-operative planned and unplanned)

- 102 cases have recorded radical (curative or adjuvant) radiotherapy. This is 74 per cent of the 137 cases with recorded radiotherapy.
- Those with radical radiotherapy make up 16 per cent of the 634 with some recorded treatment, and 10 per cent of the total 986 cases.
- 1 case of lateral border of tongue cancer was recorded as receiving brachytherapy.
- The 35 other cases with recorded radiotherapy break down as; 11 with palliative intent and 14 not known and 10 with no intent recorded.

#### Good Practice Standard

A general theme of the analysis is that the second phase of treatment is not being well captured. This may reflect MDT data capture processes. Teams are encouraged to capture all parts of the patients' careplan.

#### 8.7.7 Percentage having palliative treatment by type (ie radiotherapy, chemotherapy, surgery)

- 17 patients have recorded palliative treatment, 2 per cent of the total 986 registrations, 2.5 per cent of the 686 with recorded treatment.
- The 17 cases break down as: 1 case of palliative surgery, 11 cases of palliative radiotherapy and 6 cases with palliative chemotherapy (one patient had palliative chemoradiation).

#### 8.7.8 Percentage having chemotherapy (including categories such as 'adjuvant' and 'neo adjuvant')

In the view of the Expert Panel members, there is no currently available evidence supporting the notion that chemotherapy in isolation improves long-term survival in oral cavity cancer<sup>62</sup>. There is, however, some evidence suggesting the benefits of concurrent chemoradiation<sup>63</sup>, and again it will be of interest to assess the benefits as they accrue with time.

- The intent was curative, adjuvant or neo-adjuvant for 32 of the 48 cases with recorded chemotherapy (67 per cent).

- These 48 cases are 7 per cent of the 686 with some recorded treatment, and 5 per cent of the total 986 cases.
- The 48 cases with a chemotherapy record breakdown by intent is; 19 curative, 7 neo-adjuvant, 6 adjuvant, 6 palliative and 7 with unknown intent and 3 not coded.
- A review where it appeared that patients had chemotherapy as sole treatment in oral cavity cancer, identified that the majority were given as part of chemo radiotherapy regimen, but there were deficiencies in capturing the complete patient pathway.

### 8.7.9 Percentage referred to specialist palliative care team

There was only data in 15 cases of referral to a specialist palliative care team.

Specialist palliative care practitioners should be essential members of the core MDT team. Current processes of data capture may not pick up this activity as the provision can occur in a variety of non hospital organisations eg community and hospice care. The National Head and Neck Cancer Audit Team will be interested to hear about successful methodology to integrate this element of data capture from Cancer Networks.

#### Good Practice Standard

Data collection of care delivered along the whole patient pathway is a key requirement to understand the whole package of care. Cancer Networks are encouraged to facilitate this data collection.

### 8.7.10 Percentage receiving no specific treatment (including active monitoring category)

- 340 oral cavity cases have no recorded surgery, chemotherapy or radiotherapy.
- None of these have 'supportive' as their careplan intent.
- 12 of the other cases have 'active monitoring' as their careplan intent.

### 8.7.11 Percentage of patients where careplan agreed matches careplan delivered

- 841 of the 986 registrations have a recorded careplan (85.3 per cent).
- 511 patients of 841 (representing 578 care plans) have a treatment record matching the careplan (61 per cent).
- Where the careplan was not matched the commonest occurrence was a proposed combined therapy, where only one of the treatments was recorded. This most likely reflects poor data quality but could reflect changes to planned management in surgery patients due to resective pathology findings or morbidity from therapy.
- MDTs are encouraged to record all treatments provided

Note: Each patient can have more than one careplan and each careplan can list up to four planned treatments. Agreement between careplan and delivery was taken to require a match of every planned treatment in all recorded careplans with a recorded treatment.

## 8.8 Patient outcomes

### 8.8.1 One year, two year and three year survival

The audit is too young to provide data for survival analyses.

A case file was obtained from the Office for National Statistics of patients registered in the audit for which ONS had evidence of the registrant having died, from death certification. Of the 1,049 larynx cancers recorded 122 were deceased within 1 year of diagnosis. This includes deaths from all causes.

Of the 986 oral cavity registrants 134 had died within one year of diagnosis. One oral cavity patient was excluded with a date of death before a date of diagnosis. This includes deaths from all causes.

These deaths may be related to a number of causes such as aggressive disease or deaths from non cancer causes.

Revisiting those cases diagnosed in the second annual report, of the 742 laryngeal cancer patients 108 died within 1 year of diagnosis, and a further 51 (total 159) were deceased within 2 years of diagnosis.

Of the 692 oral cavity patients reported in the second annual report, 175 died within 1 year of diagnosis, with a further 69 deceased within 2 years of diagnosis (making a total of 244).

**8.8.2 Locoregional recurrence within 1 year and 2 years of diagnosis**

The audit is too young to provide data for analysis of recurrence.

**8.8.3 Number of treatment-related deaths (to include death within 30 days of surgery and / or within the same admission)**

Figure 8.8.3.a: Number of treatment-related deaths (to include death within 30 days of surgery and / or within the same admission)

Description	Larynx	Oral cavity
Number of reported deaths within 30 days of diagnosis or with discharge destination 'death' after any admission	12	7
Number of reported deaths within 30 days of surgery or with discharge destination 'death' after surgery	5	4
Of these patients, the number whose death followed diagnostic surgery	1	0
Of these patients, the number whose death followed recorded surgery with curative intent	3	4
Of the others, number whose death followed recorded surgery with no treatment intent recorded	1	0
<b>Total number of patients with recorded curative surgery</b>	<b>202</b>	<b>441</b>

- Overall, head and neck surgery appears a safe procedure.
- Performing complex procedures in a predominantly elderly population with significant co-existent co-morbidities will, however, inevitably lead to some deaths in the peri-operative period <sup>68,69</sup>.
- Further cycles of the audit will assist in providing nationally derived estimates of risk to patients and MDTs.

**8.9 Clinical trials**

Percentage entered into national clinical trials at cancer careplan has not been calculated.

In head and neck cancer, there is a paucity of national and international clinical trials. This remains an important area for development as trials become available.

## 9.0 Future work

### 9.1 Phase II

The start of the fourth collection period coincided with the launch of Phase II of the National Head and Neck Cancer Audit which incorporates the following major changes:

- Expansion of anatomical sites for which data collected
- Data on multiple pathologies now collected
- Move from UICC 5 – UICC 6 for staging (Effects T4 staging)
- Introduction of clinical nurse specialist (ClinNS), dietetic, swallowing and surgical voice reconstruction (SVR) dataset items
- Initial alignment with the Radiotherapy Episode Statistics (RES) dataset
- Incorporation of pathological staging
- Recording of radiological date of report
- Removal of Cancer Wait times (CWT) from the audit
- **Anatomical subsites**  
Data is now being collected on malignant neoplasms in the oropharynx, hypopharynx and nasopharynx. Additionally malignancy of major salivary glands is now included.
- **New pathologies**  
In line with the change in anatomical sites being looked at we are now collecting data on a broader range of pathologies in the above sites in addition to squamous cell carcinoma of the oral cavity and larynx. A definitive list of salivary neoplasms is now included.
- **UICC 6**  
In order to better assess the likelihood of curative intent for treatments in advanced cancer we have moved to use UICC 6 which changes the way advanced tumours are characterised into T4a and T4b. This helps determine more accurately cases where radical treatment is more or less likely to be successful.
- **Clinical Nurse Specialist, dietetic, swallowing and SVR dataset items**  
The multimodality management of head and neck cancers means that to fully understand the processes of care and the involvement of key workers in the patient journey, data recording these interventions should be recorded. Additionally this will help identify areas where resource needs to be targeted to meet Improving Outcomes Guidance.
- **RES Dataset**  
The incorporation of several fields into DAHNO brings the audit into line with the Radiotherapy Episode Statistics dataset.
- **Pathological staging**  
Pathological staging is now incorporated and will help identify influences on outcomes as the audit matures.
- **Recording of radiological date of request and date of report**  
Recording of both the date of request for radiological imaging and date of report is now included, and will help define this part of the pathway more accurately.
- **Removal of Cancer Waiting Times from the audit**  
As Cancer Wait Times (CWT) data are collected by Trusts as a statutory requirement, the CWT fields have been removed from the National Head and Neck Cancer Audit.

### 9.2 Web DAHNO

A new supporting infrastructure was introduced in January 2008 using web based technology. Information detailing how users can access this system and supporting documentation can be found on the head and neck pages at [www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits).

### 9.3 Casemix adjustment


The National Head and Neck Cancer Audit Project Team, in conjunction with the Data Management and Access Group are liaising with the Cancer Registries to utilise the currently reported cohort to develop a casemix adjustment model. The proposal is to use data from a pool of trusts with high levels of comprehensive data to examine the implications of casemix effects. This will be reported in the fourth annual report and if appropriate applied to outcome measures for next year's analysis.

# Appendix

# Appendix 1

## Project structure and membership

Project structure:



### National Head and Neck Cancer Audit Project Team

**Remit:** Provides the overall direction for the service and manages the delivery of the audit. They manage the issues and risks as well as change requests, maintain the link to Secondary User Services (SUS) to develop the requirements and assist facilitation of migration, agree communication objectives and link to the Communication Team to ensure communication delivery. The Project Team is accountable for the success of the audit and is responsible for the management of all audit groups.

**Accountable to:** The NCASP Management Board

**Representation:** Healthcare Commission, lead head and neck cancer clinicians, project manager, audit system developer, Cancer Registries, Cancer Action Team, DAHNO User Group, DAHNO Helpdesk, Clinical Oncology

**Meeting frequency:** Monthly

**Membership:** Richard Wight-Consultant ENT Surgeon and Chair of the BAHNO Audit Committee (Project Team Chair), Graham Putnam-Consultant Maxillofacial Surgeon (Project Team Vice Chair), Julie Michalowski-Project Manager, Steve Dean-Senior Project Manager (Cancer Audits), Helen Laing-Clinical Audit Commissioning Manager, Ronnie Brar-DAHNO Developer, Chris Carrigan-National Lead for Cancer Registries, Phil Hill-Cancer Action

Team, David Cunningham-CCAD Project Manager, Nancy Horseman-Data Manager, Clare Bailey-Project Support Officer

### Head and Neck Clinical Reference Group

**Remit:** Agreement and ownership of the outcome measures and related data items; provision of support to the Project Team; 'marketing' of the National Head and Neck Audit (across the professions involved); and governance of use of the data and nature of reporting

**Accountable to:** The Project Team and their professional bodies

**Representation:** National groups involved in head and neck cancer care

**Meeting frequency:** Two meetings per year

**Membership:** Richard Wight-Consultant ENT Surgeon and Chair of the BAHNO Audit Committee (Project Team Chair), Graham Putnam-Consultant Maxillofacial Surgeon (Project Team Vice Chair), Julie Michalowski-Project Manager, Steve Dean-Senior Project Manager (Cancer Audits), Clare Bailey-Project Support Officer, Ian Martin-Oral and Maxillofacial Surgeon-British Association of Head and Neck Oncologists, Patrick Bradley-Head and Neck Oncological Surgeon, Andrew Fishburn-British Association of Head and Neck Oncology Nurses, Mark Watson-British Association of Otolaryngology, Head and Neck Surgeons, Patrick Magennis-British Association of Oral and Maxillofacial Surgeons, Sarah Cameron-British Dietetic Association, Edward Odell-British Society for Oral and Maxillofacial Pathology, RD Errington-Clinical Oncology, Gerry Humphris-Clinical Psychology, Helen Laing-Healthcare Commission Gerry Robertson-Lead Clinician for Scotland head and neck cancer data, Christine Piff-Let's Face It, Jean Fraser-National Association of Laryngectomee clubs, Ged Corcoran-Palliative Care Association, AJ Downes-Royal College of General Practitioners, JFC Olliff-Royal College of Radiologists, Tim Helliwell-Royal College of Pathologists, Jo Patterson-Royal College of Speech and Language Therapists, Professor Mike Richards-National Cancer Director-Cancer Action Team, Martin Old-NCASP Programme Manager

## Data Management and Analysis Group

**Remit:** Manage requests for data received by the National Head and Neck Cancer Audit and the analysis of data collected as well as delivering the annual report and Provider Trust analysis reports and feedback

**Accountable to:** Head and Neck Clinical Reference Group

**Representation:** Lead clinicians, project manager, cancer registries, data analysis specialist, IC Caldicott Guardian

**Meeting frequency:** Four to five meetings per year

**Membership:** Richard Wight-Consultant ENT Surgeon and Chair of the BAHNO Audit Committee (Project Team Chair), Graham Putnam-Consultant Maxillofacial Surgeon (Project Team Vice Chair), Julie Michalowski-Project Manager, Steve Dean-Senior Project Manager (Cancer Audits), Ronnie Brar-DAHNO Developer, Chris Carrigan-National Cancer Registration Coordinator, Henrik Møller-National Lead for Cancer Registries, Sandra Edwards-Cancer Intelligence Analyst, Patrick Bradley-Head and Neck Oncologic Surgeon, Christine Piff-CE Let's Face It charity, Jo Patterson-Macmillan Speech and Language Therapist, Patrick Magennis-Consultant Oral and Maxillofacial Surgeon, Ruth Jack-Cancer Registration, Sarah Cuthbertson-Trent Cancer Registry, Jason Poole-Trent Cancer Registry, Ceri White-Welsh Cancer Intelligence and Surveillance Unit, Simon Hodder-Welsh Clinical Representative, Clare Bailey-Project Support Officer

## Expert Panel

**Remit:** Provide clinical expertise for the development of the annual reports

**Accountable to:** The Data Management and Analysis Group

**Representation:** Lead clinicians in oral cavity and larynx cancer, Cancer Registries

**Meeting Frequency:** Two to three times per year

**Membership:** Patrick Bradley-Head and Neck Oncologic Surgeon, Mark Watson-ENT Surgeon, David Howard-ENT Surgeon, Martin Birchall ENT Surgeon and Professor of Surgery, Jon Hayter-

Maxillofacial Surgeon, Cyrus Kerawala-Maxillofacial Surgeon, Simon Rogers-Maxillofacial Surgeon and Honorary Reader in OMFS, Chris Nutting-Consultant Oncologist and Hon. Senior Lecturer in Clinical Oncology, Simon Hodder-Maxillofacial Surgeon and Welsh Clinical Representative, Richard Wight- ENT Surgeon and Chair of the BAHNO Audit Committee (Project Team Chair), Graham Putnam-Maxillofacial Surgeon (Project Team Vice Chair), Julie Michalowski-Project Manager, Clare Bailey-Project Support Officer

## User Groups

**Remit:** User representatives who participate in the National Head and Neck Cancer Audit that ensure the views of users are appropriately reflected in the audit

**Accountable to:** The Project Team

**Representation:** Users spanning all types of job role related to head and neck cancer audit at a Cancer Network and Provider Trust level nationwide

**Meeting frequency:** Quarterly

**Membership:** To be confirmed

## Helpdesk

**Remit:** To respond to and manage technical and clinical queries from users and provide ad hoc training and support to networks and Provider Trusts

**Accountable to:** The Project Team

## NCASP Team

NCASP Team including Programme Manager Martin Old and NCASP Communications Manager Charlotte Tye

## Other Contributors

Jonathan Boyce and Dick Waite at the Healthcare Commission

## Appendix 2

### Contributing professional organisations

There are many organisations that have contributed and continue to contribute to the audit. They are listed below.

**British Association of Head and Neck Oncologists**

**British Association of Head and Neck Oncology Nurses**

**British Association of Oto-laryngologists - Head and Neck Surgeons (ENT UK)**

**British Association of Oral and Maxillofacial Surgeons**

**British Association of Plastic Surgeons**

**British Dental Association**

**British Dietetic Association**

**British Society for Oral and Maxillofacial Pathology**

**National Association of Laryngectomee Clubs**

**Royal College of Surgeons**

**Royal College of General Practitioners**

**Royal College of Radiologists**

**Royal College of Pathologists**

**Royal College of Speech and Language Therapists**

**Palliative Care Association**

**Let's Face It**

**UK Association of Cancer Registries**

**Representatives from clinical oncology**

**Representatives from clinical psychology**

**Trent Cancer Registry**

**Welsh Cancer Intelligence and Surveillance Unit**

## Appendix 3

### Technical infrastructure

The DAHNO application technical infrastructure is closely linked to the methodology employed in the national heart disease audits – the Central Cardiac Audit Database (CCAD). The success of these audits contributed to the decision to use the same structure for the DAHNO application. The client-server architecture was chosen specifically to overcome the limitations of web-based applications in an environment with poor connectivity. Although the NHS network has improved enormously since CCAD began collecting data in 2000, there are still situations where a client-server system has advantages, for instance when the network is down or the application is installed on a mobile laptop platform with only an occasional NHSnet connection. In addition, software updates are communicated automatically to users when they connect to the central servers to exchange local data, making the systems easy to maintain.

The architecture chosen for the DAHNO application and CCAD has proven robust and secure – there have been no breaches of patient confidentiality since data collection began despite collection of data on nearly a million patients. The level of encryption (of local databases and of data transmissions) ensures database security. The DAHNO/CCAD platform represents the highest level of security in the NHS environment.

# Appendix 4

## Dataset and manual

Data collected in DAHNO strictly adheres to the National Cancer Dataset including the head and neck appendage ([www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits)).

A dataset is a description of the data items, their definitions and the allowable entries that are collected when a patient undergoes an event or procedure. Hospitals have a choice of either entering the minimum amount of data required for oral cavity and larynx (minimum dataset) or entering a wider range of data that will not be analysed by the audit but can be used as reference material by the hospital itself.

The following tables are the dataset items from version 4.0 of the National Cancer Dataset for the first phase of the head and neck cancer audit.

ID	Data Item
<b>1</b>	<b>Demographics</b>
1.1	NHS number
1.2	Local patient identifier [Hospital Number]
1.3	Organisation code (code of provider)
1.4	Carespell identifier [Unique Care Spell Number]
1.5	Patient family or surname [Surname]
1.6	Patient forename of personal name [Forenames]
1.8	Postcode of usual address (at diagnosis) [Postcode at Date of Diagnosis]
1.9	Sex
1.10	Birth date [Date of Birth]
1.12	Code of GP practice (Registered GMP) [GP Practice Code]
<b>2</b>	<b>Referrals</b>
2.1	Source of referral for cancer [Source of Referral]
2.3	Referral code [Referred by]
2.4	Cancer referral priority type [Priority of Referral]
2.5	Cancer referral decision date [Date of Decision to Refer]
2.6	Referral request received date [Date of Receipt of Referral]
2.9	Date first seen
2.10	Delay reason referral to first seen (cancer)
2.11	Delay reason comment (first seen)
2.12	Urgent cancer referral type
2.14	<b>Waiting time adjustment (first seen)</b>
2.15	Waiting time adjustment reason (first seen)
2.16	<b>Source of referral for out-patients</b>
<b>3</b>	<b>Imaging</b>

ID	Data Item
3.2	<b>Clinical intervention date (cancer imaging)</b> [Date of imaging]
3.3	<b>Cancer imaging modality</b> [Imaging Modality]
3.4	<b>Anatomical examination site</b> [Anatomical Site Examined]
<b>4</b>	<b>Diagnosis</b>
4.1	Diagnosis date (cancer) [Date of diagnosis]
4.2	Primary diagnosis (ICD) [Primary Site]
4.3	Tumour laterality [Laterality]
4.4	<b>Basis of diagnosis (cancer)</b> [Basis of diagnosis]
4.5	<b>Histology (SNOMED)</b> [Histology]
<b>5</b>	<b>Cancer Care Plan</b>
5.1	MDT discussion indicator [Was this cancer care plan discussed at an MDT meeting?]
5.2	Multi-disciplinary team date [The date of the MDT meeting at which the cancer care plan was discussed]
5.3	<b>Careplan agreed date</b> [Cancer care plan date]
5.5	<b>Cancer careplan intent</b> [Cancer care plan intent]
5.6	<b>Planned cancer treatment type</b> [Management modality]
5.7	<b>Treatment type sequence (cancer)</b> [Treatment type sequence]
5.9	<b>Co-morbidity index for adults-ACE 27</b> [Co-morbidity index]
5.10	<b>Performance status (adult)</b> [Performance status]
<b>6</b>	<b>Staging</b>
6.1	<b>T category (final pre-treatment)</b> [Final pre-treatment T category]
6.2	<b>Staging certainty factor (T category)</b> [Certainty factor for T category]
6.3	<b>N Category (final pre-treatment)</b> [Final pre-treatment N category]
6.4	<b>Staging certainty factor (N category)</b> [Certainty factor for N category]
6.5	<b>M category (final pre-treatment)</b> [Final pre-treatment M category]
6.6	Staging certainty factor (M category) [Certainty factor for M category]
6.7	TNM category (final pre-treatment) [Overall pre-treatment stage group]
6.8	Staging certainty factor (TNM category) [Certainty factor for TNM stage]
6.10	TNM category (integrated) [Overall Pathological TNM stage grouping - integrated stage]
6.11	T category (integrated stage) [Integrated stage - T category]
6.12	N category (integrated stage) [Integrated stage - N category]
6.13	M category (integrated stage) [Integrated stage - M category]
<b>7</b>	<b>Surgery and Other Procedures</b>
7.4	Cancer treatment intent [Treatment intent]
7.5	Decision to treat (surgery) [Date of decision to operate]
7.9	Procedure date [Date of surgery]

ID	Data Item
7.10	Primary procedure (OPCS) [Main surgical procedure]
7.11	Procedure (OPCS) [Sub-procedure]
7.13	Discharge destination (hospital provider spell) [Discharge destination]
<b>8</b>	<b>Pathology Details</b>
8.1	Pathology investigation type [Report Type]
8.3	Investigation result date [Date specimen reported]
8.10	Histology (SNOMED) [Histology]
8.13	Excision margin [Excision Margins]
8.22	Specimen nature [Nature of specimen]
<b>9</b>	<b>Chemotherapy and other drugs</b>
9.4	Decision to treat date (Anti-cancer drug regimen) [Date of decision to treat with drug therapy]
9.7	Drug therapy type [Drug therapy type]
9.8	Drug treatment intent [Treatment intent]
9.10	Start date (anti-cancer drug regimen) [Drug treatment start date]
<b>10</b>	<b>Radiotherapy (Teletherapy)</b>
10.3	Decision to treat date (teletherapy treatment course) [Date of decision to treat]
10.6	Cancer treatment intent [Treatment intent]
10.7	Radiotherapy anatomical treatment site [Anatomical treatment site]
10.8	Start course (teletherapy treatment course) [Teletherapy start date]
<b>11</b>	<b>Radiotherapy (Brachytherapy)</b>
11.3	Decision to treat date (Brachytherapy treatment course) [Date of decision to treat]
11.6	Cancer treatment intent [Treatment intent]
11.9	Start date (Brachytherapy treatment course) [Brachytherapy start date]
<b>12</b>	<b>Palliative Care</b>
12.1	Decision to treat date (specialist palliative treatment course) [Date of decision to treat]
12.2	Start date (specialist palliative treatment course) [Specialist Palliative Care start date]
<b>13</b>	<b>Clinical Trials</b> Note: Clinical Trials information will be completed for every Clinical Trial in which the patient is involved.
13.1	Patient trial status (cancer) [Clinical trial status]
<b>14</b>	<b>Clinical Status Assessment</b>
14.1	Clinical status assessment date (cancer) [Date of contact]
14.2	Primary tumour status [Primary tumour status]
14.3	Nodal status [Nodal status]
14.4	Metastatic status [Metastatic status]
14.10	Morbidity code (chemotherapy) [Treatment related morbidity]
14.11	Morbidity code (radiotherapy) [Treatment related morbidity]
14.12	Morbidity code (combination) [Treatment related morbidity]
<b>15</b>	<b>Death Details</b>
15.1	Death date [Date of death]

# Appendix 5

## First priority outputs (larynx and oral cavity)

### AGREED BY BAHNO AUDIT AND DATASET GROUP AND THE HEAD AND NECK CLINICAL REFERENCE GROUP – VERSION 1.0 FEBRUARY 2003

#### DEMOGRAPHY, CASEMIX AND SOCIO ECONOMIC STATUS

- 8.3.1** Number of patients registered per year with new head and neck primaries of the larynx and oral cavity (divided into the total seen by the specialist team and the local 'denominator' population derived from all available sources – eg cancer registries, HES data, pathology records etc.)
- 8.3.3** Submission, by network and provider trust, of patients with new head and neck primaries of the larynx and oral cavity.
- 8.4** Demography, casemix and socio economic status
  - 8.4.1** Age and sex distributions
  - 8.4.2** Distribution of Stage at point of treatment decision, and final definitive staging to Include pathological TMN (pTMN) (including 'C' certainty factor relating to TNM stage and date of staging)
  - 8.4.3** Distribution of Performance Status at point of treatment decision
  - 8.4.4** Presence or absence of significant co-morbidity at index point of diagnosis (ACE-27)
  - 8.4.5** Distribution of diagnosis, treatment and outcome by socio economic super-group, derived from the postcode
- 8.5** Diagnostic and staging process, waiting times
  - 8.5.1** Source of referral to specialist team (2ww v non 2ww)(primary v secondary )
  - 8.5.3** Interval from first symptom to referral to specialist team
  - 8.5.4** Time to first appointment from referral
  - 8.5.5** Time to diagnosis from referral
    - 8.5.5.1** Time from biopsy to its reporting
  - 8.5.7** Time to decision to treat from diagnosis, expressed as :
    - 8.5.7.1** Time to MDT ('triage' date) from diagnosis
    - 8.5.7.2** Time to care plan date agreed from diagnosis
    - 8.5.7.3** Time to sending communication to primary care from date care plan agreed
  - 8.5.6** % discussed at MDT meeting
  - 8.5.8** Number and % with histological confirmation prior to cancer care plan
  - 8.5.9** Number and % with staging information recorded at time cancer care plan
  - 8.5.10** % having chest imaging by CXR or CT prior to cancer care plan
  - 8.5.11** Time from decision to make imaging request to reporting for imaging (CT/MRI) contributory to pre treatment staging complying with college guidelines
    - 8.5.11.1** Imaging types where interval from imaging request to imaging performed is four weeks or more
  - 8.5.12** Time to first definitive treatment from diagnosis
  - 8.5.14** Time from surgical resection to histological reporting on resective specimen
  - 8.5.13** Time from referral to first definitive treatment in England
  - 8.5.15** Time from date of surgery to first treatment for post operative radiotherapy
- 8.6** Treatment: squamous cell carcinoma larynx (all sites) – recognising the need to record more than one treatment modality if applicable

<b>8.6.1</b>	% having surgical resection with curative intent	<b>8.7.4</b>	% having pre operative/pre treatment dietetic assessment
<b>8.6.2</b>	% by category of clearance for surgical resection margins	<b>8.7.5</b>	% receiving each category of surgical procedure (including surgery to neck)
<b>8.6.3</b>	% having pre treatment dental assessment	<b>8.7.5</b>	type of flap repair (if applicable)
<b>8.6.4</b>	% having pre operative speech and swallowing assessment (includes for laser cordectomy)	<b>8.7.6</b>	% having radical radiotherapy (including brachytherapy, post operative planned and unplanned)
<b>8.6.4</b>	% having pre operative/ pre treatment (includes radio and chemo therapy) dietetic assessment	<b>8.7.7</b>	% having palliative treatment by type (ie. radiotherapy, chemotherapy, surgery)
<b>8.6.5</b>	% receiving each category of surgical procedure (including surgery to neck, surgical voice restoration)	<b>8.7.8</b>	% having chemotherapy (including categories such as 'adjuvant' and 'neo-adjuvant')
<b>8.6.6</b>	% having radical radiotherapy (including post operative planned and unplanned)	<b>8.7.9</b>	% referred to specialist palliative care team
<b>8.6.7</b>	% having palliative treatment by type (ie. radiotherapy, chemotherapy, surgery)	<b>8.7.10</b>	% receiving no specific treatment (including active monitoring category)
<b>8.6.8</b>	% having chemotherapy (including categories such as 'adjuvant' and 'neo adjuvant')	<b>8.7.11</b>	% patients where care plan agreed matches care plan delivered
<b>8.6.9</b>	% referred to specialist palliative care team	<b>8.8</b>	Patient outcomes
<b>8.6.10</b>	% receiving no specific treatment (including active monitoring category)	<b>8.8.1</b>	1 year survival (survival to be expressed in a variety of ways including age-adjusted all-cause mortality and disease-specific mortality – which will require the recording of cause of death and source of this information)
<b>8.6.11</b>	% patients where care plan agreed matches care plan delivered	<b>8.8.2</b>	2 year survival
<b>8.7</b>	Treatment: squamous cell carcinoma oral cavity (all sites) – recognising the need to record more than one treatment modality if applicable	<b>8.8.3</b>	3 year survival
<b>8.7.1</b>	% having pre treatment dental assessment	<b>8.8.4</b>	Number (%) treatment-related deaths (to include within 30 days of surgery and/or within the same admission)
<b>8.7.2</b>	% having surgical resection with curative intent	<b>8.8.5</b>	Loco regional recurrence within 1 year and 2 years of diagnosis (by treatment and tumour type- which will require recording of recurrence by type)
<b>8.7.3</b>	% by category of clearance for surgical resection margins	<b>8.9</b>	Clinical trials
<b>8.7.4</b>	% having pre operative speech and swallowing assessment	<b>8.9</b>	% entered into National Clinical trials at cancer care plan – not calculated in 2007 report

# Appendix 6

## UICC 6 TMN Classification of Malignant Tumours

UICC International Union Against Cancer

TNM Classification of Malignant Tumours Sixth Edition 2002 – Edited by L.H. Sobin and Ch. Wittekind - John Wiley and Sons Inc.

### Larynx

#### Supraglottis T – Primary Tumour

- T1** Tumour limited to one subsite of supraglottis with normal vocal cord mobility
- T2** Tumour invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis(eg, mucosa of base of tongue, vallecula, medial wall of piriform sinus) without fixation of the larynx
- T3** Tumour limited to to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, pre-epiglottic tissues, paraglottic space, and/or with minor thyroid cartilage erosion (eg, inner cortex)
- T4a** Tumour invades through the thyroid cartilage and/or invades tissues beyond the larynx, eg, trachea, soft tissues of neck including deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), strap muscles, thyroid, oesophagus
- T4b** Tumour invades prevertebral space, mediastinal structures, or encases carotid artery
- TX** Primary tumour cannot be assessed

#### Glottis T – Primary Tumour

- T1** Tumour limited to vocal cord(s) (may involve anterior or posterior commissure) with normal mobility
- T1a** Tumour limited to one vocal cord
- T1b** Tumour involves both vocal cords

- T2** Tumour extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility
- T3** Tumour limited to larynx with vocal cord fixation and/or invades paraglottic space, and/or with minor thyroid cartilage erosion (eg inner cortex)
- T4a** Tumour invades through the thyroid cartilage, or invades tissues beyond the larynx eg trachea, soft tissues of neck including deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), strap muscles, thyroid, oesophagus
- T4b** Tumour invades prevertebral space, mediastinal structures, or encases carotid artery
- TX** Primary tumour cannot be assessed

#### Subglottis T – Primary Tumour

- T1** Tumour limited to subglottis
- T2** Tumour extends to vocal cord(s) with normal or impaired mobility
- T3** Tumour limited to larynx with vocal cords fixation
- T4a** Tumour invades through cricoid or thyroid cartilage and/or invades tissues beyond the larynx, eg, trachea, soft tissues of neck including deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), strap muscles, thyroid, oesophagus
- T4b** Tumour invades prevertebral space, mediastinal structures, or encases carotid artery
- TX** Primary tumour cannot be assessed

#### Larynx N – Regional Lymph Nodes

- N0** No regional lymph node metastasis

- N1** Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
- N2** Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
- N2a** Metastasis in a single ipsilateral lymph nodes, none more than 3 cm but not more than 6 cm in greatest dimension
- N2b** Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
- N2c** Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
- N3** Metastasis in a lymph node more than 6 cm in greatest dimension
- NX** Regional lymph nodes cannot be assessed

### M – Distant Metastasis

- M0** No distant metastasis
- M1** Distant metastasis
- MX** Distant metastasis cannot be assessed

### Stage Grouping (Larynx)

Stage	T value	N value	M value
Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T1, T2 T3	N1 N0, N1	M0 M0
Stage IVa	T1, T2, T3 T4a	N2 N0, N1 N2	M0 M0
Stage IVb	T4b Any T	Any N N3	M0 M0
Stage IVc	Any T	Any N	M1

### Oral Cavity T – Primary Tumour

- T1** Tumour 2 cm or less in greatest dimension
- T2** Tumour more than 2 cm but not more than 4 cm in greatest dimension
- T3** Tumour more than 4 cm in greatest dimension
- T4a** Tumour invades through cortical bone, into deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), maxillary sinus, or skin of face
- T4b** Tumour invades masticator space, pterygoid plates, or skull base, or encases internal carotid artery
- TX** Primary tumour cannot be assessed

### Oral Cavity N – Regional Lymph Nodes

- N0** No regional lymph node metastasis
- N1** Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
- N2** Metastasis in a single ipsilateral lymph nodes, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
- N2a** Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
- N2b** Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
- N2c** Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
- NX** Regional lymph nodes cannot be assessed

**M – Distant Metastasis****M0** No distant metastasis**M1** Distant metastasis**MX** Distant metastasis cannot be assessed**Stage Grouping (Oral Cavity)**

Stage	T value	N value	M value
Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T1, T2, T3	N1 N0, N1	M0 M0
Stage IVa	T1, T2, T3 T4a	N2 N0, N1 N2	M0 M0
Stage IVb	Any T T4b	N3 Any N	M0 M0
Stage IVc	Any T	Any N	M1

# Appendix 7

## Adult Co-morbidity Evaluation (ACE-27) UK Values

The following form was developed as an extract from the National Cancer Dataset v4.0. We acknowledge that the intellectual property rights remain with Washington University in St. Louis, Campus Box 8013, 660 So. Euclid Avenue, St Louis MO 63110. It originates from and was developed with the permission of Washington University in St Louis.

Cogent comorbid ailment	Grade 3 Severe Decompensation	Grade 2 Moderate Decompensation	Grade 3 Mild Decompensation
Cardiovascular System			
Myocardial Infarct	<ul style="list-style-type: none"> <li>MI &lt; 6 months</li> </ul>	<ul style="list-style-type: none"> <li>MI &gt; 6 months ago</li> </ul>	<ul style="list-style-type: none"> <li>Old MI by ECG only, age undetermined</li> </ul>
Angina / Coronary Artery Disease	<ul style="list-style-type: none"> <li>Unstable angina</li> </ul>	<ul style="list-style-type: none"> <li>Chronic exertional angina</li> <li>Recent (&lt; 6 months) Coronary Artery Bypass Graft (CABG) or Percutaneous Transluminal Coronary Angioplasty (PTCA)</li> <li>Recent (&lt; 6 months) coronary stent</li> </ul>	<ul style="list-style-type: none"> <li>ECG or stress test evidence or catheterization evidence of coronary disease without symptoms</li> <li>Angina pectoris not requiring hospitalization</li> <li>CABG or PTCA (&gt; 6 months)</li> <li>Coronary stent (&gt; 6 months)</li> </ul>
Congestive Heart Failure (CHF)	<ul style="list-style-type: none"> <li>Hospitalized for CHF within past 6 months</li> <li>Ejection fraction &lt; 20%</li> </ul>	<ul style="list-style-type: none"> <li>Hospitalized for CHF &gt;6 months prior</li> <li>CHF with dyspnea which limits activities</li> </ul>	<ul style="list-style-type: none"> <li>CHF with dyspnea which has responded to treatment</li> <li>Exertional dyspnea</li> <li>Paroxysmal Nocturnal Dyspnea (PND)</li> </ul>
Arrhythmias	<ul style="list-style-type: none"> <li>Ventricular arrhythmia &lt; 6 months</li> </ul>	<ul style="list-style-type: none"> <li>Ventricular arrhythmia &gt; 6 months</li> <li>Chronic atrial fibrillation or flutter</li> <li>Pacemaker</li> </ul>	<ul style="list-style-type: none"> <li>Sick Sinus Syndrome</li> </ul>
Hypertension	<ul style="list-style-type: none"> <li>DBP&gt;130 mm Hg</li> <li>Severe malignant papilledema or other eye changes</li> <li>Encephalopathy</li> </ul>	<ul style="list-style-type: none"> <li>DBP 115-129 mm Hg</li> <li>DBP 90-114 mm Hg while taking antihypertensive medications</li> <li>Secondary cardiovascular symptoms: vertigo, epistaxis, headaches</li> </ul>	<ul style="list-style-type: none"> <li>DBP 90-114 mm Hg while not taking antihypertensive medications</li> <li>DBP &lt;90 mm Hg while taking antihypertensive medications</li> <li>Hypertension, not otherwise specified</li> </ul>
Venous Disease	<ul style="list-style-type: none"> <li>Recent PE (&lt; 6 months)</li> <li>Use of venous filter for PE's</li> </ul>	<ul style="list-style-type: none"> <li>DVT controlled with Coumadin or heparin</li> <li>Old PE &gt; 6 months</li> </ul>	<ul style="list-style-type: none"> <li>Old DVT no longer treated with Coumadin or Heparin</li> </ul>
Peripheral Arterial Disease	<ul style="list-style-type: none"> <li>Bypass or amputation for gangrene or arterial insufficiency &lt; 6 months ago</li> <li>Untreated thoracic or abdominal aneurysm (&gt;6 cm)</li> </ul>	<ul style="list-style-type: none"> <li>Bypass or amputation for gangrene or arterial insufficiency &gt; 6 months ago</li> <li>Chronic insufficiency</li> </ul>	<ul style="list-style-type: none"> <li>Intermittent claudication</li> <li>Untreated thoracic or abdominal aneurysm (&lt; 6 cm)</li> <li>s/p abdominal or thoracic aortic aneurysm repair</li> </ul>

Cogent comorbid ailment	Grade 3 Severe Decompensation	Grade 2 Moderate Decompensation	Grade 3 Mild Decompensation
<b>Respiratory System</b>			
	<ul style="list-style-type: none"> <li>Marked pulmonary insufficiency</li> <li>Restrictive Lung Disease or COPD with dyspnea at rest despite treatment</li> <li>Chronic supplemental O<sub>2</sub></li> <li>CO<sub>2</sub> retention (pCO<sub>2</sub> &gt; 6.7 kPa)</li> <li>Baseline pO<sub>2</sub> &lt; 6.7 kPa</li> <li>FEV1 (&lt; 50%)</li> </ul>	<ul style="list-style-type: none"> <li>Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, or asthma) with dyspnea which limits activities</li> <li>FEV1 (51%-65%)</li> </ul>	<ul style="list-style-type: none"> <li>Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, or asthma) with dyspnea which has responded to treatment</li> <li>FEV1 (66%-80%)</li> </ul>
<b>Gastrointestinal System</b>			
Hepatic	<ul style="list-style-type: none"> <li>Portal hypertension and/or esophageal bleeding &lt; 6 months (Encephalopathy, Ascites, Jaundice with Total Bilirubin &gt; 34mmol/l)</li> </ul>	<ul style="list-style-type: none"> <li>Chronic hepatitis, cirrhosis, portal hypertension with moderate symptoms "compensated hepatic failure"</li> </ul>	<ul style="list-style-type: none"> <li>Chronic hepatitis or cirrhosis without portal hypertension</li> <li>Acute hepatitis without cirrhosis</li> <li>Chronic liver disease manifested on biopsy or persistently elevated bilirubin (&gt;51mmol/l)</li> </ul>
Stomach / Intestine	<ul style="list-style-type: none"> <li>Recent ulcers &lt; 6 months requiring &gt; 6 units of blood transfusion</li> </ul>	<ul style="list-style-type: none"> <li>Ulcers requiring surgery or transfusion of &lt; 6 units of blood</li> </ul>	<ul style="list-style-type: none"> <li>Diagnosis of ulcers treated with meds</li> <li>Chronic malabsorption syndrome</li> <li>Inflammatory bowel disease (IBD) on meds or h/o with complications and/or surgery</li> </ul>
Pancreas	<ul style="list-style-type: none"> <li>Acute or chronic pancreatitis with major complications (phlegmon, abscess, or pseudocyst)</li> </ul>	<ul style="list-style-type: none"> <li>Uncomplicated acute pancreatitis</li> <li>Chronic pancreatitis with minor complications (malabsorption, impaired glucose tolerance, or GI bleeding)</li> </ul>	<ul style="list-style-type: none"> <li>Chronic pancreatitis w/o complications</li> </ul>
<b>Renal System</b>			
End-stage renal disease	<ul style="list-style-type: none"> <li>Creatinine &gt; 265 umol/l with multi-organ failure, shock, or sepsis</li> <li>Acute dialysis</li> </ul>	<ul style="list-style-type: none"> <li>Chronic Renal Insufficiency with creatinine &gt; 265 umol/l</li> <li>Chronic dialysis</li> </ul>	<ul style="list-style-type: none"> <li>Chronic Renal Insufficiency with creatinine 177-265umol/l.</li> </ul>
<b>Endocrine System (Code the comorbid ailments with the (*) in both the Endocrine system and other organ systems if applicable)</b>			
Diabetes Mellitus	<ul style="list-style-type: none"> <li>Hospitalization &lt; 6 months for DKA</li> <li>Diabetes causing end-organ failure <ul style="list-style-type: none"> <li>retinopathy</li> <li>neuropathy</li> <li>nephropathy*</li> <li>coronary disease*</li> </ul> </li> <li>peripheral arterial disease*</li> </ul>	<ul style="list-style-type: none"> <li>IDDM without complications</li> <li>Poorly controlled AODM</li> </ul>	<ul style="list-style-type: none"> <li>AODM controlled by oral agents only</li> </ul>
<b>Neurological System</b>			
Stroke	<ul style="list-style-type: none"> <li>Acute stroke with significant neurologic deficit</li> </ul>	<ul style="list-style-type: none"> <li>Old stroke with neurologic residual</li> </ul>	<ul style="list-style-type: none"> <li>Stroke with no residual</li> <li>Past or recent TIA</li> </ul>
Dementia	<ul style="list-style-type: none"> <li>Severe dementia requiring full support for activities of daily living</li> </ul>	<ul style="list-style-type: none"> <li>Moderate dementia (not completely self-sufficient, needs supervising)</li> </ul>	<ul style="list-style-type: none"> <li>Mild dementia (can take care of self)</li> </ul>
Paralysis	<ul style="list-style-type: none"> <li>Paraplegia or hemiplegia requiring full support for activities of daily living</li> </ul>	<ul style="list-style-type: none"> <li>Paraplegia or hemiplegia requiring wheelchair, able to do some self care</li> </ul>	<ul style="list-style-type: none"> <li>Paraplegia or hemiplegia, ambulatory and providing most of self care</li> </ul>

<b>Cogent comorbid ailment</b>	<b>Grade 3</b> Severe Decompensation	<b>Grade 2</b> Moderate Decompensation	<b>Grade 3</b> Mild Decompensation
Neuromuscular	<ul style="list-style-type: none"> <li>MS, Parkinson's, Myasthenia Gravis, or other chronic neuromuscular disorder and requiring full support for activities of daily living</li> </ul>	<ul style="list-style-type: none"> <li>MS, Parkinson's, Myasthenia Gravis, or other chronic neuromuscular disorder, but able to do some self care</li> </ul>	<ul style="list-style-type: none"> <li>MS, Parkinson's, Myasthenia Gravis, or other chronic neuromuscular disorder, but ambulatory and providing most of self care</li> </ul>
<b>Psychiatric</b>			
	<ul style="list-style-type: none"> <li>Recent suicidal attempt</li> <li>Active schizophrenia</li> </ul>	<ul style="list-style-type: none"> <li>Major depression or bipolar disorder uncontrolled</li> <li>Schizophrenia controlled w/meds</li> </ul>	<ul style="list-style-type: none"> <li>Major depression or bipolar disorder controlled w/meds</li> </ul>
<b>Rheumatologic (Incl. Rheumatoid Arthritis, Systemic Lupus, Mixed Connective Tissue Disorder, Polymyositis, Rheumatic Polymyositis)</b>			
	<ul style="list-style-type: none"> <li>Connective Tissue Disorder with secondary end-organ failure (renal, cardiac, CNS)</li> </ul>	<ul style="list-style-type: none"> <li>Connective Tissue Disorder on steroids or immunosuppressant medications</li> </ul>	<ul style="list-style-type: none"> <li>Connective Tissue Disorder on NSAIDs or no treatment</li> </ul>
<b>Immunological System (AIDS should not be considered a co-morbidity for Kaposi's Sarcoma or Non-Hodgkin's Lymphoma)</b>			
AIDS	<ul style="list-style-type: none"> <li>Fulminant AIDS w/KS, MAI, PCP (AIDS defining illness)</li> </ul>	<ul style="list-style-type: none"> <li>HIV+ with h/o defining illness. CD4+ &lt; 200/<math>\mu</math>L</li> </ul>	<ul style="list-style-type: none"> <li>Asymptomatic HIV+ patient.</li> <li>HIV+ w/o h/o AIDS defining illness. CD4+ &gt; 200/<math>\mu</math>L</li> </ul>
<b>Malignancy (Excluding Cutaneous Basal Cell Ca., Cutaneous SCCA, Carcinoma in-situ, and Intraepithelial Neoplasm)</b>			
Solid Tumor including melanoma	<ul style="list-style-type: none"> <li>Uncontrolled cancer</li> <li>Newly diagnosed but not yet treated</li> <li>Metastatic solid tumor</li> </ul>	<ul style="list-style-type: none"> <li>Any controlled solid tumor without documented metastases, but initially diagnosed and treated within the last 5 years</li> </ul>	<ul style="list-style-type: none"> <li>Any controlled solid tumor without documented metastases, but initially diagnosed and treated &gt; 5 years ago</li> </ul>
Leukemia and Myeloma	<ul style="list-style-type: none"> <li>Relapse</li> <li>Disease out of control</li> </ul>	<ul style="list-style-type: none"> <li>1st remission or new dx &lt;1yr</li> <li>Chronic suppressive therapy</li> </ul>	<ul style="list-style-type: none"> <li>H/o leukemia or myeloma with last Rx &gt; 1 yr prior</li> </ul>
Lymphoma	<ul style="list-style-type: none"> <li>Relapse</li> </ul>	<ul style="list-style-type: none"> <li>1st remission or new dx &lt;1yr</li> <li>Chronic suppressive therapy</li> </ul>	<ul style="list-style-type: none"> <li>H/o lymphoma w/ last Rx &gt;1 yr prior</li> </ul>
<b>Substance Abuse (Must be accompanied by social, behavioral, or medical complications)</b>			
Alcohol	<ul style="list-style-type: none"> <li>Delirium tremens</li> </ul>	<ul style="list-style-type: none"> <li>Active alcohol abuse with social, behavioral, or medical complications</li> </ul>	<ul style="list-style-type: none"> <li>H/o alcohol abuse but not presently drinking</li> </ul>
Illicit Drugs	<ul style="list-style-type: none"> <li>Acute Withdrawal Syndrome</li> </ul>	<ul style="list-style-type: none"> <li>Active substance abuse with social, behavioral, or medical complications</li> </ul>	<ul style="list-style-type: none"> <li>H/o substance abuse but not presently using</li> </ul>
<b>Body Weight</b>			
Obesity		<ul style="list-style-type: none"> <li>Morbid (ie., BMI&gt;38)</li> </ul>	

**OVERALL CO-MORBIDITY SCORE (Circle one.)**

**0**      **1**      **2**      **3**      **9**  
**None**   **Mild**   **Moderate**   **Severe**   **Unknown**

# Appendix 8

## Data Quality Trust Score Calculation

### 1. Measure of level of submission

Numbers of cases submitted overall versus index cases

### 2. Measure of Data Completeness

For all cases submitted measure of data completeness:

By 3 months from referral date, if have feature score

- Demographics 1
- Or Demographics and NHS number 2
- Referral event only 1
- Imaging event 1
- Diagnostic Pathology/Procedure event 1
- Diagnostic Summary with Site 1
- Care Plan only 1
- Or Care Plan and staging 2
- And Care Plan and at least one related treatment document 2

### 3. Convert to weighted score for Network/Trust.

This would need index cases by trust per year.

For Trusts providing diagnostics only:-

$$\frac{\text{Numbers submitted Within time period}}{\text{Index cases}} \times \frac{100 \times \text{Score}}{8} =$$

For Trusts providing diagnostics and treatment:

$$\frac{\text{Numbers submitted Within time period}}{\text{Index cases}} \times \frac{100 \times \text{Score}}{10} =$$

### 4. Interpretation of weighted score

<b>&gt; 60</b>	Very Good
<b>26 – 59</b>	Average
<b>1 – 25</b>	Poor

## Glossary

<b>2WW</b>	Two Week Wait
<b>Adjuvant</b>	a treatment given in concert with another to boost its activity
<b>Aetiology</b>	part of medical science dealing with the causes of disease
<b>Alveolus</b>	the portion of the jaw containing the teeth
<b>Aspiration</b>	withdrawal of fluids or gases from a cavity
<b>BAHNO</b>	British Association of Head and Neck Oncologists
<b>Barium</b>	a metallic element (in barium sulphate form) used in diagnostic imaging due to its propensity to absorb X-rays
<b>Biopsy</b>	removal and examination of tissue for diagnostic purposes
<b>Brachytherapy</b>	treatment modality using implantation of radioactive material
<b>Buccal mucosa</b>	mucous membrane of the mouth or inside of cheek
<b>Cancer centre</b>	specialised unit within a single or multiple hospitals that refers, diagnoses and treats cancer patients
<b>Cancer site</b>	area where cancer is located
<b>CaNISC</b>	Cancer Network Information System Cymru.
<b>Careplan</b>	represents the point in the patient pathway where a plan of treatment is proposed and thus an appropriate point to assess and record a patient's fitness
<b>Casemix</b>	a means of classifying hospital patients to provide a common basis for comparing cost effectiveness and quality of care across hospitals.
<b>CCAD</b>	Central Cardiac Audit Database
<b>CDS</b>	Community Dental Service
<b>CEU</b>	Clinical Effectiveness Unit
<b>CHART</b>	continuous hyper fractionated accelerated radiotherapy
<b>Chemoradiation</b>	a combination of chemotherapy and radiotherapy
<b>Chemotherapy</b>	drugs used in the treatment of cancer
<b>Child document</b>	sub-document of a parent (top level) document
<b>Co-morbidity</b>	co existent illness(es) to the disease under consideration
<b>Corpectomy</b>	removal of the vocal chords
<b>CSV</b>	Comma Separated value
<b>CT scan</b>	computerised tomography scan - a radiological investigation
<b>Curative</b>	intending to cure
<b>CXR</b>	chest X-ray
<b>Cytologist</b>	medically qualified specialist in the study of cells and disease
<b>Cytology</b>	study of cells and disease
<b>DAHNO</b>	Data for Head and Neck Oncology
<b>DAHNO application</b>	software used to collate national, comparative head and neck cancer data
<b>Dataset</b>	collection of data items
<b>Decompensation</b>	the functional deterioration of a previously working structure or system. Decompensation may occur due to fatigue, stress, illness, or old age. When a system is "compensated", it is able to function despite stressors or defects. Decompensation describes an inability to compensate for these deficiencies
<b>Demographic</b>	a statistic characterizing human populations (or segments of human populations) broken down by age or sex or income etc.
<b>Deprivation</b>	absence of expected level of social provision

<b>DH</b>	Department of Health
<b>Diagnosis</b>	confirming the presence of a disease
<b>Dietician</b>	Allied Health Professional specialising in aspects of nutrition
<b>Dorsal</b>	top surface
<b>DSCN</b>	Data Set Change Notification
<b>Early adopter</b>	team or individual taking up a new idea ahead of majority
<b>Endolaryngeal</b>	describing treatment of the larynx via a hollow endoscope
<b>Endoscopy</b>	visualisation of hollow organs
<b>ENT</b>	Ear, Nose and Throat
<b>Epidemiologist</b>	specialist in the study of prevalence of disease
<b>Excision</b>	removal of an area of tissue
<b>Extensive resection</b>	extension of surgical procedure to remove greater volume of tissue than normally required for named procedure
<b>Flap repair</b>	reconstructive surgery utilising a flap of tissue
<b>GDP</b>	General Dental Practitioner
<b>Gingiva</b>	mucosal tissue between and around teeth
<b>Glossectomy</b>	removal of the tongue
<b>Glottis</b>	the vocal apparatus of the larynx; the true vocal folds and the space between them where the voice tone is generated
<b>GMP</b>	General Medical Practitioner
<b>GP</b>	General Practitioner
<b>Healthcare Commission</b>	an independent body, to promote and drive improvement in the quality of healthcare and public health in England and Wales.
<b>Hemimandibulectomy</b>	removal of half the mandible
<b>Histology</b>	microscopic study of cells and tissues
<b>Histopathologist</b>	medically qualified specialist in histology and pathology
<b>HNCRG</b>	Head and Neck Clinical Reference Group
<b>Homogeneous</b>	of similar consistency
<b>Hypopharynx</b>	the lowest section of the pharynx
<b>IBM Lotus Domino®</b>	the server architecture upon which the central DAHNO application database replica resides
<b>IBM Lotus Notes®</b>	the client software that renders the functionality of the DAHNO database to its users
<b>IC</b>	The Information Centre for health and social care (NHS body)
<b>ICD-10</b>	International Classification of Diseases version 10 (a coding nomenclature prepared by the World Health Organisation).
<b>IMD</b>	Index of Multiple Deprivation
<b>IOG</b>	Improving Outcomes Guidance - issued by NICE
<b>ISB</b>	Information Standards Board
<b>Laryngeal</b>	of the larynx
<b>Laryngectomy</b>	removal of larynx (voice box)
<b>Larynx</b>	voice box - anatomic cartilage and soft tissue structure
<b>LDP</b>	local delivery plans
<b>Lesion</b>	abnormal area of tissue
<b>Linear accelerator</b>	radiotherapy machine to deliver high energy beam to treat cancer
<b>Locoregional</b>	area surrounding tumour and its expected lymph node drainage
<b>Lymph node</b>	a bean shaped focus of lymphoid tissue present in many areas of the body forming part of the immune system

<b>Malignant</b>	cancerous
<b>Mandibulectomy</b>	removal of mandible
<b>Mandibulotomy</b>	division of mandible - usually for surgical access
<b>Maxillectomy</b>	removal of maxilla
<b>Maxillofacial</b>	of the face and jaws
<b>MDT</b>	Multi Disciplinary Team – a team of clinical specialists assembled to discuss and agree the appropriate care for a patient
<b>Meta analysis</b>	statistical technique to summate separate statistical analyses
<b>Metastasis</b>	distant spread of tumour
<b>MRI scan</b>	Magnetic Resonance Imaging – a scanning technique using magnetic and radio-waves
<b>Mucosa</b>	mucous membrane
<b>Multimodality</b>	combination of treatments
<b>NCASP</b>	National Clinical Audit Support Programme
<b>NCDS</b>	National Cancer Dataset – the standardised set of data items used in the collection of cancer data
<b>Neo-adjuvant</b>	a substance given ahead of another treatment to boost its effect
<b>Neoplasm</b>	new growth of tissue in part of body
<b>NHSIA</b>	NHS Information Authority – the name of the NHS body now known as ‘The Information Centre’
<b>NICE</b>	National Institute for Clinical Excellence - an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health
<b>NOS</b>	Not Otherwise Specified
<b>NSF</b>	National Service Framework – Dept. of Health long term strategies for improving specific areas of care. They set measurable goals within set time frames.
<b>Oncologists</b>	medically qualified non surgical specialists in cancer management
<b>ONS</b>	Office for National Statistics
<b>Oral cavity</b>	the mouth: anatomic area bounded by the lips palate and pharynx
<b>Oropharyngeal</b>	anatomical subsite the oropharynx e.g. a tumour arising in the oropharynx
<b>Osteoradionecrosis</b>	breakdown of bone as a consequence of previous radiotherapy
<b>Palate</b>	'roof of the mouth' comprising bony anterior portion and soft tissue portion posteriorly
<b>Palliative care</b>	care to alleviate a disease without intent of cure
<b>Parent document</b>	top level document that has subdocuments beneath it
<b>PAS</b>	Patient Administration System
<b>Pathology</b>	study of organs of the body in disease
<b>Pathway</b>	describes stages in the journey of care for a disease
<b>PCT</b>	Primary Care Trust
<b>PET scan</b>	Positron Emission Tomography - a nuclear medicine technique which produces a three-dimensional image or map of functional processes in the body.
<b>Pharynx</b>	anatomical area from back of nose to start of oesophagus (gullet)
<b>PIAG</b>	Patient Information Advisory Group - PIAG was established to provide advice on issues of national significance involving the use of patient information and to oversee arrangements created under Section 60 of the Health and Social Care Act 2001. Its membership is drawn from patient groups, healthcare professionals and regulatory bodies.
<b>Prognosis</b>	predicted outcome of a disease
<b>Radiologist</b>	medically qualified imaging specialist
<b>Radiotherapy (RT)</b>	cancer treatment using high energy beams

<b>RCT</b>	Randomised Control Trial - the essential characteristics of a RCT are that there will be a comparison between a treatment and placebo group. Great care is taken to avoid bias when collecting the data and assigning subjects (randomly) to their respective groups.
<b>Resective pathology</b>	pathology of a surgically removed specimen
<b>Retromolar area</b>	the area directly behind the molar teeth
<b>SALT</b>	Speech and Language Therapists
<b>Squamous cell carcinoma (SCC)</b>	the commonest cancer of mucous membranes in the head and neck
<b>Stage certainty</b>	validation of diagnostic method used to derive stage of cancer
<b>Subglottis</b>	area of voice box below vocal cords
<b>Supraglottis</b>	upper portion of voice box above vocal cords
<b>SUS</b>	Secondary Uses Services
<b>Surgeon</b>	medically qualified specialist who performs diagnostic assessments and operative procedures
<b>SWAHN</b>	South West Audit of Head and Neck Cancer
<b>Teletherapy</b>	high energy external beam used in the treatment of cancer
<b>Thorax</b>	chest cavity
<b>TNM</b>	Tumour, Node, Metastasis. Clinical Classification of anatomical extent of cancer
<b>Tomography</b>	multiple slice x-ray
<b>Triage</b>	preliminary assessment to determine future pathway of care
<b>Tuberculosis</b>	infectious granulomatous disease
<b>Tumour</b>	swelling or abnormal growth
<b>Voice Restoration</b>	means of achieving voice in a patient who has had a laryngectomy
<b>UICC</b>	International Union Against Cancer (French Acronym - Union Internationale Contre le Cancer)
<b>Ulceration</b>	erosion of a mucosal lining
<b>Ultrasonography</b>	technique of high frequency sound scans to visualise body structures
<b>Upper aero- digestive tract</b>	anatomic area from nose and mouth to start of gullet, includes both respiratory passages (nose and voice box) as well as mouth and pharynx

## References

1. Cancer statistics. Registrations of cancer diagnosed in 2004, England. Series MB1, No. 35 Office for National Statistics, London HMSO 2004
2. Welsh Cancer Intelligence and Surveillance Unit – Publication SA6/02 Cancer Incidence in Wales 2001-2005
3. Batsakis, J. G. (1981) - The pathology of head and neck tumours: the occult primary and metastases to the head and neck, Part 10. Head and Neck Surgery 1981, 3, 409-23
4. Ferlito, A., Syhaha, A. R., Buckley, G., Caruso, G., & Rinaldo, A. (2001) - Metastatic Cervical Lymph Nodes from Urogenital Tract Carcinomas: A Diagnostic and Therapeutic Challenge. Acta Otolaryngol 2001, 121, 556 - 564
5. Thorne, P., Etherington, D., & Birchall, M. A. (1997) - Head and neck cancer in the South West of England: influence of socio-economic status on incidence and second primary tumours. Eur J Surg. Oncol. 1997 Dec, 23(6), 503-508
6. Gospodarowicz MK et al (2001) Prognostic factors in Cancer (2nd edition) New York: Wiley-Liss. 2001
7. National Head and Neck Cancer Audit – DAHNO first annual report: Key findings from the National Head and Neck Cancer Audit. 2006  
[www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits)
8. National Head and Neck Cancer Audit - DAHNO second annual report: Key findings from the National Head and Neck Cancer Audit. 2007  
[www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits)
9. The NHS Cancer Plan. Department of Health, September (2000):  
<http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Cancer/fs/en>.
10. Designed for Life:- Creating World Class Health and Social Care for Wales in the 21st Century. Designed to Tackle Cancer in Wales: A Welsh Assembly Government Policy Statement  
[www.wales.nhs.uk/documents/Designed-to-tackle-Cancer.pdf](http://www.wales.nhs.uk/documents/Designed-to-tackle-Cancer.pdf)
11. Improving Outcomes Guidance in Head and Neck Cancers 2004:  
[www.nice.org.uk/pdf/csgn\\_themanual.pdf](http://www.nice.org.uk/pdf/csgn_themanual.pdf).
12. National Standards for Head and Neck Cancer Services 2005  
[www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=362&id=43257](http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=362&id=43257)
13. Informing Healthcare: Cancer Information Framework (CaNISC)  
<http://www.wales.nhs.uk/IHC>
14. National Cancer Dataset (NCDS):  
[www.icservices.nhs.uk/datasets/pages/cancer/cancerdataset.asp?om=m1](http://www.icservices.nhs.uk/datasets/pages/cancer/cancerdataset.asp?om=m1)
15. National Head and Neck Cancer Dataset:  
[www.ic.nhs.uk/canceraudits](http://www.ic.nhs.uk/canceraudits)
16. O'Dowd A, (2005) Lifestyle contributes most to distribution of cancer, report says BMJ 331, 65
17. Bradley, P. J., Chairman (2001) - Practice Care Guidance for Clinicians Participating in the Management of Head and Neck Cancer Patients in the UK. Eur. J. Surg. Oncol. 2001, 27, S1-S18
18. BAHNO –British Association of Head and Neck Oncologists [www.bahno.org.uk](http://www.bahno.org.uk)
19. British Association of Otolaryngologists Head and Neck Surgeons BAO-HNS (1998) - Effective Head and Neck Cancer Management. 1st Ed. London, Royal College of Surgeons of England
20. British Association of Otolaryngologists Head and Neck Surgeons BAO-HNS (2000) - Effective Head and Neck Cancer Management. 2nd Ed. London, Royal College of Surgeons of England
21. British Association of Otolaryngologists Head and Neck Surgeons BAO-HNS (2002) - Effective Head and Neck Cancer Management. 3rd Ed. London, Royal College of Surgeons of England
22. Cancer Reform Strategy Department of Health 2007  
[www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_081006](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081006)

23. Lilford J, Brown CA, Nicholl J (2007). Use of process measures to monitor the quality of the clinical practice. *British Medical Journal* 2007;335:648-650
24. Black, N. (1999) - High quality clinical databases: breaking down barriers. *Lancet* 1999, 353, 1205-1206
25. Annual Healthcheck. Healthcare Commission [www.healthcarecommission.org.uk/healthcareproviders/serviceproviderinformation/annualhealthcheck.cfm](http://www.healthcarecommission.org.uk/healthcareproviders/serviceproviderinformation/annualhealthcheck.cfm)
26. Applying High Impact changes to cancer care. Cancer Services Collaborative Improvement Partnership [www.cancerimprovement.nhs.uk/View.aspx?page=/default.html](http://www.cancerimprovement.nhs.uk/View.aspx?page=/default.html)
27. Llewellyn, C. D., Johnson, N. W., & Warnakulasuriya, K. A. (2001) - Risk factors for squamous cell carcinoma of the oral cavity in young people-a comprehensive literature review. *Oral Oncol* 2001; 37, 401-18
28. R D Alston, S Rowan, T O B Eden, A Moran, J M Birch (2007) – Cancer incidence patterns by region and socioeconomic deprivation in teenagers and young adults in England. *British Journal of Cancer* 2007; 96:1760-6
29. Sobin, L. H., & Wittekind, C. (2002) - TNM Classification of Malignant Tumours. (6th ed.) New York: Wiley-Liss
30. Piccirillo, J.F. (2000) - Importance of comorbidity in head and neck cancer. *Laryngoscope* 2000, 110, 593-602
31. Piccirillo, J. F. (1995) - Inclusion of comorbidity in a staging system for head and neck cancer. *Oncology* 1995; 9, 831-836
32. Paleri, V., Wight, R. G. (2002) - Applicability of the adult co-morbidity evaluation-27 and the Charlson indexes to assess co-morbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. *Journal of Laryngology and Otology* 2002; 116(3), 200-205
33. Paleri, V., & Wight, R. G. (2003) - Impact of Comorbidity on the outcome of laryngeal squamous cancer. *Head Neck* 2003; 25(12), 1019-1026
34. Office of the Deputy Prime Minister's website- Index of Multiple Deprivation (IMD) [www.odpm.gov.uk/stellent/groups/odpm\\_urbanpolicy/documents/page/odpm\\_urbpol\\_029534.pdf](http://www.odpm.gov.uk/stellent/groups/odpm_urbanpolicy/documents/page/odpm_urbpol_029534.pdf). ref imd p73
35. Welsh Index of Multiple Deprivation (WIMD) [www.lgdu-wales.gov.uk/eng/WimdProject.asp?id=1758](http://www.lgdu-wales.gov.uk/eng/WimdProject.asp?id=1758)
36. The 2-week rule for suspected head and neck cancer in the United Kingdom: Referral patterns, diagnostic efficacy of the guidelines and compliance *Oral Oncol.* 2008 Jan 28; [Epub ahead of print]
37. Amir, Z., Kwan, S.Y., Landes, D., & Feber, T. (1999) - Diagnostic Delays in Head and Neck Cancers. *Eur J Cancer Care* 1999; 8, 198-203
38. Hollows, P., McAndrew, P.G., & Perini, M. G. (2000) - Delays in the Referral and Treatment of Oral Squamous Cell Carcinoma. *Br Dental J.* 2000; 188, 2 -5
39. Jones, T.M., Hargrove, O., Lancaster, J., Fenton, J., Shenoy, A., & Roland, N.J. (2000) - Waiting times during the management of Head and Neck Tumours. *J Laryngol Otol.* 2002; 116, 275-279
40. Kowalski, L. P., & Carvalho, A. L. (2001) - Influence of time delay and clinical upstaging in the prognosis of head and neck cancer. *Oral Oncology* 2001; 37, 94-98
41. Scott, S. E., Grunfeld, E. A., & McGurk, M. (2005) - The idiosyncratic relationship between diagnostic delay and stage of oral squamous cell carcinoma. *Oral Oncology* 2005; 41, 396-403
42. Allison, P., Franco, E., Black, M., & Feine, J. (1998) - The role of professional diagnostic delays in the prognosis of upper aerodigestive tract carcinoma. *Oral Oncology* 1998; 34, 147-153
43. Brouha, X. D. R., et al. (2005) - Laryngeal cancer patients: Analysis of patient delay at different tumour stages. *Head and Neck* 2005; 289-295

44. Health Service Circular 1999/205
45. Fast track referral for cancer Editorial British Medical Journal 2007;335:267-268
46. Alarm symptoms in primary care Editorial British Medical Journal 2007;334:1013-14
47. Jones R, Latinovic R, Charlton J, Guillford MC (2007) – Alarm symptoms in early diagnosis of cancer in primary care: cohort study using General Practice Research Database British Medical Journal 2007;334:1040-44
48. Corbridge, R., & Cox, G. (2000) - The Cost of Running a Multidisciplinary Head and Neck Oncology Service – an Audit. Rev. Laryngol. Otol. Rhinol. 2000, 121, 151 – 153
49. Birchall, M. A., Bailey, D., & Lennon, A. (2000) Performance and standards for the process of head and neck cancer care; South and West audit of head and neck cancer 1996-1997 (SWAHN I) South and West Regional Cancer Organisation, Tumour panel for head and neck cancer. Br J Cancer 2000; 83, 421-425
50. Bailey, D., & Baldwin, D. on behalf of the Head and Neck Tumour Panel (2001) - Second Head and Neck Audit Report – SWAHN II Audit SWAHN I Outcome at 2 years, South West Cancer Intelligence Service, September 2001
51. Bailey, D., & Baldwin, D. on behalf of the Head and Neck Tumour Panel (2005) - Third Head and Neck Cancer Audit Report, South West Cancer Intelligence Service, May 2005
52. Arunachalam, P. S., Putnam, G., Jennings, P., Messersmith, R., & Robson, A. K. (2002) - Role of computerized tomography (CT) scan of the chest in patients with newly diagnosed head and neck cancers. Clin Otolaryngol. Oct (2002); 27 (5), 409-411
53. An improving picture? Imaging services in acute and specialist trusts. Healthcare Commission 2007  
[www.healthcarecommission.org.uk/\\_db/\\_documents/Imaging\\_AHP\\_report\\_tag.pdf](http://www.healthcarecommission.org.uk/_db/_documents/Imaging_AHP_report_tag.pdf)
54. Board of Faculty of Clinical Oncology, The Royal College of Radiologists (1999) -Good Practice Guide for Clinical Oncologists. BFCO (99)5
55. Huang, J., Barbera, L., Brouwers, M., Browman, G., & Mackillop, W. J. (2003) - Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J. Clin. Oncology. 2003; 21, 555-563
56. Nassif et al (2006) Negative pathology following endoscopic resection of T1a squamous carcinoma of the glottis. Journal of Laryngology and Otology 2006;120:514
57. Nicholls, C., & Ilankovan, V. (1998) - An audit of oral and dental health regimes practised in the management of oropharyngeal cancer. Br J Oral Maxfac Surgery. 1998; 36, 63–66
58. Duke, R. L. et al (2005) - Dental status and quality of life in long term head and neck cancer survivors. Laryngoscope 2005; 115, 678-683
59. Perry, R., Shaw, M. A., & Cotton, S. (2003) - An evaluation of functional outcomes (speech, swallowing) in patients attending speech pathology after head and neck cancer treatment(s): results and analysis at 12 months post intervention. J Laryngol. Otol. 2003; 117, 368–381
60. Hilgers, F. J. M., & Ackerstaff, A.H. (2000) - Comprehensive rehabilitation after total laryngectomy is more than voice alone. Pholia. Phoniater. Logop. 2000; 52, 65-73
61. Collins, M. M., Wight, R. G., & Partridge, G. (1999) - The nutritional consequences of radiotherapy in early laryngeal cancer. Annals of the Royal College of Surgeons of England (1999); 81, 376-381
62. Munro, A. J. (1995) - An overview of randomised trials of adjuvant chemotherapy in head and neck cancer. Br. J. Cancer 1995, 71, 83-91
63. Pignon, J. P., Bourhis, J., Domenge, C., & Designe, L. (2000) -Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355, 949-55

64. Bonfils P, Trotoux J, Bassot V (2007) – Chemotherapy alone in laryngeal squamous cell carcinoma. *Journal of Laryngology and Otology* 2007;121:143-148
65. The Royal College of Pathologists (2005) – Standards and Datasets for Reporting Cancers Datasets for histopathology reports on head and neck carcinomas and salivary neoplasms, Second Edition 2005, London
66. Loree, T. R., & Strong, E. W. (1990) – Significance of positive margins in oral cavity squamous carcinoma. *American J. Surg.* 1990; 160, 410-414
67. Woolgar, J. A., & Triantafyllou, A. (2005) – A histopathological appraisal of surgical margins in oral and oropharyngeal cancer resection specimens. *Oral Oncology* 2005; 4.p118
68. Gueret, G. et al (2002) – Sudden death after neck dissection for cancer. *Ann. Otol. Rhinol. Laryngol.* 2002; 111, 115-119
69. Bhattacharyya, N., & Fried, M. P.(2001) – Benchmarks for mortality, morbidity and length of stay for head and neck surgical procedures. *Arch Otolaryngo Head Neck Surg.*, 2001; 127, 127-132

